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2 Abstract  
University of Manchester 
Sahena Haque 
PhD 
 
Premature senescence, endothelial turnover and accelerated 
atherosclerosis in SLE: the relationship between circulating endothelial 
cells, telomere length and lupus factors 
 
30th September 2010 
 
Systemic lupus erythematosus (SLE) is associated with premature onset 
of coronary heart disease and endothelial dysfunction. To date the 
mechanisms underlying this remain unclear.  
We hypothesise there is premature biological ageing in patients with 
SLE as evidenced by a reduction in the mean telomere length of PBMC. 
Premature biological ageing is also evident in the vasculature of patients with 
SLE and reflected by relatively shortened telomeres of cells involved in 
vascular repair and regeneration i.e. endothelial progenitor cells (EPC).  
Furthermore, senescent EPC result in cellular imbalance with a relatively 
reduced number and/or function of circulating healthy EPC.  
We studied 200 SLE patients longitudinally over an average of 5.8 (5.2, 
6.3) years and demonstrated progression of carotid plaque burden in 17.5%. 
Baseline traditional CHD risk factors did not influence plaque progression.  
We measured CD34/CD133+ EPC using flow cytometry in 54 SLE 
patients and 49 controls in cross-sectional study and demonstrated no 
significant difference between the groups. We further investigated number and 
function of EPC by enumerating colony-forming unit (CFU) in culture in 39 
SLE patients and 27 controls and demonstrated a significant reduction in CFU 
number in SLE [median (IQR) CFU 5.7 (2.3, 8.0) in SLE vs. 10.0 (5.7, 15.0) in 
controls; p= 0.0016] and this difference was particularly marked in those 
under the age of 40 years [4 (2, 8) vs. 10.5 (7, 19), p= 0.03].   
We measured relative telomere length of PBMC in SLE compared to 
age–matched controls using real-time qPCR in a cross-sectional study and 
demonstrated a significant reduction in SLE patients [0.97 (0.47, 1.57) and 
1.53 (0.82, 2.29), p = P = 0.0008]. Further, telomere length of DNA extracted 
from CFU after 7 days in culture was quantified in a preliminary study of 5 
SLE patients and 5 controls and demonstrated a trend to telomere length 
reduction in SLE patients.  
In conclusion there was evidence of significant progression of carotid 
plaque is in this cohort of female SLE patients. Further there is evidence of 
abnormal endothelial repair and premature senescence in SLE. Results 
support the hypothesis that there is a premature senescent phenotype in SLE 
and as such may present a novel therapeutic target to attenuate the risk of 
CHD in SLE.    
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6 Introduction  
6.1 Systemic Lupus Erythematosus (SLE) 
SLE is a complex inflammatory disease characterised by autoimmune 
dysregulation predominantly affecting women. The first comprehensive 
descriptions of the disease were documented in the 1800s by Kaposi and 
Osler [175, 261] but the first classification criteria were recommended by 
committee consensus in 1971 [72]. Patients with SLE are known to have a 
wide spectrum of manifestations that evolve over time.  An accurate 
estimation of disease onset can be difficult to determine and for the purpose 
of clinical studies patients with SLE are usually defined as those that meet the 
1997 American College of Rheumatology (ACR) revised classification criteria 
[155]. These criteria are summarised in Error! Reference source not found.. 
The epidemiology, pathogenesis, major organ involvement and current 
therapeutic options are summarised below.  
6.1.1 Epidemiology of SLE  
 SLE displays a strong female preponderance, with a female to male 
ratio of 9 - 13:1.  The overall incidence in the UK is approximately 3 – 5 per 
100,000 per year although the condition more commonly affects Afro-
Caribbean and Asian individuals compared to white individuals [173, 229, 
324].  Incidence rates have increased over the past forty years and this might 
partly be attributed to an increased awareness and recognition of the 
condition, as well as the introduction and revisions of the classification criteria 
[155, 336]. Mortality rates in the pre-steroid era were low and the 5-year 
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survival in the 1950s was estimated at 50% [235]. Recent studies however, 
have demonstrated improved 5-year survival rates of 95% in Europe and 
North America [59, 177]. Despite the increased awareness of the disease and 
improvements in the management of some aspects of the condition, there 
remains considerable morbidity associated with SLE and the estimated 10 -15 
year survival remains significantly reduced at 85% [345].   
Table1 Adapted from 1997 Updated Revised Criteria for the  
Classification of SLE 
 
 
 
 
Clinical Features * 
 
Description 
1. Malar Rash Fixed erythema, flat or raised, over the malar eminences 
2. Discoid rash Erythematous raised patches with adherent keratotic scales 
3. Photosensitivity Skin rash as a result of unusual reaction to sunlight 
4. Oral Ulcers Oral or nasopharyngeal, usually painless 
5. Arthritis Non erosive, 2 or more peripheral joints 
6. Serositis Pleuritis or pericarditis 
7. Renal disorder Persistent proteinuria > 0.5 g/d  or> 3+ or cellular casts 
8.Neurological disorder Seizures or psychosis 
9.Haematological disorder 
Haemolytic anaemia or leucopenia or lymphopenia or 
thrombocytopenia 
10.Immunologic disorder Anti-dsDNA or anti-Sm and/or anti phospholipid antibody 
11.Antinuclear antibody In the absence of drugs 
 
*4 criteria required during the course of the disease [155] 
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6.1.2 Pathogenesis of SLE  
The pathogenesis of SLE is multifactorial involving both genetic and 
environmental factors ultimately resulting in the formation of antibodies and 
immune dysfunction. 
6.1.2.1 Genetic factors 
The heritability of SLE has been recognised for several decades and 
family clustering of disease in SLE is greater than observed in other 
autoimmune diseases such as type 1 diabetes or Graves‟ disease [76]. Twin 
studies have demonstrated disease concordance between monozygotic twins 
to be between 24 - 69% compared to 2 to 9 % of dizygotic twins [38, 83]. 
Recent advances in genotyping, such as candidate gene studies and the 
genome-wide association studies, have resulted in increased interest in the 
genetic basis of SLE.  Several genetic polymorphisms or DNA alterations of 
importance to SLE susceptibility have been identified and the expression and 
function of genes have furthered the understanding of SLE pathogenesis.   
As in other autoimmune diseases, HLA class II genes, in particular those 
coding for T-cell signalling, have been associated with SLE in European and 
Asian cohorts [118, 130, 141].  HLA class III genes which contain important 
immune genes e.g. TNF and complement pathway genes have also been 
found to be associated with SLE [366].  
A number of non-HLA genes have been shown to be prevalent in SLE 
patients. Recent reviews cite more than 25 confirmed susceptibility loci and 
these include interferon (IFN) regulatory factor 5 (IRF5), which has an 
important role within the interferon pathway, signal transducer and activator of 
19 
 
transcription 4 (STAT4), which is involved in cytokine signalling and T cell 
responses, PTPN22, which plays a role in T-cell receptor inhibition, and Fc 
receptors for immunoglobulin G (FcγR) genes which are involved in immune 
complex clearance and antibody-dependant responses [85, 108]. 
Interestingly, several polymorphisms have been demonstrated in patients from 
differing ethnicities and are also common to other autoimmune diseases such 
as rheumatoid arthritis and inflammatory bowel disease, suggesting 
autoimmune diseases have a similar genetic foundation [149]. Clearly other 
factors determine the development of differing clinical phenotypes between 
individual diseases. The genes identified have been shown to have a small 
effect and there is likely to be significant contribution of gene-environment 
interactions and epigenetic factors.   
6.1.2.2 Environmental factors 
The predilection for disease amongst individuals from some ethnicities is 
well recognised. However it is also recognised that the risk of SLE varies 
between individuals of the same ethnic background situated in different 
geographical regions suggesting that environmental factors have an important 
role in SLE susceptibility e.g. reduced exposure to endemic pathogens such 
as malaria may lead to loss of protective factors [41]. Conversely some viral 
infections have been shown to be prevalent in SLE and may trigger immune 
dysfunction resulting in autoimmunity such as parvovirus B19, 
cytomegalovirus and Ebstein-Barr virus [282, 342].  
Given the striking female preponderance of SLE, several studies have 
attempted to study the role of hormones on disease susceptibility and activity.  
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The increased incidence of disease flares in pregnancy and subsequent 
pregnancy morbidity is well recognised [71, 267]. The role of hormone 
contraceptives has been studied in several small investigations and a recent 
systematic review has concluded it is likely that the oral contraceptive pill does 
not increase the rate of flares in SLE and can safely be used, except in the 
subgroup of patients with the antiphospholipid syndrome given the increased 
risk of thrombosis in this group [77].  
6.1.2.3 Immune dysfunction  
Elements of both the innate and adaptive immune systems have been 
shown to be defective in SLE. However, the exact nature of these 
abnormalities remains unclear and it is not known if immune dysfunction 
observed is the cause or consequence of SLE. Autoimmunity is thought to 
result from loss of self tolerance and the subsequent formation of antibodies 
to self-antigens. Autoantibodies have been shown to be present in individuals 
for many years before the onset of clinical features of SLE [9]. One of the 
major contributors to the formation of autoantibodies in SLE is thought to be 
the inadequate recognition and clearance of apoptotic cells resulting in 
exposure of intracellular antigens to the immune system [129]. Several 
components of the immune system are likely to contribute to the process of 
defective clearance of immunogenic material in SLE.  Dendritic cells, which 
primarily have a role in antigen presentation and T cell activation, have been 
shown to be dysfunctional in SLE [91]. Furthermore abnormalities of T and B 
cell activation and signalling have been demonstrated in SLE [75]. Toll-like 
receptors, which have an important role in the activation of both B cells and 
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dendritic cells, may also play a role in the defective processing of 
autoantigens in SLE [156]. The role of the complement system in SLE is 
interesting. C1q is a component of the classical pathway and individuals with 
homozygous C1q deficiency have a greater than 90% risk of developing SLE 
[344, 366]. Abnormalities of complement receptors have been demonstrated 
in SLE and have been implicated in accelerated atherosclerosis in SLE [180, 
293].       
6.1.2.4 Cytokines profiles in SLE  
Abnormalities of cytokine pathways in SLE and their role in 
pathogenesis have emerged over the past decade. These include cytokines 
with effects on B cells such as B-cell activating factor (BAFF) also known as 
B-lymphocyte stimulator (BLyS) protein, interleukin-6 and interleukin-10. 
Increased levels of BLyS have been demonstrated in SLE and shown to be 
associated with disease activity [385].   
Another important cytokine is interferon (IFN)-α, a member of the type 1 
interferon cytokine family. These proteins have a role in immune defence and 
increased levels are observed in the context of viral infections. They also have 
a role in physiological growth and differentiation [140]. Increased levels of 
IFN-α can be detected during a flare in SLE and may have a role in SLE 
pathogenesis [19, 186].  BLyS and IFN-α are the target of recently developed 
biologic therapies which may be beneficial in SLE [291].  
The pathogenesis of SLE is complex and multifactorial. Pathogenic 
processes are likely to occur over a long period and ultimately result in 
clinically apparent manifestations of SLE.    
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6.1.3 Clinical manifestations of SLE  
SLE can result manifest in several organs as illustrated by the 
classification criteria (Table1). Disease onset is usually insidious and the 
clinical course is highly variable with a chronic relapsing and remitting pattern. 
Most patients will have constitutional symptoms, mild skin, musculoskeletal or 
serological manifestations and slight derangements in the haematological 
system. However, a proportion of patients will have more severe disease with 
renal, pulmonary or neuropsychiatric involvement, requiring aggressive 
immunosuppressant therapy [358].   
6.1.4 Antiphospholipid syndrome   
A subgroup of patients with SLE will have the antiphospholipid syndrome 
(APS). APS is characterised by the presence of antibodies to phospholipids in 
a moderate to high titre, pregnancy morbidity and thrombotic disease [240]. 
Commonly measured anti-phospholipid antibodies are anticardiolipin antibody 
(aCL), β2-glycoprotein I (β2GPI) or the lupus anticoagulant (LA). Common 
thrombotic manifestations are deep vein thrombosis or stroke however a 
minority of patients, estimated at less than 1%, have catastrophic involvement 
associated with a high mortality [51]. Management strategies include anti-
platelet and anticoagulation as well as avoidance of thrombogenic factors e.g. 
smoking or hormonal contraceptives [100].  Over a third of patients with APS 
also have SLE i.e. secondary APS [60] and between 23 – 40% of SLE 
patients have been shown to have antiphospholipid antibodies [214, 308]. 
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6.1.5 Autoantibodies in SLE 
Autoantibody formation is a pivotal feature of SLE. A number of 
immunological factors are likely to contribute to the formation of 
autoantibodies as briefly discussed in section 6.1.2.3.  All patients with SLE 
are positive for the antinuclear antibody (ANA) in a significant titre, however 
the ANA is also positive in a number of other autoimmune conditions as well 
as in a small proportion of healthy individuals [181, 322].  
Antibodies directed double-stranded DNA (anti-dsDNA) are very specific 
for SLE, in a moderate to high titre [321]. Additionally, a number of antibodies 
directed against extractable nuclear antigens (ENA) are also found in varying 
proportions of SLE patients depending on the laboratory methodology used 
and the population of SLE patients studied and these include anti-Ro/SSA, 
anti-La/SSB, anti-Sm and anti- UI RNP [271].  Antibody detection is a useful 
diagnostic tool in SLE although the variability of positivity would suggest that 
these are not directly pathogenic. Anti-dsDNA titres have been shown to 
correlate with disease activity in some patients with SLE but not all [307].  
Anti-dsDNA have been shown to inversely correlate with the more reliable 
measure of disease activity, C3 and C4 components, which represent 
activation of the complement system [237].  
6.1.6 Overview of management of SLE 
Current therapies for SLE include supportive measures such as smoking 
cessation and avoidance of sunlight, which is known to cause exacerbations 
of cutaneous SLE [73]. Pharmacological therapies include the use of non-
steroidal anti-inflammatories and anti-malarials for mild musculoskeletal 
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manifestations and immunosuppressive therapies for organ specific disease, 
although there is little documented evidence for their use. As such there is 
variation in the therapies used across continents.    
Anti-malarial agents such as hydroxychloroquine and chloroquine 
phosphate have been shown to be effective for cutaneous and 
musculoskeletal manifestations [363].  Corticosteroid (CS) therapy has been 
the mainstay of therapy for the last several decades and likely to have had the 
largest effect on mortality rates in SLE. CS are often used in conjunction with 
other immunosuppressive, steroid-sparing agents in moderate to severe 
disease activity. Azathioprine, a purine analogue, is often used as a first line 
steroid sparing agent and also has effects in the maintenance of severe 
disease such as lupus nephritis [4].  Mycophenolate mofetil (MMF) is an 
inhibitor of purine synthesis commonly used in the setting of renal transplants. 
MMF has shown to be effective for both the induction and maintenance of 
lupus nephritis as well for non-renal manifestations of SLE [274]. 
Cyclophosphamide is currently the mainstay of treatment for severe life-
threatening disease and is the standard of therapy for lupus nephritis [327]. 
Therapy for SLE has moved into a new era over the last decade with the 
development of targeted biological therapies.  Improved understanding of the 
pathogenesis of SLE has lead to the use of B cell depleting agents. The anti-
CD20 drug, rituximab has shown much promise in case series and anecdotal 
reports however randomized placebo-controlled trials have not shown 
consistent positive results. Belimumab is an inhibitor of BLyS has been shown 
to be efficacious in two large phase 3 trials [198]. Targets for anti-cytokine 
therapy of interest currently include IL-10, IL-6, IL-1 and IFN-α [379].  
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6.2 SLE and Clinical Coronary Heart Disease 
The striking incidence of coronary heart disease (CHD) in SLE was first 
reported over thirty years ago by Urowitz et al. [346]. During a 5-year 
prospective follow-up of 81 patients with SLE, it was observed that the causes 
of death appeared to follow a distinctive pattern.  Those that died early in the 
course of the disease had evidence of active SLE, whereas all those that died 
late in the disease had had recent myocardial infarction [346].  This 
observation has since been confirmed in several studies.  Overall, women 
with SLE have a 5-6 fold increased risk of CHD compared to women in the 
general population [223].  In addition to the increased overall risk, patients 
with SLE are susceptible to CHD at a younger age than would be expected.  A 
retrospective study of acute hospital admissions of patients with SLE revealed 
that in the 18 - 44 years age group, females with SLE were 8.5 times more 
likely to be admitted due to acute myocardial infarction (MI), compared with 
non-SLE female patients [369].  A study of 498 females with SLE at the 
University of Pittsburgh Medical Centre revealed that between the ages of 35 - 
44 years, patients were over 50 times more likely to have an MI compared 
with females of a similar age in the Framingham Offspring study [223] and a 
case control study of 53 SLE patients with CHD found more than half of the 
patients developed the coronary event before the age of 55 years [143]. 
Observational and retrospective studies point to an undeniable relative excess 
of clinical CHD in SLE, however, because of the low number of actual events, 
prospective studies to investigate contributing factors would require long 
periods of follow up and include large numbers of patients. Several 
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investigators have therefore used surrogate end-points for clinical CHD to 
investigate factors that may be related to atherosclerotic progression.    
6.3 SLE and Subclinical Atherosclerosis 
In addition to clinically apparent disease, a significant proportion of 
patients appear to have evidence of subclinical disease.  Several studies have 
attempted to quantify the burden of subclinical atherosclerosis in patients with 
SLE.  
6.3.1 Circulating Markers of endothelial function  
Several previous studies have attempted to measure circulating 
biological markers of endothelial function using ELISA.  E selectin is an 
endothelial cell-specific surface marker [96] and be detected following 
endothelial cell activation by cytokines such as TNF-α or IL-1 [356]. Soluble E 
selectin has been shown to correlate with CHD [329].  The intercellular 
adhesion molecules ICAM-1 and VCAM 1 are expressed on the endothelium 
and promote the adhesion inflammatory cells [248, 273].  They have been 
demonstrated in pathological specimens of atherosclerotic plaque and found 
to correlate with CHD [137, 278].  These markers however are not specific to 
the endothelium.  Several previous studies have demonstrated increased 
levels of E selectin, ICAM-1 and VCAM-1 within SLE and these markers are 
thought to correlate with both SLEDAI and subclinical disease [94, 301, 343, 
361].  The non-specific nature of these markers makes the interpretation of 
increased levels difficult.   
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6.3.2 Surrogate measures of arthrosclerosis  
Uncontrolled cross sectional studies of patients with SLE have found 
the prevalence of subclinical atherosclerosis to be between 30 – 40% using a 
variety of markers of subclinical disease including single photon emission 
computed tomography dual isotope myocardial perfusion imaging [47], 
coronary artery calcification (CAC) score [222], ankle brachial pressure index 
[340] and exercise thallium-201 cardiac scintigraphy [311]. Amongst the most 
widely used measures of subclinical arthrosclerosis in SLE are carotid IMT, 
carotid plaque, coronary artery calcification scores, pulse wave velocity  and 
flow medicated dilation. The relative attributes of these measures are 
summarised in Table 2.   
CAC scores are measured using electron beam computed tomography 
(EBCT) and multidetector computed tomography (MDCT). CAC has been 
shown to occur more frequently and severely in patients with SLE [14]. The 
main disadvantages are exposure to radiation and expense. Although this 
technique has good predictive value for coronary events, to date CAC has 
failed to show sensitivity to change within interventional studies, most notably 
with statin therapy [231].  
Flow mediated dilation (FMD) is measured using ultrasound. This 
technique assesses brachial artery endothelial response to increased blood 
flow following shear stress after a period of ischemia in the distal circulatory 
bed. FMD has been widely used and despite the wide range of variability 
between individuals, it has been shown to have good sensitivity to intervention 
at a group level [150, 191]. Subjects may find application of a tourniquet to 
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induce ischemia difficult, particularly in the context of Raynaud‟s phenomenon 
in SLE. 
Carotid IMT/carotid plaque and pulse wave velocity will be used in this 
study owing to local expertise and availability and are discussed in more detail 
below.  
Table 2 Measures of subclinical atherosclerosis 
Attribute 
Carotid 
plaque 
CIMT FMD APWV     CAC 
Predictive value 
of coronary 
event 
Excellent Good Fair Good Excellent 
Technical 
difficulty 
Low Low High Low High 
Reproducibility Good Excellent Fair Fair Fair 
Cost Low Low Low Low High 
Safety / 
tolerability 
Good Good 
Fair 
(tourniquet 
application) 
Fair 
(patient 
exposure) 
Poor 
(radiation 
exposure) 
CIMT - Carotid intima media thickness; FMD - Flow mediated dilation; APWV – Aortic pulse 
wave velocity; CAC – Coronary artery calcification 
 
6.3.2.1 Aortic pulse wave velocity  
Aortic pulse wave velocity (APWV) is a non-invasive measure of aortic 
stiffness used as a research tool.  Left ventricular contraction causes ejection 
of blood into the ascending aorta resulting in acute dilation and generates a 
pulse wave that propagates along the arterial tree at a finite speed.  The 
propagation velocity can be used as a measure of the aortic distensibility and 
stiffness, i.e. increased velocity is a reflection of increased aortic stiffness 
[256].  APWV has been found to correlate with increasing age, CHD- and 
stroke-associated mortality in hypertensive patients, patients with end-stage 
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renal disease as well as healthy subjects, independent of cardiovascular risk 
factors [34, 228, 318].  In addition, cross-sectional study, suggests APWV 
appears to correlate with burden of carotid plaque and may provide a marker 
of subclinical atherosclerosis that precedes carotid plaque formation, although 
prospective studies are lacking [232].  Recent studies have suggested APWV 
is increased in SLE compared to control, particularly in a pre-menopausal 
cohort [78, 380].  
6.3.2.2 Carotid ultrasonography  
High-resolution B-mode carotid wall ultrasonography allows real-time in 
vivo visualisation of the distance between the lumen-intima interface and 
media-adventitia interface, interpreted as the carotid intima-media thickness 
(IMT), as well as detection of carotid plaque.  Previous large studies have 
used IMT to measure all stages of atherosclerosis and found IMT to be an 
independent predictor of CHD [61, 157] as well as cardiovascular risk factors 
such as hypertension, hyperlipidaemia and family history of CHD [116, 197, 
275].   
Cross-sectional studies using carotid ultrasonography have 
demonstrated the prevalence of carotid plaque to be between 29 - 37% in 
SLE patients compared with 15 - 22% in controls and the excess of carotid 
plaque in SLE patients has been shown to be particularly marked in those 
under 55 years [7, 290].   
Four recent short-term longitudinal studies have attempted to estimate 
the rate of progression of subclinical atherosclerosis and elucidate 
contributing factors.  Roman et al. [289] followed 158 patients with SLE over a 
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mean of 2.8 (±0.75) years. This uncontrolled study demonstrated 28% (10% 
per year) of patients had progressive carotid plaque, defined as an increase in 
number or more extensive plaque. Factors related to plaque progression in 
the multivariable analysis were age, disease duration and baseline 
homocysteine level.  Additional factors noted in the univariate analysis that 
differed significantly between those with no plaque (which represented 49% of 
patients) and those with progressive plaque, were less aggressive 
immunosuppression and lower average prednisolone dose. Thompson et al. 
[341] followed 217 SLE patients over 4.19 (±1.97) years and 104 age-
matched controls over 4.97 (±0.5) years. Plaque burden was estimated using 
the plaque index, a summary score of number and size of plaque. SLE 
patients had a significantly increased rate of plaque progression compared to 
the controls (27% vs. 10% over study period) and a similar rate of change of 
intima media thickness (IMT) (0.011mm ± 0.03 vs. 0.008mm ± 0.01 per year). 
Eleven (5%) SLE patients demonstrated a reduction in plaque.  Factors 
associated with plaque progression in the univariable analysis were age, 
smoking status and baseline immunosuppressant use. An additional factor 
identified in the multivariable analysis was a higher baseline C3 level. Rua-
Figeuroa et al. [293] conducted an uncontrolled study of 101 patients with 
SLE over a mean of 2.03 years (range 1.49–2.82) and in contrast to 
Thompson et al. demonstrated a significant mean change in the IMT of 0.078 
(0.071) mm over the study period. Factors associated with IMT progression in 
the multivariable analysis were age at diagnosis, postmenopausal status, 
homocysteine, C3 and C5a levels. This study did not demonstrate any change 
in the proportion of patients with plaque over 2 years (19%).   Lastly de Leeuw 
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et al.  [82] followed 52 SLE patients over 2.7(±0.58) years and demonstrated 
an IMT progression of 0.012 ± 0.04 mm/year. Of a number of traditional and 
novel risk factors assessed, only age was found to be associated with IMT 
progression.  
These studies examined patients with established SLE (>10 years of 
disease duration) of similar age (38-45 years) with relatively quiescent 
disease activity. Perhaps unsurprisingly age or age at diagnosis was found to 
be persistently correlated to atherosclerosis progression across the studies, 
however, not all analyses adjusted for age which may have aided in 
disentangling age-related variables e.g. age at diagnosis and disease 
duration. The progression of carotid plaque was greater in the SLE cohort in 
the only controlled study published. A general population-based study of 
women aged between 59 – 71 years demonstrated plaque progressed by 
18% over 4 years [388] and by this estimate the progression observed in the 
SLE population in the Roman study is also greater than would be expected. 
The study conducted by Rua-Figeuroa did not demonstrate a change in the 
prevalence of plaque over time and this may indicate that a 2 year follow-up is 
inadequate to detect changes or may be a reflection of the small sample size. 
IMT progression was less consistent. Differences observed in the change of 
IMT over time may relate to the relatively short length of follow up or to 
differences between scanning techniques or perhaps due to inherent gender 
or ethnicity differences between the cohorts. Correlation of atherosclerosis to 
traditional risk factors and SLE-related factors were inconsistent. 
It should be noted that these measures of subclinical atherosclerosis 
require specialist equipment or expertise and are not widely available in 
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routine clinical practice. Further, it is unclear what proportion of patients with 
progressive subclinical atherosclerosis will develop clinical coronary events.    
6.4 Factors Influencing CHD in SLE 
Several factors are thought to contribute, at least in part, to clinical and 
subclinical CHD in SLE including „classic‟ Framingham risk factors, as well as  
SLE-related factors such as systemic inflammation, therapy such as 
corticosteroids, renal disease and antiphospholipid antibodies.  These factors 
are discussed below. 
6.4.1 Classic risk factors  
Several studies have attempted to quantify the burden of cardiovascular 
risk factors in SLE and to estimate the contribution of these factors to either 
subclinical or clinical CHD.  
6.4.1.1 Prevalence of classic CHD risk factors in SLE  
It was noted in the Baltimore lupus cohort that 53% of SLE patients had 
more than 3 risk factors for CHD [269]. Bruce et al. demonstrated in a case 
control study of SLE patients compared with non-SLE controls without clinical 
CHD, patients with SLE were more likely to have hypertension, diabetes, 
dyslipidaemia (raised VLDL and triglycerides) and premature menopause [49].  
Recent lipid literature would suggest that individuals at high risk of CHD have 
persistently elevated levels of an altered or pro-inflammatory (pi) HDL. PiHDL 
not only results in loss of usual atheroprotective actions of HDL, such as 
cholesterol transport out of vessel walls through the actions of carrier proteins 
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including Apo-A1, and prevention of LDL oxidation via the actions of the 
enzyme paraoxonase, but is also thought to have additional deleterious 
effects such as to enhance LDL oxidation [351].   A higher proportion of SLE 
patients were found to have piHDL when compared patients with rheumatoid 
arthritis or healthy controls and piHDL was also found to be associated with 
CHD in SLE patients in this study [233]. In addition to overt type 2 diabetes, 
patients with SLE have also been shown to exhibit insulin resistance and the 
associated clustering of risk factors as part of a metabolic syndrome.  The 
variation of insulin sensitivity in the healthy population is well recognised as an 
antecedent to type 2 diabetes and probably plays a role in several stages of 
the development of CHD  [20, 158].  Within SLE, compared with age-matched 
healthy controls, patients have been shown to have an increased incidence of 
insulin resistance and the metabolic syndrome [69, 95]. The interaction of 
corticosteroid and traditional risk factors should be noted.  In particular, 
corticosteroid therapy has been shown to be a major factor influencing 
dyslipidaemia and is discussed below. 
6.4.1.2 Classic risk factors and subclinical atherosclerosis in SLE  
Cross-sectional studies measuring carotid plaque and IMT have 
identified the association of classic risk factors with subclinical atherosclerosis 
in SLE. Manzi et al. demonstrated a mean IMT of 0.71 ± 0.14 mm and focal 
plaque in 40% of SLE females. Hypertension and age were independently 
associated with plaque and older age was associated with IMT in the 
multivariable analysis [224].  In contrast to this study Roman et al. 
demonstrated in a similarly aged cohort, that SLE patients with carotid plaque 
34 
 
(37% of the cohort) were more likely to be older, have a higher systolic blood 
pressure and higher serum cholesterol in the univariable analysis only. 
However in the multivariable analysis, age at onset and disease duration were 
the only significant associations with carotid plaque and the authors 
concluded that SLE was a risk factor for atherosclerosis, independent of 
classic risk factors [290]. Common carotid IMT was 0.61 ± 0.016mm in this 
study and did not differ from controls. Ahmad et al. demonstrated the median 
carotid IMT to be 0.51mm (0.44–0.58) and the prevalence of plaque to be 
29% in SLE patients. Consistent with the Roman study, Ahmad et al. noted a 
number of classic risk factors associated with carotid plaque in the univariable 
analysis but that these factors performed less well in multivariable models for 
SLE. In contrast traditional risk factors performed well in control subjects with 
regard to carotid plaque [7].  
Overall, the contribution of classic CHD risk factors to subclinical 
atherosclerosis, measured by carotid plaque or IMT, appears to be less 
important in SLE patients than in the general population.   
6.4.1.3 Classic risk factors and clinical CHD in SLE  
Few studies have examined clinical CHD as an outcome in SLE. These 
are summarised in Table 3. In contrast to studies using subclinical 
atherosclerotic disease as an outcome, recent studies using clinical events as 
an outcome would suggest a significant contribution of traditional 
cardiovascular risk factors in SLE [143]. It may be that risk factors vary in their 
impact at the various stages of atherosclerosis, e.g. systemic inflammation 
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may play a role in the development of endothelial dysfunction and traditional 
risk factors may be important factors for plaque rupture.        
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Table 3 Summary of studies examining risk factors for clinical cardiovascular events in patients with SLE 
Author 
Mean (range or 
±SD) age at time 
of event 
Cardiovascular 
outcomes 
Classic risk factors Lupus / other factors 
Gladman (1987) 
[123]  
(N=45) 
48 years (25 - 73) CHD Hypertension 
Congestive heart failure 
Hypercholesterolaemia 
Hypertriglyceridaemia 
Hyperglycaemia 
Diabetes mellitus 
Pericarditis 
Myocarditis 
 
Manzi (1997) 
 [223] §  
(N=33) 
48 years (22 - 72) CHD Hypercholesterolaemia 
Postmenopausal status 
Older age at diagnosis* 
Longer disease duration* 
Duration of steroid use 
Svenungsson 
(2001)  
[333]  
(N= 26) 
 CHD  
Stroke or peripheral 
vascular disease (PVD)  
 
High VLDL, LDL 
Lipoprotein a 
Low HDL 
 
ESR, CRP, Orosomucoid 
α-1-antitrypsin 
Lupus anticoagulant  
Homocysteine 
Osteoporosis 
Cumulative steroid dose 
Petri (1992) 
 [268]  
(N=19) 
 CHD Hypercholesterolaemia 
Hypertension 
 
Older age at diagnosis 
Longer disease duration 
Duration of steroid use 
Bessant(2006) 
 [30] 
 (n=29) 
 „survivors‟ only 
Stroke 
PVD 
Hypertension 
High total cholesterol 
High triglycerides 
 
Lupus anticoagulant 
Less hydroxychloroquine use  
Freire (2006)  
[110] 
(N=10) 
43 years CHD  
Stroke  
Older age  Longer disease duration 
SLE clinical features not assessed 
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Ho (2005)  
[154] 
(N=42) 
 CHD 
Stroke 
PVD  
Venous thrombosis  
Smoking  
 
Mucocutaneous manifestations  
Serosal manifestations 
SDI 
Systemic lupus activity measure 
Steroid therapy  
Urowitz (2007) 
 [348]  
(N=118) 
51 years (± 12.3) CHD 
Stroke  
PVD  
Hypertension 
Smoking  
Hypercholesterolaemia  
Number of traditional risk 
factors  
Raynaud‟s  
Renal disease 
Neuropsychiatric disease 
Vasculitis 
Elevated prothrombin time 
Steroid therapy / immunosuppressives  
Less Anti-malarials 
Haque (2010)  
[143] 
(N=53) 
53 years (± 10) CHD Male gender 
Hypercholesterolaemia 
Hypertension 
SDI 
Azathioprine therapy 
Steroid therapy 
 
*Significant variables after controlling for age 
§ SLE cases vs. non-SLE controls 
N = number of cases with events 
 
Adapted from Haque et al. [143] 
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6.4.1.4 Risk of CHD associated with classic risk factors  
The excess of traditional risk factors in some patients with SLE must, at 
least in part, explain the clinical picture observed.  However the literature also 
suggests that they do not fully explain the prevalence of CHD observed.  
Esdaile at al. examined 296 patients with SLE in Canada at entry to an 
observational cohort.  They found that over an 8.6 year follow-up period, 34 
patients developed a cardiovascular event (defined as CHD, cardiac failure or 
stroke).  When retrospectively estimating the expected risk using the 
Framingham model, it was demonstrated that the rate of clinical events was 
greater than expected.  After controlling for common risk factors at baseline, 
patients with SLE were 10 times more likely to have a non-fatal MI and 17 times 
more likely to die from CHD [99].  Similarly, a case control study of 26 patients 
with SLE compared with age-matched non-SLE patients with premature CHD 
found that SLE patients had, on average, one less classic risk factor compared 
to the population controls [280].  A case control study from the UK-based 
General Practice Research Database (GPRD) compared 8,688 patients with 
myocardial infarction with 33,923 controls and demonstrated an odds ratio of MI 
in the SLE patients, after adjusting for all traditional risk factors, aspirin and non-
steroidal anti-inflammatory use, was 2.67 (1.34–5.34), again suggesting that 
factors other than classic risks are contributing to CHD in SLE [107].   
The precise contribution of classic risk factors remains unclear. A 
randomised placebo controlled trial of atorvastatin (40mg daily) in 200 SLE 
patients did not show any benefit of the statin using coronary artery calcification 
as the primary end-point or carotid IMT and plaque as secondary end-points 
[270]. A number of factors may account for the negative result and include the 
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relatively short follow up period of 2 years, use of 40mg of atorvastatin rather 
than 80mg and importantly the use of a primary end-point that is likely to be a 
relatively fixed, advanced stage of atherosclerosis. Similar results were attained 
in a small randomised controlled trial using rosuvastatin (10mg daily) that 
demonstrated no difference in carotid IMT at 2 years between the statin and 
placebo  group [241]. In contrast, a small study has demonstrated an 
improvement of flow mediated dilation in SLE over a 8 week period with the use 
of atorvastatin (20mg) [106].   Parallels can be drawn with the use of statins in 
chronic kidney disease, where studies have shown inconsistent results. Two  
large clinical trial have suggested there is no reduction in cardiovascular events 
with lipid lowering agents, however the initial results of the SHARP study, a 
large randomised placebo controlled trial, has shown a reduction in all-cause 
cardiovascular events but not in MI [105, 313, 368].   
Given the diversity of pathologies observed in SLE i.e. thrombosis, 
immunologically mediated processes, neoplastic disease and iatrogenic effects 
related to potent therapies e.g. steroids and cytotoxic drugs, perhaps it is not 
surprising that traditional risk factors do not fully explain the CHD risk.   
6.4.2 SLE-related risk factors and CHD  
6.4.2.1 Role of corticosteroids 
The adverse effect of corticosteroids (CS) on lipid profiles, hyperglycaemia 
and hypertension status is well recognised.  The correlation of previous steroid 
use and cardiovascular morbidity in SLE has been documented in several 
studies [223, 268]. Post-mortem examinations of 36 SLE patients with prior CS 
therapy were carried out by Bulkley and Roberts and the findings were 
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compared with the results of autopsies of 20 SLE subjects undertaken in 1941 
(pre-steroid era).  Age and presence of renal disease (present in approximately 
80%) were comparable between the two groups.  Sixty-four percent of CS-
treated patients had left ventricular hypertrophy (hypertension had been present 
in 69%) compared with 15% of patients from the pre-steroid era [52].  This study 
also appears to indicate that the duration of exposure of CS is relevant.  Those 
that had steroids for longer than 12 months were more likely to have coronary 
artery narrowing.  Furthermore, a case control study of 46 female patients with 
SLE compared with 30 matched healthy controls, found that patients treated 
with CS had higher triglyceride and total cholesterol levels.  SLE patients not 
taking CS had a lipid profile similar to that of non-SLE controls with the 
exception of lower levels of HDL in this small study [101].  Bruce et al. 
demonstrated that the cumulative dose of CS correlates with sustained 
hypercholesterolemia in SLE patients with early disease [48].  A higher average 
daily dose of CS has been implicated in causing dyslipidaemia in other studies 
[205], however, steroid treatment may not adversely affect the risk of 
dyslipidaemia across the whole dose range [217].  Roman et al. using carotid 
plaque measurement as an outcome found that patients with plaque were 
exposed to a lower average daily dose of CS over the previous 5 years than 
those without plaque, suggesting that incomplete suppression of inflammation 
might be a factor and optimal doses of CS might have a beneficial effect on 
atherosclerosis.  It is possible that CS could represent a marker for another 
confounding factor, such as disease activity (i.e. inflammation), severity or 
duration.  The importance of inflammation in the pathogenesis of 
atherosclerosis is discussed in section 6.4.2.4. The impact on the risk of CHD of 
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the various biological effects of CS is difficult to assess.  In addition, accurate 
documentation of the amount of CS exposure is complex, as they are frequently 
prescribed by different practitioners in both primary and secondary care, as well 
as being self-administered by patients.  Direct comparisons between studies is 
often not possible as various measures of exposure have been used in different 
studies e.g. cumulative dose, average daily dose, maximum dose ever or length 
of exposure.  All these factors should be taken into account when considering 
the effect of CS on the risk of CHD in SLE.   
6.4.2.2 Renal disease  
The prevalence of renal disease in SLE is estimated at 22 - 41% [59, 165].  
The high incidence of cardiovascular morbidity and mortality associated with 
chronic kidney disease and proteinuria is well documented in the general 
population [125, 300]. However, within SLE, studies have not shown a 
consistent association [222, 290]. Notably, nephrotic range proteinuria has been 
shown to be a major risk factor for carotid atherosclerosis in juvenile-onset SLE 
and renal disease has also been found to be predictive carotid atherosclerosis 
in a small prospective observational study [92, 104].   Difficulties arise when 
making comparisons between studies as measures of renal function vary e.g.  
serum creatinine level, creatinine clearance and proteinuria. Invariably the 
therapy profile of patients with renal disease will also differ from non-renal SLE 
patients, therefore introducing potential confounding variables.  
6.4.2.3 Antiphospholipid antibodies 
The prevalence of antiphospholipid antibodies in SLE is estimated at 30 - 
40% in different studies [145, 214].  The prothrombotic nature of these 
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antibodies is well documented in the context of APS. Serum lipoproteins contain 
phospholipids and modified LDL and therefore it is conceivable that they may 
be a target for antiphospholipid antibodies.  Crossreactivity between 
anticardiolipin antibody (aCL) and antibodies to oxidized LDL has been reported 
[349].  The possible association between antiphospholipid antibodies and 
oxidized LDL is interesting, however the exact nature and function of these 
antibodies is not clear.  The key antigenic target for antiphospholipid antibody is 
β2-glycoprotein I.  In vitro studies have shown that β2-glycoprotein I inhibits 
uptake of oxidized LDL by macrophage scavenger receptors but that in the 
presence of antibodies to β2-glycoprotein  I (β2GPI), uptake of oxidized LDL is 
increased, suggesting a pro-atherogenic role of antiphospholipid antibodies 
[146]. Furthermore β2GPI have been shown to immunolocalise to 
atherosclerotic plaque and interact with oxLDL [120, 188]. These processes 
would suggest a role for aCL in both the initiation and instability of 
atherosclerotic plaque. Autoantibodies directed at the oxLDL/β2GPI complex 
have been demonstrated in several groups at high risk of CHD and more 
recently been demonstrated to predict a poor outcome in patients with the acute 
coronary syndrome [131]. Recent research has focused on the interaction 
between aCL and annexin A5. Annexin A5 is a calcium and phospholipid-
binding protein that interacts with cellular membranes and is thought to have 
plaque-stabilising properties. Plasma from SLE patients has been demonstrated 
to result in reduced binding of annexin A5 to endothelium [58] and a recent in 
vitro study has demonstrated a dose-dependent reduction of annexin A5 
binding to human umbilical venous endothelial cells (HUVECS) by monoclonal 
antibody to anticardiolipin which was abrogated by preincubation of HUVECS 
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with neutralising pooled intravenous immunoglobulins. The investigators 
suggest aCL directly interfere with annexin A5 binding to endothelium and may 
contribute to plaque instability [113].   
Animal studies using LDL receptor-deficient mice have demonstrated 
increased atherosclerotic lesions following immunisation with aCL and β2GPI 
(reviewed in [314]).  Within human SLE studies, the association of aCL and 
athrosclerosis is not clear. aCL have been shown to be associated with carotid 
plaque in patients with SLE [7, 7].  In contrast, another study demonstrated aCL 
were less likely in SLE patients with plaque compared to SLE patients without 
plaque [290].  It is unclear if antiphospholipid antibodies may represent a 
surrogate marker for an underlying affinity for atherosclerosis and further 
research is needed to establish whether they are directly pathogenic.  It is likely 
that certain subtypes of aCL represent a proatherogenic process, whereas 
others maybe atheroprotective [253].   
6.4.2.4 Atherosclerosis and the immune system  
Atherosclerosis was previously considered as a disorder of lipid storage 
however it has become clear over the last decade that the innate immune 
system and in particular, inflammation play a key role.  
6.4.2.4.1 Innate immunity and atherosclerosis  
The innate immune system comprises the non-specific defence processes 
of the body. These defences include barriers such as the skin and mucosal 
surfaces, the inflammatory response, pathogen recognition via toll-like receptors 
(TLR), immune cell recruitment and signalling via cytokines, and complement 
activation.  
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The stages of atherosclerosis are now well recognised and schematically 
described in Figure 1.  The initial step in the process is thought to be endothelial 
cell activation and upregulation of adhesion molecules and chemokines. 
Recruitment and activation of immune cells such as monocytes and T helper 
cells are pivotal processes in atherogenesis and likely to be mediated by the 
local release of chemotactic cytokines such monocyte chemotactic protein-1 
(MCP-1), regulated upon activation normal T cell expressed and secreted 
(RANTES), interferon inducible protein (IP)-10 and interferon-inducible T cell 
alpha chemoattractant (I-TAC) [42, 136, 218, 354]. Uptake of oxLDL by 
macrophage scavenger receptors in the subendothelial layer results in the 
formation of foam cells. The earliest detectable lesion in the formation of 
atheroma is the fatty streak which is rich in inflammatory cells. This lesion is 
thought to be dynamic with the potential to regress [212].  The atheromatous 
lesion later in the developmental stages of CHD consists of a core of foam cells 
and lipid droplets with a surrounding cap of smooth muscle cells and a collagen-
rich matrix. The lesion also contains T cells, macrophages and mast cells which 
exhibit signs of immune activation and produce pro-inflammatory cytokines.  An 
atheromatous lesion can be relatively stable for many years with the potential 
for thrombus formation and plaque rupture, causing acute coronary syndromes.  
Activation of immune cells and release of inflammatory cytokines and proteases 
are thought to contribute to plaque instability and rupture [142].  Inflammation is 
therefore thought to contribute to initiation, formation and rupture of 
atheromatous plaque.  
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Figure 1 Developmental stages of atherosclerotic plaque.  Adapted from C 
Erridge, Journal of Innate Immunity 2009 [97] 
 
The importance of immune cells in atherosclerosis has become well 
established, however, more recently another component of the innate immune 
system, toll-like receptors (TLR), have been shown to have an important role. 
TLR consist of 10 transmembrane receptors that are involved in recognition and 
defence against microbial infections. These receptors recognise and engage 
microbial motifs termed pathogen-associated molecular pathogens (PAMP), 
such as single-stranded RNA motifs associated with viral infections, resulting in 
the initiation of inflammatory signalling [182].  Some or all of the 10 subtypes of 
TLR receptors are expressed on most immune cells and often result in 
upregulation of expression of inflammatory genes such as endothelial adhesion 
molecules and chemokines. In particular macrophages express all 10 types. A 
number of TLR have also been shown to be expressed on arterial endothelial 
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and smooth muscle cells [98, 378].  Mouse models would suggest a central role 
for TLR in atherosclerosis. Deletion of specific TLR or their signalling pathways 
in the atherosclerosis prone ApoE–/– and LDLR–/– mice models have 
demonstrated a significant reduction in atherosclerotic burden. Furthermore, 
infusion of TLR ligands has been shown to accelerate atherosclerosis in mice 
[33, 219, 236, 247]. TLR may also contribute to uptake of oxLDL by 
macrophages to form foam cells [21, 55]. The exact physiological link between 
TLR signalling and various stages of atherosclerosis remains a subject of much 
interest.   
The complement system consists of cascade fashion activation of several 
proteins down 3 separate pathways (classical, mannose binding lectin and 
alternative) that ultimately collaboratively lead to cleaving of C3 to form C3a and 
C3b. These fragments subsequently participate in processes involved in the 
removal of unwanted material from the immune system. The complement 
system is a key player within the innate immune system and also interacts with 
the adaptive immune system [364, 365].  Complement components have been 
shown to be involved in endothelial cell activation and immune cell recruitment 
via upregulation of MCP-1, IL-6 and VCAM-1 [357]. Complement activation 
cannot be detected in intact arteries however several in vitro studies have been 
able to demonstrate complement activation in atherosclerotic plaque and in 
particular within vulnerable plaque [193, 259, 310].  Several mouse studies 
have also contributed to elucidating the role of complement in atherosclerosis. 
Controlled studies using atherosclerosis prone LDLr-/- and ApoE-/- knockout 
mice have demonstrated larger plaque and accelerated atherosclerosis in the 
context of C3 deficiency or CD59 (complement regulatory protein) deficiency 
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[53, 266, 377, 384]. C1q has a role in activating the classical pathway and is 
involved in clearance of apoptotic cells. C1q-/-/ LDLr-/- mice have been shown to 
have accelerated formation of early atherosclerotic lesions containing more 
apoptotic cells compared to control mice [31, 338]. Of interest, studies have 
shown high serum levels of C3 to be associated with traditional risk factors and 
also predictive of MI independent of traditional risk factors [249, 250].  
Inadequate clearance of cell debris by the complement system has been 
implicated in the pathogenesis of SLE and SLE-like syndromes are well 
recognised in the context of congenital deficiencies of C1q and C4 [272]. The 
relationship between the complement system and SLE, particularly in the 
context of atherosclerosis, requires further clarification.            
6.4.2.4.2 Inflammatory biomarkers and atherosclerosis  
Evidence of immune activation has been demonstrated in the peripheral 
circulation of patients in the general population with acute coronary syndromes.  
A small case control study examining patients with stable and unstable angina 
found an association of clonally expanded T cells with unstable atherosclerotic 
plaque.  Similar T cell receptor sequences were detected in different subjects in 
this study, implying that chronic antigenic stimulation by a common antigen, 
possibly triggered by inflammation or infection, contributes to plaque instability 
and rupture [211]. Vulnerable unstable plaques have been shown to occur more 
commonly in patients with inflammatory conditions than in controls [16]. 
Several prospective studies have demonstrated raised baseline levels of 
inflammatory markers in subjects that have subsequently developed clinical 
coronary events such as IL-6, CD40L, macrophage inhibitory cytokine-1 and 
TNF-α [46, 285, 286, 305]. The most widely researched inflammatory biomarker 
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for CHD to date has been the C-reactive protein (CRP).  Several large 
prospective studies have demonstrated that baseline CRP, assessed using a 
high sensitivity (hs) assay measuring low levels of inflammation, generally 
considered to be less than 10mg/l, is predictive of future CHD in both men and 
women [277, 284, 287]. Moreover, it would appear that hsCRP level may reflect 
the risk of CHD more accurately than the Framingham risk score [287]. A 
prospective study of 25,000 healthy women followed over a 10 year period 
demonstrated that a risk prediction model incorporating the hsCRP and history 
of premature parental CHD event allowed more accurate prediction of CHD 
events than the Framingham risk prediction model, in those individuals 
classified in the  „intermediate risk‟ category [283]. This observation lead to the 
JUPITER trial (Justification for the Use of Statins in Primary Prevention: An 
Intervention Trial Evaluating Rosuvastatin); a randomised controlled study. The 
recently reported findings demonstrated that statin therapy significantly reduced 
coronary events in patients with a normal LDL (<3.4mmol/l) and raised hsCRP 
(>2mg/l) compared with a placebo drug [288].  
Whilst biomarkers such as the CRP are classically not particularly raised 
in SLE, one recent study has demonstrated a CRP level greater than 9 mg/l is 
predictive of atherosclerotic damage in SLE defined as the development of 
angina, MI, heart failure or coronary intervention [276].    
6.4.2.4.3 Inflammation, atherosclerosis and SLE 
In addition to the wealth of evidence demonstrating subclinical 
atherosclerosis, autopsy studies have also demonstrated the presence of the 
„usual‟ type of coronary atherosclerotic plaque in SLE patients. Accordingly, the 
majority of coronary events have been demonstrated to be the result of 
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atheromatous plaque and not coronary vasculitis [115, 139]. The role of 
inflammation in atherosclerosis is particularly interesting as systemic 
inflammation is the hallmark of SLE. Inflammatory processes have been shown 
to contribute at all stages of the atherosclerosis process, including the initiation 
with endothelial cell damage. It is increasingly recognised that maintenance of 
endothelial integrity is crucial to prevent atherosclerosis.     
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6.5 Endothelial cells 
6.5.1 Vascular damage and endothelial dysfunction  
The vascular endothelium comprises a single layer of endothelial cells with 
essential anti thrombotic and barrier functions as well as a role in the regulation 
of vascular tone.  Endothelial dysfunction (ED) can be characterised as a 
deviation from normal function to a vasoconstrictive, procoagulant, platelet-
activating and anti-fibrinolytic state.  ED is thought to have a key role in 
atherosclerosis and related diseases and found to be present in all stages of 
atherosclerosis [142].  Mechanisms by which vascular damage is repaired are 
not well understood.  Several recent studies have suggested that two groups of 
endothelial cells (EC) can be detected in the peripheral circulation of individuals 
with vascular damage.  A population of endothelial progenitor cells (EPCs) are 
thought to be bone marrow-derived and involved in the repair of the 
endothelium. A population of „inflammatory‟ or „activated‟ endothelial cells 
(IECs) are thought to have been shed from the endothelium following an insult 
[159].  In addition to IEC, endothelial microparticles (EM), thought to be shed 
from damaged endothelial cells, with a potential role in cell signalling, have also 
been identified from the serum of individuals with acute coronary syndromes 
[26, 27, 221]. It is believed that damage to endothelial cells can result in 
endothelial dysfunction and this is thought to be critical in the formation of 
atheroma [79, 142].  Understanding endothelial repair mechanism is therefore 
very important. 
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6.5.2 Characterisation of Endothelial progenitor cells  
Endothelial progenitor cells were first reported by Asahara et al. as CD34+ 
mononuclear cells with the ability to form island-like colonies in culture in the 
late 1990s [12]. These bone marrow derived cells were shown in a mouse 
model, under the influence of vascular endothelial growth factor (VEGF), to 
have the ability to incorporate into blood vessels with experimentally induced 
ischaemia [13].  These landmark experiments have given an important insight 
into the biology of vascular repair.   
6.5.3 Methods of EPC quantification     
 Two main methods have been utilised to identify EPC. The first aims to 
identify cells with specific surface markers for EPC using flow cytometry and the 
second attempts to identify in vitro cell culture characteristics.    
6.5.3.1 Flow cytometry identification of EPC  
Flow cytometry allows the rapid analysis of multiple characteristics of a 
population of cells and has been used since the 1950s [74].   Cells labelled with 
fluorescently-conjugated antibodies are injected in suspension into a fine 
nozzle, encouraged to flow in single file and illuminated by a laser beam.  The 
direction and intensity of light scattered from an individual cell along with 
emitted fluorescence is converted into a numerical value and plotted on a 
histogram.  For a given cell, information is recorded relating to light scatter in a 
forward direction (forward scatter), side scatter and wavelength of fluorescence 
emitted.  Several groups have used fluorescently-conjugated antibodies to 
specific cell surface markers for analysis with flow cytometry to identify EPC. 
Flow cytometry has several advantages including good sensitivity, specificity 
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and reproducibility [183]. The choice of surface markers that correctly identify 
EPC is the subject of much debate and discussed below.  
6.5.3.2 Surface markers to identify EPC 
A variety of surface markers to identify EPC have been used by different 
groups. The majority of studies using flow cytometry have used at least one 
surface marker to identify a cell of immaturity and at least one marker to identify 
a cell from the endothelial cell lineage. 
The most widely used marker to identify immaturity is CD34 positivity. 
CD34 is an 110kD surface marker expressed on haematopoietic stem cells, 
although the exact origin and signals for differentiation of these cells remain 
unclear. CD34 can be detected on approximately 0.1% of circulating 
mononuclear cells and thought to act as an adhesion molecule related to 
endothelial and haematopoietic cells [64]. In addition to CD34, other studies 
have demonstrated CD14+ (a surface marker found on monocyte populations) 
cells can also form similar colonies in vitro.  It is possible both these cell types 
originate from a common precursor, the „haemangioblast‟ [119]. More recently 
CD14+ cells have been shown not to have an association with CHD or related 
risk factors [162]. CD133 is a 120kD glycoprotein expressed on progenitor and 
haematopoietic stem cells [381]. Although the exact function is not clearly 
understood they are thought to identify an immature population of EPC.  
Piechev et al. demonstrated a subpopulation of CD34+ / VEGFR2+ cells that are 
also positive for CD133. However CD133 was no longer expressed on mature 
CD34+ / VEGFR2+   in cells in vitro leading the authors to conclude that CD34+/ 
CD133-/ VEGFR2+ represent a more mature differentiated population of 
endothelial cells [263]. Furthermore, Friedrich et al isolated CD34-/ CD133+/ 
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VEGFR2+ and demonstrated that when cultured, these cells upregulate the 
surface expression of CD34 suggesting that CD34-/ CD133+/ VEGFR2+ are 
precursors of CD34+/ CD133+/VEGFR2+ EPC [112]. It is possible that 
CD34+/VEGFR2+ and CD133+/VEGFR2+ may represent different subtypes of 
EPC and CD34+/ CD133+/VEGFR2+ may identify a restricted EPC phenotype. 
One major disadvantage is that these triple labelled cells represent a very small, 
and therefore difficult to quantify, population of cells. Despite this limitation 
combinations of these markers have been repeatedly demonstrated to be good 
biomarkers for disease as summarised in  
Table 44. 
 
Table 4 Endothelial progenitor cell surface markers 
 
It is widely accepted that EPC express vascular endothelial growth factor 
receptor-2 (VEGFR2 or KDR in humans). The roles of the VEGF receptor family 
in angiogenesis and vasculogenesis are well recognised [292].  Other 
endothelial antigens include CD31 and von Willebrand factor. CD31 or platelet 
endothelial cell adhesion molecule-1(PECAM-1) is known to have roles in 
Experimental model/ tissue type Cell surface markers Reference 
Circulating PBMCs CD133+ [119] 
Circulating PBMCs CD34+/ CD133+/ VEGFR2+ [263] 
Cord blood CD34+ /CD11b+ [151] 
Circulating PBMCs – markers induced in 
culture from CD133- cells 
CD34+/ CD133+/ VEGFR2+ [331] 
Circulating PBMCs 
CD34-/ CD133+ /VEGFR2+ 
(?precursor) 
& CD34+/ CD133+/ VEGFR2+ 
[112] 
Circulating PBMCs CD34+KDR+ [303] 
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angiogenesis, platelet function, thrombosis and regulation of leukocyte 
migration through vascular walls [375]. Von Willebrand factor has a role in 
platelet adhesion to the vascular wall in injury and is a carrier protein of 
coagulation factor VIII [86]. In addition, the vessel wall itself may be a source of 
progenitor cells [167].  
Another important factor to consider is the units in which cell populations 
are expressed. Some studies have favoured expression of cells as a count per 
unit of volume of blood. EPC are estimated to represent between 0.0001% and 
0.01% of peripheral cells, making them a „rare event‟ in flow cytometric analysis. 
Given the rarity of these events in peripheral blood and the variations in 
haemodilution between individuals, particularly in patients with cardiovascular 
disease, this measure can be misleading and likely to be inappropriate. A more 
suitable measure of cells identified using flow cytometry would be cell number 
or proportion of total cytometry events.   
Identification and quantification of EPC using flow cytometry can be 
challenging but despite this several studies have reported associations with 
disease states. Therefore, EPC quantification using surface marker 
identification remains a relatively widely used technique.    
6.5.3.3 Cell culture characteristics of EPC 
Flow cytometry allows enumeration of EPC, a population occurring in 
peripheral blood in low frequency, using a limited number of surface markers. 
Cell culture has the advantage of allowing expansion of cell numbers and 
enabling qualitative characteristics to be gathered. In the landmark publication 
described above, Asahara et al. described EPC as cells in vitro with the ability 
to adhere to fibronectin and form colonies (CFU - colony forming units) as early 
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as following 3 days in culture. Cells in culture were shown to have typical 
endothelial cell characteristics such as uptake of DiI-labeled acetylated low 
density lipoprotein (Dil-aCLDL) and expression of surface markers including 
CD31, KDR, CD34 and Tie-2 [12]. This initial study used CD34+ and KDR+ 
enriched cells in culture; however several investigators have subsequently 
utilised unfractionated mononuclear cells and included a pre-plating stage to 
increase specificity and exclude mature endothelial cells. This modified protocol 
identifies CFU between 4 – 9 days after culture termed „early-outgrowth‟ 
colonies or CFU-Hill [152] (see Figure 2).  
 
Figure 2 Endothelial cell colony forming unit [152] 
Another commonly used protocol identifies „late outgrowth‟ colonies 
derived from adherent mononuclear cells following 7 – 21 days in culture [210] 
(see Figure 3).  
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Figure 3 'Late outgrowth' CFU with typical cobbled appearance [210] 
Early and late outgrowth cells share a number of features including uptake 
of Dil-aCLDL and expression of CD31 but differ with regards to surface 
expression of CD133. They are likely to represent EPC at differing stages of 
maturation. It should be noted that EPC identified using cell culture are unlikely 
to represent the same cells identified using flow cytometry and the precise 
relevance to EPC in the in vivo situation remains unclear. Nonetheless, several 
groups have successfully utilised CFU number as a biomarker in several 
different disease states including CHD-related diseases and inflammatory 
rheumatic diseases.  
6.5.4 Role of EPC in vascular regeneration 
Prior to experiments conducted by Asahara et al in 1997, it was largely 
believed that „vasculogenesis‟ or the de novo formation of vessels from 
uncommitted precursor cells occurred only in the developing foetus.  It has 
since been demonstrated in several animal models that stem cell transfusion 
and systemic transfusion of expanded ex vivo EPC can induce functionally 
intact endothelial regeneration [174, 190, 316]. EPC induced vasculogenesis is 
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yet to be demonstrated in human models.  However within the setting of CHD, 
re-endothelialisation of „EPC-capturing‟ anti-CD34 coated coronary stents has 
been shown to have a beneficial effect in terms of stent re-stenosis [8]. In 
addition, fascinatingly, a recent case report has described treatment of critical 
limb ischemia with the injection of autologous peripheral blood CD133+ purified 
stem cells into the gastrocnemius muscle without any side effect resulting in 
limb salvage and symptomatic relief sustained at 17 months of follow-up [54].  
Further examination of the role of EPC in human vasculogenesis and factors 
influencing this process is required.         
  
6.5.5 EPCs and CHD risk factors 
Few studies have quantified EPC using flow cytometry in the context of 
cardiovascular risk factors. Vasa et al. demonstrated a significant reduction of 
CD34/KDR+ EPC in patients with CHD compared to healthy controls but also 
found a correlation of these cells to smoking and family history of CHD across 
all participants [352]. CFU-Hill formation has been the most widely used 
measure of EPC number and function in association with CHD risk factors. Hill 
et al. measured CFU number in 45 men with a mean (±SE) age of 50 (±2) years 
and demonstrated a negative correlation with the Framingham risk score (R2–
0.47, P=0.001). In addition, CFU were reported to be a better predictor of 
vascular reactivity (measured using flow-mediated brachial-artery reactivity) 
than traditional CHD risk factors [152]. Increasing age, total cholesterol, 
triglycerides, low HDL,  smoking and diabetes have also been shown to 
correlate with a reduction in EPC number in culture [63, 134, 189, 264, 339]. A 
58 
 
recent report has demonstrated CD34/KDR+ cells and CFU have a negative 
correlation with the metabolic syndrome [171]. Importantly there have been 
reports of enhancement of EPC number with pharmacological agents and these 
studied are discussed briefly below.  
6.5.6 EPCs and CHD disease  
    Werner et al. recently reported findings of a study examining 519 
patients with angiographically documented CHD.  Independent of 
cardiovascular risk factors including age and gender, increased 
CD34+/VEGFR2+ EPC level was associated with better outcome over a one 
year follow-up period. Patients with a higher EPC level had a reduced risk of a 
major cardiovascular event and death from a cardiovascular event [372].  
Schmidt-Lucke et al. compared 44 patients with stable CHD (no acute coronary 
syndrome for at least 3 months) with 33 patients with unstable angina and 43 
healthy (not matched for age) controls.  They demonstrated a reduction in 
CD34+/VEGFR2+ EPC number in patients with CHD compared with healthy 
controls and a negative correlation, independent of risk factors, between EPC 
number and cardiovascular events [303].  Shaffer et al. reported, in a small 
study, a reduction in CD133+, CD34+ and CD133+ /CD34+ cells in elderly 
patients with and without peripheral vascular disease compared to healthy 
younger adults [312].  Moreover, Fadini et al., demonstrated CD34+/VEGFR2+ 
EPC level has a negative correlation with carotid IMT (intima-media thickness) 
in healthy individuals, independent of risk factors [103].  In addition, EPCs levels 
have been shown to rise in the first few days following acute myocardial 
infarction and peak at 7 days post event [226, 315] which may suggest that 
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EPCs are mobilised as a repair mechanism in response to an acute stress.  
Therefore any study quantifying EPC in disease states should note the 
occurrence of recent coronary events to avoid skewing of results. 
Overall, several studies to date suggest that EPC number is independently 
associated with cardiovascular outcome and could be a clinically useful 
biomarker.  Further study is required to establish optimal surface markers for 
the identification of EPC.  Some studies have defined EPC as CD34+/VEGFR2+ 
cells, others as CD34+/ CD133+/ VEGFR2+and some have described an „early‟ 
population of cells as CD34-/ CD133+/ VEGFR2+.  CFU number provides a 
robust and uniform method of detecting EPC and has been shown to be a good 
biomarker in CHD and related risk factors.  
6.5.7 Other factors influencing EPC number and function  
    Endogenous factors that influence the number and function of 
EPC remain unclear and of much interest.  However, in addition to the 
pathological processes above, several other exposures have been shown to 
influence EPC levels. 
6.5.7.1 Lifestyle modification  
    The influence of tobacco smoking on EPC level is interesting.  
Chronic smoking as discussed above results in a reduction of EPC.  However 
low concentrations of nicotine have been associated with increased EPC levels 
[367], perhaps representing a physiological response to a low grade insult.  
Importantly, smoking cessation has been shown to result in a rise in EPC within 
4 weeks [189].  In addition, physical activity has been shown to increase EPC in 
both healthy individuals and patients with CHD [200, 299].  
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6.5.7.2 Pharmacological agents   
    HMG-CoA reductase inhibitors have been shown to increase the 
number of circulating EPC in a mouse model and this might be another 
mechanism by which statin medications exert a cardioprotective effect [90, 352].  
Angiotensin converting enzyme (ACE) inhibiting agents and angiotensin 2 
receptor blockers have also been shown to have a positive effect on EPC 
numbers [166, 238] and this has also been demonstrated within a diabetic 
population [207].  Chemokines and cytokines such as erythropoietin, GM-CSF 
and VEGF have also been shown to increase EPC levels [17, 121, 334].  These 
reports suggest that treatment of CHD risk factors can influence EPC number.   
6.5.8 EPCs and SLE  
Over the last 4 years since the commencement of this study, other groups 
have reported on EPC using flow cytometry in SLE. As described above these 
groups have used a combination of CD34, CD133 and KDR to identify EPC.  
Westerweel et al. studied 15 females with SLE aged 37 (3) years with 
inactive disease for at least a year prior to the study and taking low doses of 
prednisolone (<10mg) compared to 15 age matched healthy females aged 37 
(3) years. They demonstrated a reduction of the overall CD34 fraction of cells 
described as haematopoietic stem cells as well as a reduction of CD34+KDR+ 
EPCs in SLE patients compared with healthy controls. EPC number correlated 
positively with ankle brachial pressure index (R2=0.532, p=0.042) and inversely 
with cholesterol level (R2=-0.587, p=0.021). There was no association with 
disease related factors including disease activity, therapy or serological 
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findings. CFU-Hill formation was not different between the two groups and the 
influence of CHD risk factors was not assessed [373]. 
Denny et al. defined EPC as CD34/CD133+ cells in SLE compared to 
controls. The overall cohort consisted of 135 SLE patients aged 38 (3) years 
and 60 controls aged 41 (1) years. It should be noted 55% of the controls were 
females compared with 95% of SLE patients. The proportion of participants 
included in subgroups of the study is not reported. They found a reduction of 
EPC in SLE compared to control which remained statistically significant when 
limiting the analysis to females only. In addition they documented a correlation 
of EPC with the SLEDAI (R2=0.42, p = <0.01). Other disease related factors and 
CHD risk factors were not correlated. Interestingly this study demonstrated SLE 
EPC have increased Interferon-α (IFN-α) expression in culture compared with 
controls.  Denny et al.  propose the increased levels of IFN-α in SLE EPC 
suggest IFN- α  may potentiate abnormal vascular repair in SLE [88]. 
Moonen et al. I studied CD34/CD133+ EPC in 44 SLE patients aged 40 ± 
12 years and 35 age-matched female controls aged 41 ± 12 years. They 
demonstrated a reduction of CD34/CD133+ EPC and CFU-Hill in SLE 
compared to controls. No correlation was noted between EPC or CFU number 
with regard to disease-related factors. CHD-related factors were not analysed 
[242]. 
All these studies consistently noted a reduction of EPC in SLE but varied 
with regards to clinical correlates. The populations studied were of a similar 
age. Possible explanations for the discrepancy of the findings between different 
studies may be related to small sample sizes or due to the differences within the 
study population such as ethnicity, therapies, disease activity or differences in 
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disease phenotype. More recently other groups have been unable to 
demonstrate a difference in EPC as measured by flow cytometry and therefore 
focussed on CFU formation.  
Grisar et al. reported on 31 SLE females aged 35 (± 2) years compared   
14 healthy female controls aged 39 (± 5) years.  They found no difference in 
CD34/CD133/KDR+ cells between SLE and controls. EPC did appear to 
correlate with previous renal disease but not with other clinical parameters. 
They also reported on CFU number in 13 SLE patients and 12 controls and 
found CFU number was similar between the 2 groups. However, they reported a 
reduction in migratory and adhesive properties of cells in SLE patients [135]. 
Ablin et al. reported no significant difference in CFU number of 28 SLE 
patients aged 38 (15) years and 50 controls aged 43 (18) years [3].  SLE 
patients included males and patients with a prior history of high dose steroid, 
cyclophosphamide or MMF use were excluded suggesting the group studied 
were of a „milder‟ phenotype. Ablin and colleagues did note an impaired 
adhesion of cells to fibronectin in SLE patients which was interpreted as a 
marker of impaired function. CFU number or adhesion scores did not vary with 
disease activity.   
Lee et al. enumerated CFU-Hill from 70 SLE patients aged 35 (27–45) and 
31 control aged 36 (26.5–44) years.  Ninety-two percent of SLE patients were 
female compared to 84% of the controls. They demonstrated a significantly 
reduced number of CFU in SLE compared to controls which was independent of 
leucopoenia. They also quantified CD34/KDR+ cells using flow cytometry and 
also demonstrated a reduction in SLE compared to controls. Neither 
CD34/KDR+ cells nor CFU were found to have any significant correlation to 
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disease-related factors or CHD risk factors.  CFU did however have an inverse 
correlation with CRP.   This group measured expression of an interferon 
inducible gene, MX1 as a surrogate for serum IFN-I levels. PBMC of SLE 
patients were found to have significantly increased expression of MX1 
compared to controls. MX1 levels were also found to have an association with 
CFU in SLE.  In addition, cell culture with recombinant IFNα2 resulted in a dose-
dependent reduction of CFU number. The authors conclude type IFN can be 
regarded as a novel risk factor for EPC depletion and endothelial dysfunction in 
SLE [201].  
Lastly, Ebner et al. measured EPC in 19 SLE females aged 36 (6) years 
and 19 female controls aged 37 (8) years.  They demonstrated reduced 
CD34//KDR+ cells in SLE but increased level of CD133/KDR+ cells compared 
to controls. Clinical correlates were not analysed. The authors suggested low 
levels of endothelial damage may result in increased mobilisation of immature 
CD133/KDR+ cells in cells [93].  
Overall studies of EPC measured using flow cytometry have consistently 
demonstrated a reduction in CD34/KDR+ cells compared to controls[93, 201, 
373]. Two studies have also demonstrated a reduction in CD34/CD133+ cells 
[88, 242]. Grisar et al. al measured the smaller population of 
CD34/CD133/KDR+ cells and found no difference between SLE and controls. 
All studies had small sample sizes but the larger of these studies demonstrated 
a reduction in CFU in SLE compared to controls [201, 242]. The smallest of the 
studies and that which included patients with a mild phenotype did not find any 
difference in CFU number in SLE patients suggesting that CFU number may be 
related to overall inflammatory burden over time. Studies to date have been too 
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small to detect clinical correlates to EPC or CFU. An interesting link between 
type I IFN and CFU is emerging within the SLE population and may provide a 
mechanistic explanation for some observations as well as a potential 
therapeutic target to attenuate EPC/CFU abnormalities observed.  
 
6.5.9 Inflammatory or damaged endothelial cells in SLE  
   Somers et al. measured apoptotic endothelial cells with CD146/Annexin 
V surface markers in 75 patients with SLE and reported a correlation with 
carotid IMT but not with lupus-related factors such as disease activity, damage 
or duration or with serum markers of vascular damage [323].  In keeping with 
the findings of Somers et al. two other groups have reported increased 
circulating levels of damaged endothelial cells (EC).  Clancy et al. reported 
increased levels of circulating EC positively stained for P1H12 (identifying 
CD146+ cells) in 38 patients with SLE compared to 16 healthy controls [70] and 
Rajagopalan et al. reported increased CD146/Annexin V positive cells in 43 
patients with SLE compared to the same number of age-matched healthy 
controls and older patients with known CHD.  In addition, EC number in this 
study were found to correlate with brachial artery flow-mediated dilation, a 
marker for endothelial dysfunction [281].  
   These preliminary studies lend support to the theory that an imbalance 
in EC subpopulations with evidence of increased EC apoptosis and reduced 
numbers of EPC in patients with SLE leads to a reduced vascular regenerative 
capacity and endothelial dysfunction. Further investigation is required to 
determine factors associated with endothelial cell abnormalities in SLE. Studies 
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of clinical and subclinical atherosclerosis in SLE using carotid scanning would 
suggest age is a significant contributing factor in SLE and that on average 
atherosclerosis occurs earlier in SLE than controls. Most studies to date 
examining EPC have matched for age and therefore the contribution of age has 
not been explored.   
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6.6 Telomeres and cellular senescence  
6.6.1 Telomere structure and function  
The unique structures that form the physical ends of linear chromosomes 
were first reported in the 1930s.  McClintock et al. noted that, unlike broken 
ends, the natural ends of maize chromosomes appeared to be protected from 
forming random attachments to other fragments of chromosomes [230].  In the 
late 1930s these highly conserved repetitive DNA-protein complexes of 
hexanucleotide sequences were given the name „telomeres‟ originating from the 
Greek words ‘telos’ meaning end and „meros‟ meaning part [245] (Figure 4).  
 
Figure 4 Telomeres at chromosome ends demonstrated using quantitative 
fluorescence in situ hybridization (Q-FISH). Adapted from Oeseburg et al.  
[257] 
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 The DNA sequence of human telomeres was identified in the 1980s, as 
repeats of TTAGGG, highly conserved in evolution [244].  Human telomeres are 
constituted by tandem DNA repeats ending with a 150 to 200 nucleotide G-rich 
3‟ single-stranded overhang and associated proteins [68, 80, 386]. The G-rich 
single strand is protected by a complex of proteins. Whilst several associated 
proteins including those involved in DNA synthesis have been demonstrated in 
the telomere region, there are thought to be six proteins that are specific to 
telomeres. These telomere-specific proteins, TRF1, TRF2, hRap, TIN2, POT1 
and TPP, form the protective complex termed shelterin [43, 81, 185, 208, 213, 
386] (see Figure 5). The proteins contained within shelterin are able to bind 
double stranded DNA enabling the formation of a loop-like structure termed the 
telomere- or T-loop. POT1 specifically has been shown to bind single stranded 
DNA and is thought to bind to the G-rich overhang forming a lesser loop termed 
the displacement or D-loop, thereby protecting the structure from the enzyme 
telomerase (see below) involved in telomere elongation [202]. It is likely the 
protein complex is a dynamic structure that undergoes conformational changes 
during the different phases of the cell cycle to enable elongation, protection and 
regulation of the telomere [203, 204].    
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Figure 5 Schematic of telomere structure and associated proteins of 
shelterin complex  
 
The length of telomeres in human cells varies between tissue types and is 
typically between 5 and 15kb in somatic cells [244]. Importantly, DNA 
polymerases are unable to replicate the DNA lagging single strand of 
chromosomes ends.  As a result of which, telomeres shorten with cell division, a 
process referred to as the „end-replication problem‟. With each cell division it is 
approximated between 50 and 150 base pairs are lost and this loss is 
cumulative.  Therefore, the mean length of telomeres can provide an estimate 
of the replicative age of a cell [144, 163].  Somatic cells appear to have a finite 
replicative life span often referred to as the Hayflick limit [147].  Telomere 
erosion beyond a critical length leads to loss of protection of chromosomes 
resulting in genomic instability, degradation or end to end fusion.  This 
chromosomal dysfunction will result in proliferative senescence i.e. cessation of 
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replication or cell apoptosis or less frequently, undergo continued proliferation 
and develop tumourogenic potential [328].  The mechanisms that trigger these 
processes remain unclear.  For any given cell it might be that a threshold 
number of short telomeres are required or alternatively perhaps the length of 
the shortest telomere in the repertoire is the important factor.   
6.6.2 Mechanisms of telomere attrition 
There is also a great deal of uncertainty regarding the mechanism(s) by 
which telomere attrition leads to cell cycle arrest or senescence.  One of the 
potential mechanisms is thought to be via activation of the transcription factor 
p53.  Expression of p53 is initiated by cellular assaults such as oxidative stress 
or DNA damage.  Expression of p53 can lead to the activation of several genes 
and ultimately lead to cellular senescence enabling DNA repair processes or 
apoptosis [178] [138].  In a mouse model the effects of telomere attrition has 
been found to be linked to p53 status.  In the presence of p53, shortened 
telomeres and subsequent exposed or damaged DNA do not result in malignant 
transformation of cells and induce an „aged‟ phenotype i.e. premature greying or 
reduced wound healing [132, 294].  However, in the absence of p53, genomic 
instability induced by telomere attrition leads to accelerated tumourogenesis 
[66].  This would suggest that telomere attrition and involvement with p53 is an 
important safeguarding mechanism against tumourogenesis despite the 
disadvantage of leading to „ageing‟.  
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6.6.3 Determinants and maintenance of telomere length 
Telomere length between individuals of the same age can be highly 
variable [260, 335].  The mean length of an individual‟s telomeres of a given 
cell/tissue type at any given time will be influenced by many factors.  Marked 
variation of telomere length at birth between individuals is observed and the 
influence of foetal or stem cell telomere length may be of importance.  There is 
much uncertainty about the factors that influence the determinants of variation 
of mean length of telomeres between individuals.  Interestingly, in the case of 
peripheral blood mononuclear cell (PBMC) telomere length, there appears to be 
some genetic influence [128, 254].  Analysis of 115 monozygotic and dizygotic 
twin pairs between the ages of 2 and 95 years indicated 78% heritability [320].  
There are likely to be several environmental factors that influence the rate of 
replicative senescence of a cell and some of these are discussed below.  In 
addition to these factors that impact on the rate of telomere erosion, telomere 
length will also be influenced by mechanisms that are present to maintain 
telomere length.   
6.6.4 Telomerase and telomere maintenance  
 An important mechanism involved in the maintenance of telomeres 
involves the enzyme telomerase. Components required for the active 
telomerase complex are telomerase reverse transcriptase (TERT) protein and 
the telomerase RNA component, often referred to as TERC (Figure 6). The 
RNA component of this unique enzyme complex provides a template for de 
novo addition of telomere repeats [133].   
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Figure 6 Telomerase structure demonstrating de novo addition of base 
pairs using the hTERC template 
 
 
The TERT component of the complex appears to have an essential 
catalytic role [370].  Although human somatic cells express telomerase RNA, 
telomerase activity is absent from most of these cells and this leads to the 
gradual telomere attrition incurred with cell division.  The inactivity of telomerase 
in this context is usually associated with the absence of TERT [39, 279].  
Telomerase is known to be expressed in some human germ cell lines [234], 
epithelial and haematopoietic cell lines [67] and activated lymphocytes [153].  
Interestingly, the expression of telomerase appears to cease at some stage 
during differentiation [10, 109]. In those cells containing telomerase, DNA 
elongation is thought to occur in the S-phase of the cell cycle and access to the 
telomere is thought to be regulated by the telomere protein complex [227].  
Tumours present an interesting model in which to study telomere 
elongation mechanisms. The majority of tumours express active telomerase and 
maintain stable telomeres with proliferation [184] however, this is not the case in 
all tumour types [50].  Additionally, other conditions exhibit telomere 
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maintenance in the absence of telomerase.   Cells from individuals with Werner 
Syndrome, a condition characterised by premature ageing, do not exhibit 
telomerase activity and have been found to have stable telomere lengths.  This 
leads to the notion that there are non-telomerase dependant pathways capable 
of maintaining telomere length and these have been termed alternative 
lengthening of telomere (ALT) [199].  Further elucidation of ALT pathways was 
possible when a telomerase deficient yeast model was developed and it was 
observed that whilst most telomerase deficient cells died a small subpopulation 
regained replicative potential by recombination of telomeric tracts.  These 
chromosomal rearrangements were found to be dependant on 2 different 
genes, RAD50 and RAD51.  Strains deficient of these genes lost the survival 
advantage [215, 216].  To date however, equivalent genetic predispositions in 
replicating human telomerase-defective cells have not been identified. 
6.6.5 Telomere length variation with age  
The relationship between telomere shortening and age can be 
demonstrated in telomerase-deficient mice that develop rapid telomere attrition. 
In vitro studies in mouse models can provide an insight into the consequences 
of reduced proliferative capacity of cells and the potential regenerative role of 
telomerase.  Mice with telomerase deficiency develop age-related disease such 
as infertility, heart failure, immunosenescence-related diseases and decreased 
tissue regeneration (digestive system, skin and haematopoietic system) [36, 37, 
148, 206].   
Correlative evidence from in vitro studies in premature ageing syndromes 
also provides evidence for variation of telomere length with ageing in humans.  
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Such models, however, require caution as in vitro cells are unlikely to accurately 
reflect the in vivo situation.  Dyskeratosis Congenita is a rare genetically 
heterogeneous syndrome characterised by premature mortality related to bone 
marrow failure, infections, fatal pulmonary complications or malignancy.  Cells 
from individuals with this condition have been found to have a lower level of 
telomerase RNA, produce lower levels of telomerase activity and have shorter 
telomeres than cells from matched controls [239, 360].  Werner Syndrome is a 
rare autosomal recessive syndrome characterised by development skin atrophy, 
greying of hair and onset of cataracts, osteoporosis, diabetes and malignancies, 
typically following puberty and resulting in early mortality.  Cells from subjects 
with this syndrome also exhibit shortened telomeres compared to age-matched 
controls and interestingly, in vitro, the life span of these cells can be extended 
with the introduction of telomerase [39, 353].  Additionally, cells from older 
donors do appear to undergo replicative senescence in culture more rapidly 
than cells from younger donors indicating that telomere length does reflect 
chronological ageing [144, 304].   
Accumulating epidemiological evidence would also suggest that telomere 
length declines with human ageing. It is thought that telomere length varies 
greatly between individuals at the extremes of age and can be relatively stable 
in healthy humans during adult life as demonstrated in Figure 7. Of interest, a 
study examining the mean length of telomeres of peripheral blood cells of 812 
individuals aged between 70 and 100 years of age did not find any association 
between telomere length and survival [32].  Similar findings are reported in 598 
individuals over the age of 85 years [225].   Genomic instability in the „very old‟ 
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is likely to be multifactorial and the effects of telomere length may be less 
significant in this context.   
 
Figure 7 Results of calculated median telomere length in lymphocytes and 
granulocytes of 400 normal individuals over the entire age range 
(Baerlocher and Lansdorp, unpublished data) cited by Aubert et al.  
 
Additionally some studies have suggested there are gender and ethnicity 
differences with females and African Americans having longer telomeres [65, 
164]. Difficulties arise in study design as telomere length is highly variable 
between species as well as between individuals within the same species but 
also between different cells within the same organism [65]. Much of the 
evidence relating to human ageing and telomere length is based on cross-
sectional studies. The results of such studies present the potential issues of 
cohort effect and censorship with the risk of missing those people with the 
shortest telomeres due to death prior to sampling.  Longitudinal studies can be 
difficult to conduct as telomere length changes slowly over time and owing to 
the wide variation, large samples sizes would be required to attain meaningful 
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results and as such there are no prospective population studies examining age-
dependent telomere attrition in „healthy‟ individuals. 
 Many questions remain unanswered.  It is not known if premature ageing 
of cells is caused directly by telomere length reduction or both phenomena are 
driven by a common process.  Also it is unclear if it is possible to modify the 
mean telomere length of human tissue in vivo or in fact whether such an 
alteration would have an effect on the entire organism. The importance of mean 
cellular telomere length with regards to whole organism senescence remains an 
area of much interest.    
6.6.6 Measuring telomere length  
6.6.6.1 Techniques for measurement of telomere length  
Cell population telomere length has been quantified using three main 
methods namely Southern blotting, quantitative polymerase chain reaction 
(qPCR) and in situ hybridization methods (Q-FISH and flow FISH). Previously 
the most commonly used of these techniques was Southern blotting to estimate 
absolute values of telomere repeats. However there are several disadvantages 
to this method including the requirement of relatively large amounts of DNA, 
long length of time required to carry out the technique and the potential to 
underestimate the length of telomeres [18].  Q-FISH uses a peptide nucleic acid 
probe to visualise telomeres in metaphase spreads. Since cells approaching 
senescence are less able to enter mitosis, this method can lead to variable 
results in a mixed population of cells (i.e. senescent and proliferating). In 
addition, specialist knowledge and equipment is required to perform this 
technique [295]. Real-time qPCR presents a much faster method of telomere 
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length measurement. This method uses modified PCR primers to avoid the 
formation of primer-dimers as far as possible. The final measure is a relative 
telomere length expressed as a ratio of telomere quantity to a single copy gene 
quantity (T/S).  Advantages of this method are that relatively small amounts of 
DNA are required and a large number of samples can be measured in a short 
time [57]. The main disadvantage is that the measure attained is relative 
telomere length and therefore whilst valid within a population, comparisons 
between populations cannot easily be made.  Measurements of telomere length 
using qPCR have been shown to have a good correlation to measurements 
using Southern blotting [45, 56] and therefore this technique is increasingly 
utilised.  
6.6.6.2 Choice of cell population  
 The techniques available to measure telomere length have the potential 
to allow measurement of cell populations, single cells or single chromosomes. 
Peripheral blood mononuclear cell (PBMC) telomere length has been measured 
extensively to study both ageing in normal populations and in disease states. 
PBMC telomere length measurement has the advantage of being relatively easy 
to obtain from study participants as it can be measured from a few millilitres of 
peripheral blood and can be easily processed. Several studies measuring 
PBMC telomere length have been shown to have a correlation to ageing and to 
disease states and therefore PBMC telomere length appears to be a marker for 
disease.  
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6.7 Association between telomere length, CHD and risk factors 
Cardiovascular disease and CHD risk factors are major contributors to 
age-related morbidity and mortality in the general population and as such the 
association of telomere length, a marker of senescence, is of particular interest 
in this subject. There is a growing body of evidence in both animal and human 
studies that telomere length is associated not only with clinical CHD but also 
risk factors associated with CHD.    
6.7.1 Telomere length and CHD risk factors  
Several studies have explored the association of telomere length with 
cardiovascular risk factors and some of these studies are summarised in Table 
5.  There are several small studies indicating an inverse correlation between 
telomere length and most cardiovascular risk factors. Brouilette et al. 
demonstrated in a case control study of 203 patients with a premature MI (<50 
years) and 180 controls, that hypertension, diabetes smoking status and serum 
cholesterol did not account for reduced telomere length in cases vs. controls 
[44].  Patients with SLE have been shown to have an excess of traditional 
cardiovascular risk factors [269] and to what extent these factors account for 
telomere attrition observed in SLE will be addressed in the current study.  
Despite the findings of many correlative studies the question remains 
whether telomere attrition is a cause or consequence of CVD.  Supporting 
evidence for causation is provided by studying the TERC-deficient mice.  
Amongst other features of premature ageing these mice develop cardiac 
dilatation and heart failure [206].  Although, given that telomere maintenance 
can occur in the absence of telomerase, this mouse model could be considered 
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to be informative about the effects of telomerase deficiency rather than the 
effects of telomere ablation per se.  Nonetheless, several studies suggest that 
PBMC telomere length appears to correlate with CHD risk factors. 
Table 5 CHD risk factors & telomere length 
CHD Risk Factor Cell/Tissue Type Main Findings Reference 
Gender / oestrogen 
Rat kidney, liver, 
pancreas, lung, brain 
tissue 
Reduced telomere 
length in males vs. 
females in all tissue 
types except brain 
Cherif 2003 [65] 
 Human WBC* 
Age-adjusted
 
telomere 
length longer in women 
than in men 
Benetos 2001 [24] 
Diabetes mellitus Human WBC* 
Reduced telomere 
length of monocytes 
from type 2 diabetic 
patients vs. controls 
Sampson 2006 [298] 
 Human WBC* 
Weight gain and insulin 
resistance associated 
with accelerated 
telomere attrition 
Gardner 2004 [117] 
 Human WBC* 
Age- adjusted telomere 
shorter in type 1 
diabetes vs. non 
diabetic controls 
Jeanclos 1998 [169] 
Hypertension Human WBC* 
Inverse correlation 
between pulse pressure 
and telomere length 
Jeanclos 2000 [170] 
 Human WBC* 
Shorter telomere length 
associated with 
hypertension, increased 
insulin resistance and 
oxidative stress 
Demissie 2006 [84] 
 
Telomerase deficient 
mice 
TERC deficient mice 
exhibit increased 
plasma endothelin-1 
levels and higher 
systolic and diastolic 
blood pressure 
compared with wild type 
mice 
Perez-Rivero 2006 [265] 
Obesity Human WBC* 
Inverse correlation of 
telomere length with 
BMI. Also shorter 
telomere length in 
smokers and ex 
smokers vs. non 
smokers 
Valdes 2005 [350] 
Hypercholesterolemia Human WBC* 
No significant 
relationship between 
telomere length and  
cholesterol 
Brouilette 2003 [44] 
Smoking   See above – Valdes 
 Human WBC* 
In COPD§ patients - 
reduced telomere length 
of smokers compared to 
non smoking patients 
Morla 2006 [243] 
*WBC – white blood cells; §COPD – chronic obstructive airways disease 
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6.7.2 Telomere length and carotid atherosclerosis  
A recent large study within the Framingham cohort of 496 men and 566 
women has demonstrated a significant negative association to carotid IMT with 
PBMC telomere length. Following adjustment for several factors, telomere 
length remained significantly associated to obesity in men. A further study 
measured carotid IMT in 762 volunteers and found a significant association that 
persisted after adjustment for age and CHD risk factors. In the gender stratified 
analysis, the association remained only in the male cohort [255, 262].      
Two recent small studies within a hypertensive cohort and a diabetic 
cohort have demonstrated significant reduction in PBMC telomere length in 
those with carotid plaque compared to those without [6, 23].      
6.7.3 Telomere length and CHD 
   Recent studies have examined the role of PBMC telomere length in 
clinical CHD. Brouilette et al. reported significantly reduced telomere length in 
white blood cell (WBC) DNA from 203 patients with MI under the age of 50 
years compared to 180 controls and this was independent of traditional risk 
factors.  In contrast to studies indicating telomere length has a poor correlation 
with clinical outcome in elderly individuals, Cawthon et al. found, in a 
longitudinal study, mortality in persons aged over 60 years from a cardiac cause 
was highest in the proportion of individuals with the lowest WBC telomere 
length [57].  Similarly, a case control study of 20 patients with severe CHD and 
20 healthy individuals reported significantly reduced WBC telomeres in cases 
compared to controls after adjusting for age and gender [297].  A recent 
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prospective study followed 484 individuals that subsequently developed CHD 
events and 1058 individuals that remained CHD-free.  The risk of CHD was 
found to be significantly higher in patients with mean telomere length (measured 
at baseline) within the middle and lowest tertiles compared to the highest tertile. 
In addition, when patients were stratified for pravastatin therapy this risk 
appeared to be attenuated despite similar lipid levels between the three groups 
[45].  
   The concept that atherosclerosis is an inflammatory process has 
become widely accepted in recent years [142].  It might be that WBC telomere 
attrition is a reflection of a systemic inflammatory response or alternatively it 
might be representative of a more general premature ageing process and 
increased susceptibility to CHD.  Alternatively enhanced telomere attrition may 
be the result of subclinical atherosclerosis and is therefore apparent prior to the 
onset of clinically apparent CHD.   
6.7.4 Telomere length of endothelial cells 
  Endothelial dysfunction is recognised as the earliest pathology in the 
formation of atheroma. There is an emerging body of evidence suggesting that 
endothelial cells may exhibit a reduction in telomere length. A small 
comparative study examining coronary endothelial cells obtained during post 
mortems from 11 patients with CHD found that these cells had shorter telomere 
length when compared to samples obtained from the coronary arteries of 22 
non-CHD patients [258]. Chang et al. also examined specimens retrieved at 
post mortems or after coronary artery bypass surgeries.  They reported that 
increased telomere erosion in vessels correlated with age.  In addition, they 
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reported increased telomere erosion in cells from the iliac artery (a vessel 
thought to be exposed to high haemodynamic stress) compared to cells from 
the iliac vein or internal thoracic artery [62].  
In conclusion, telomere length reduction has been to be significantly 
associated with CHD and CHD-related risk factors independently of age.  
Emerging evidence suggests that telomere attrition and premature cellular 
senescence might be a potential mechanism by which endothelial dysfunction 
occurs.   
6.8 Telomere length and SLE 
To date there have been a few preliminary studies examining the 
association of telomere length and telomerase in SLE.  
 Kurosaka et al. measured telomere length of PBMC using Southern 
blotting in 30 SLE patients including 3 males, aged 38 (±11) years and 39 
controls including 3 males aged 40 (±11) years. They demonstrated a 
significantly reduced telomere length in SLE patients compared to controls 
under the age of 40 years. Telomere length tended to be similar in older SLE 
patients and age-matched controls suggesting premature ageing of PBMC in 
the younger SLE age group. The report did not include correlations of telomere 
length to clinical measures [194]. Kurosaka et al. also reported increased 
peripheral blood mononuclear cell (PBMC) telomerase activity in 55 patients 
with SLE aged a mean (SD) of 39 (±13) years and 45 healthy controls 42 (±13) 
years and demonstrated increased telomerase activity in SLE patients 
compared to controls on all age groups.  Telomerase activity within the SLE 
population was significantly correlated with disease activity measured using a 
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modified SLEDAI (i.e. SLEDAI excluding complement and anti-dsDNA antibody) 
with a Spearman‟s correlation coefficient (R2) of 0.524 (p<0.0001). Other 
significant correlations to telomerase activity were haemoglobin level (R2 -0.246, 
p = 0.038), CRP (R2 0.325, p = 0.007) and C4 (R2 -0.477, p = 0.005). No 
significant correlation was demonstrated with total white cell count or 
lymphocyte count [195].  The same group further elaborated this work and 
measured telomerase activity in 37 SLE patients compared with 17 healthy 
controls and found that B cell telomerase activity was significantly higher in 
patients with active SLE (SLEDAI > 6) compared with patients with inactive 
disease or healthy controls. However T cell telomerase activity was increased in 
SLE patients regardless of disease activity compared with healthy controls.  In 
addition, T lymphocyte telomere length was reduced in SLE patients vs. 
controls but no significant difference was noted with B cell telomere length 
[196].  These findings might suggest that there is continuous T cell activity in 
SLE and increased telomerase activity but this is inadequate to maintain 
telomere length. However in active disease, B cell activation and division occurs 
and increased telomerase activity is able to maintain telomere length in this 
population of cells.   
Klapper et al. measured telomerase activity of CD19+, CD4+, and CD8+ 
lymphocytes isolated from the peripheral blood of 9 patients with SLE and 9 
age-matched healthy controls (details of age not published).  Similar to the 
findings of Kurosaka, Klapper et al. found increased telomerase activity in B 
cells and T cells in the SLE patients [187]. This group attempted to measure 
telomere length using Southern blotting in these cells but owing to high DNA 
requirements for this technique, were only able to assess telomere length of 
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CD4+ cells in 6 SLE patients and 5 healthy controls and did not demonstrate a 
difference.  
 A larger study by Honda et al. measured telomere length of PBMC using 
Southern blotting in 58 SLE patients and 51 controls. They found a reduction in 
telomere length in SLE compared to controls in the overall analysis which was 
particular marked in those under the age of 45 years and abrogated in those 
over 55 years. Correlations to potential contributing factors was not analysed in 
this small study [160].  
Wu et al. measured PBMC telomere length using Southern blotting in 60 
SLE patients with a median (range) age of 34 (16 – 76) years and 26 gender-
matched controls aged 30 (29 – 79) years. They demonstrated an overall 
reduction in telomere length in SLE patients compared to controls which was 
particularly marked in those under the age of 45 years. The multivariable 
analysis of selected factors that may influence telomere length demonstrated a 
significant negative correlation with age and a trend towards a negative 
correlation with SLEDAI and immunosuppressant use in the previous 6 months 
[376]. 
Beier et al. used flow-FISH to measure telomere length of PBMC in 22 
SLE patients and 20 controls (details of age not reported). Using this technique 
no difference in telomere length was noted in lymphocyte subpopulations 
between SLE and control. Neither were there any significant correlations of 
clinical features to telomere length within the SLE group [22]. The authors noted 
there was no correlation between telomere length and lymphocyte count.  
    Overall there would appear to be a reduction in PBMC telomere length 
in SLE compared to controls [160, 195]. Studies that have analysed telomere 
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length of lymphocyte subpopulations have not found a significant reduction in 
SLE compared to controls [22, 187, 196]. The studies reported by Wu et al. and 
Beier et al.  analysed a limited number clinical factors based on prior knowledge 
and assumptions of possible associations with PBMC telomere length and did 
not demonstrate any significant correlations. Importantly, several studies have 
demonstrated that there is no correlation between lymphocyte count and 
telomere length in SLE. In addition, no correlation was noted between disease 
activity and PBMC telomere length suggesting that telomere length is not simply 
a reflection of immune cell turnover. It should be noted that the majority of 
patients studied had low disease activity. All of the above reports had relatively 
small sample sizes and not all controls were gender matched. However, these 
preliminary results do suggest a reduction in PBMC telomere length in SLE 
compared to controls that is particularly marked in those under the age of 45 
years. None of the studies measured atherosclerosis markers or CHD risk 
factors in SLE.  
6.9 Telomeres and telomerase activity in other inflammatory 
rheumatic diseases 
Lymphocyte activation and proliferation are the hallmark of many 
inflammatory rheumatic diseases such as rheumatoid arthritis.  Telomerase has 
the ability to initiate indefinite cellular proliferation as in the case of malignancies 
and telomerase activity has been shown to be increased in activated 
lymphocytes from healthy individuals [371].  These observations have 
stimulated some interest in the role of telomerase and telomere length in 
immune function of patients with inflammatory rheumatic diseases.  
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6.9.1 Systemic sclerosis  
Interestingly a small study comparing patients with connective tissue 
diseases and 10 patients with Hepatitis C and abnormal liver function tests 
found that telomerase activity could be detected in 11/17 (64.7%) patients with 
SLE, 6/11 (54.5%) patients with Sjogren‟s syndrome, 7/11 (63.6%) of patients 
with mixed connective tissue disease and 6/11 patients with systemic sclerosis 
but no telomerase activity could be demonstrated in the Hepatitis C group.  This 
would suggest that the autoimmune nature rather than inflammatory component 
of connective tissue diseases might have an effect on telomerase activity [179].  
Artlett et al. found reduced telomere length in 43 patients with systemic 
sclerosis and in their 182 family members compared to 96 age-matched 
controls [11].  Interestingly, a proportion of these family members were spouses 
indicating that in some cases there might be significant influence of 
environmental factors on telomere length such as tobacco usage.   
6.9.2 Rheumatoid arthritis (RA) 
Small controlled studies have demonstrated telomere length reduction in 
the PBMC, osteoblasts, synovial lymphocytes and CD34+ haematopoietic 
progenitor cells in patients with RA [89, 326, 383].  The findings reported with 
regard to telomerase activity however are conflicting with increased and 
reduced activity reported compared to controls [114, 382].  Of particular interest 
in the rheumatoid arthritis population is the association of telomere length and 
HLA haplotype.  The presence of the HLA-DRB1 shared epitope is believed to 
convey susceptibility to RA and in particular to disease severity [127, 251, 325].  
The two widely hypothesised explanations for this association previously were 
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the possibility of presentation of an „arthritogenic‟ peptide or induction of 
autoreactive T cell responses.  In view of the diversity of the structure of these 
molecules and lack of collaborative evidence, these theories appear to be 
unlikely.  Interestingly, Schonland et al. have reported that the HLA-DRB1*04 
haplotype is associated with telomere shortening in a small sample of patients.  
Both healthy individuals (n=37) and those with RA that were HLA-DRB1*04+ 
had reduced telomere length compared to HLA-DRB1*04 – individuals [306].  
More recent data on a larger cohort (176 RA patients vs. 1151 healthy controls) 
has also reported that short telomeres correlate with shared epitope status in 
RA but not in controls.  Also there was no correlation with disease duration or 
disease activity estimated using the CRP [326].  These studies might provide a 
new insight into the role of the shared epitope and susceptibility to RA.  
Interestingly, Schonland et al. also found that reduced telomeres were not 
isolated to T cells but also found in granulocytes suggesting that senescence is 
predetermined at the haematopoietic stem cell level. These data may suggest a 
genetic susceptibility to premature senescence in several cell lines and lend 
support to the theory that patients with connective tissue diseases might be 
genetically predestined to develop disease in several different organ systems 
and environmental exposures might enhance/trigger that risk.   
In keeping with the SLE studies of telomere length, studies have 
demonstrated a reduction in telomere length but not demonstrated an 
association of disease activity and inflammatory burden with telomere length. 
The findings would suggest other unmeasured factors may contribute to 
telomere length. Studies to date have not examined telomere length in the 
context of atherosclerosis in the rheumatic diseases.   
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7 Hypothesis  
There is premature biological ageing in patients with SLE as evidenced by 
a reduction in the mean telomere length of PBMC. Premature biological ageing 
is also evident in the vasculature of patients with SLE and reflected by relatively 
shortened telomeres of cells involved in vascular repair and regeneration i.e. 
endothelial progenitor cells (EPC).  Furthermore, senescent EPC result in 
cellular imbalance with a relatively reduced number and/or function of 
circulating healthy EPC.  
8 Aims and objectives  
Overall aims  
1. Describe demographic and clinical features of study cohort  
2. Describe the burden of carotid atherosclerosis in the study cohort 
3. Describe progression of carotid atherosclerosis in SLE cohort longitudinally   
4. Measure EPC in SLE compared to healthy controls in a cross-sectional 
study, ascertain potential contributing factors and correlation to subclinical 
atherosclerosis   
5. Measure telomere length of SLE patients compared to healthy in a cross-
sectional study, ascertain potential contributing factors and correlation to 
subclinical atherosclerosis   
6. Develop a method and measure telomere length of EPC in SLE compared to 
healthy controls in a preliminary cross-sectional study 
The objectives of individual chapters will be summarised at the beginning of 
each chapter.  
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9 General methods  
9.1 Study design, venue and funding 
This is a cross sectional, secondary care based observational study.  All 
participants were assessed at a single central site (the Wellcome Trust Clinical 
Research Facility, Manchester Royal Infirmary).  All laboratory experiments 
were conducted at the University of Manchester.  The study was funded by a 
clinical research fellowship from the Arthritis Research Campaign.    
9.2 Ethical approval  
Ethical approval was secured for the study from the National Research 
Ethics Service (see Appendix 1).  Local approval was obtained from each of the 
participating centres, namely, South Manchester Hospital Trust, East 
Lancashire Hospitals NHS Trust, Stepping Hill Hospital, North Manchester 
General Hospital and Blackpool, Fylde and Wyre Hospitals NHS Trust.   
9.3 Patient recruitment  
Rheumatology centres across the Northwest region of the UK were invited 
to suggest patients with SLE for the study.  The majority of participants were 
recruited from one centre (Central Manchester and Manchester Children‟s 
University Hospital NHS trust). The study was publicised in local newspapers, 
the BBC health online pages, a Lupus UK newsletter and at Lupus patient 
education days to encourage patient and healthy control participation [2] 
(Appendix 2). Study information was forwarded to all participants and they were 
then contacted on a further occasion to allocate a clinic date and time 
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(Appendix 3).   General practitioners of all participants were informed (Appendix 
4).   
9.3.1 SLE inclusion criteria  
Patients recruited satisfy all the following criteria 
a. Modified 1997 American College of Rheumatology classification criteria for 
SLE [155]; diagnosis confirmed with direct casenote review or 
communication with their physician 
b. Female gender  
c. Age > 18 years old  
SLE patients are excluded if any of the following apply  
a. Current pregnancy  
b. Diagnosis or treatment of a malignancy in previous 12 months 
9.3.2 Comparison cohort recruitment   
Fifty cases were randomly selected to have endothelial cell quantification 
and these cases were allocated a control subject matched by gender and age 
(within 10 years) for comparison. The selected cases were asked to suggest a 
friend to be a matched control and where it was not possible for a case to 
suggest a control, an individual was allocated from a list of names of healthy 
subjects that had participated in a similar study previously.  Control participants 
underwent identical clinical and laboratory assessments to the cases with the 
exception of SLE-specific assessments e.g. SLE disease activity index.  
9.4  Clinical assessment  
All participants are reviewed by a trained member of the clinical research 
team (Ian N Bruce, Chadi Rakieh or I) on at least one occasion.  Data collected, 
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using a standardised proforma (see Appendix 5), include demographic data, 
presence of cardiovascular risk factors (defined below) and cardiovascular 
events (personal history from patient) i.e. myocardial infarction, angina, 
cerebrovascular event or coronary intervention.   
9.4.1 Definition of cardiovascular risk factors 
1. Hypertension: blood pressure of > 140/90 or current treatment with an 
antihypertensive drug  
2. Hypercholesterolemia: TC > 5.2 mmol/l or LDL-c > 3.2 mmol/l or on 
therapy  
3. A family history of cardiovascular disease: MI, angina or sudden death in 
a first degree relative: male <55 yrs or female <65yrs;  
4. Diabetes mellitus: fasting plasma glucose >7.0 mmol/l or current diabetic 
therapy 
 
Other information collected included the medical history SLE clinical features 
including details of the SLE diagnosis. „Renal disease‟ was defined as any 
patient with persistent proteinuria, otherwise unexplained microscopic 
haematuria, chronic renal insufficiency, nephrotic syndrome or any grade of 
lupus nephritis diagnosed on biopsy.  
Two composite measures of disease activity were assessed, namely, 
British Isles Lupus Assessment group (BILAG) index [168] and SLE disease 
activity index (SLEDAI) [40] ( see Appendix 8 and Appendix 9).  Cumulative 
damage was recorded using the Systemic Lupus International Collaborating 
Clinics (SLICC) damage index [122]) (see Appendix 10).   Details of current and 
previous SLE therapy were recorded as well as all other current medications.  
Detail of steroid exposure was documented including previous exposure, 
average daily dose and length of courses. A number of lifestyle factors including 
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tobacco and alcohol use and prior use of hormonal preparations were noted.   A 
systemic clinical examination was undertaken. 
9.4.2 Anthropometry  
Height, weight, pulse rate, blood pressure measurement, waist and hip 
measurement were undertaken by trained nursing staff.  
9.4.3 Laboratory assessment  
To aid the clinical assessment and cardiovascular risk assessment, a 
number of laboratory measures were undertaken and are listed below:  
a. Full blood count   
b. Renal profile, estimated GFR and urine dipstick   
c. High sensitivity C-reactive protein to assess low grade 
inflammatory activity  
d. Fasting blood glucose, insulin, HDL cholesterol and triglycerides 
as well as body mass index to assess insulin resistance and 
presence of the metabolic syndrome  
9.4.4 Estimation of subclinical CHD 
9.4.4.1 Carotid ultrasound   
Carotid ultrasound examination was undertaken by one of two vascular 
technicians on the day of the clinical assessment. Comparison of measurements 
between the two operators showed good correlation (see Appendix 6).   
9.4.4.2 Aortic pulse wave velocity (APWV) 
All measurements were performed by one of two trained nursing staff at 
the time of the clinical assessment.  The measurement was performed after an 
overnight fast and 12 to 24 hours abstinence from all anti-hypertensive 
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medications. Participants were asked to omit caffeinated beverages, smoking, 
and alcohol for 12 hours before the assessment. Comparison of 
measurements between the two operators showed good correlation (see 
Appendix 7).  
9.5  General statistical methods 
All data were collated and entered into an Access database by a trained 
research assistant.  The data were analysed using STATA 9.2 statistical 
software.  Comparisons were made between cases and controls by means of a 
two-sample t-test for normally distributed continuous variables (when explored 
by the Shapiro-Wilk test) and by chi-square analysis for categorical variables.   
For non-normally distributed variables, non-parametric tests were determined 
using Kruskal-Wallis rank test for categorical variables and Spearman's 
correlation coefficients for continuous variables.   Two sided p values (P) of less 
than 0.05 were considered to be significant. Bland-Altman plots were used to 
test the extent of agreement between pairs of measurements e.g. carotid 
measurements taken by different operators or consistency of laboratory 
experiments [35] by plotting the differences between the pairs on the vertical 
axis and the mean of each pair on the horizontal axis.  A description of the 
relevant statistical methods can be found in each section if tests other than 
those described above are utilised.  
9.6 Laboratory methods  
Methods relating to the relevant results chapter will be discussed at the 
beginning of each chapter.  
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10 RESULTS  
10.1  Description of SLE patients   
SLE patients have been reported to have an excess of CHD risk factors 
and carotid atherosclerotic burden. In this chapter we aim to ascertain these 
factors in our study population.   
The objectives of this chapter are to: 
a. Describe the characteristics of 182 female SLE patients and 70 
female controls enrolled into the cross-sectional study 
b. Describe the burden of carotid atherosclerosis  in the cross-sectional 
assessment  
c. Determine the progression of carotid atherosclerosis in a longitudinal 
study   
d. Determine factors contributing to atherosclerosis progression   
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10.1.1 Demographics of SLE patients   
A total of 182 patients were recruited to the study with a median (IQR) age 
of 53 (46, 61) years and 38% of patients were under the age of 50 years.  See 
below for age frequencies. The majority of patients were of White-Caucasian 
ethnicity and 9% of patients were of Afro-Caribbean or Asian ethnicity.  See 
Figure 9 for distribution of ethnicities.    
 
 
 
 
 
 
 
 
 
 
 
Figure 8 Age distribution of SLE patients 
 
           
           
           
           
           
   
Figure 9 Ethnicity distribution of SLE patients 
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10.1.2 Clinical and immunological features of SLE patients   
The median (IQR) disease duration was 13 (7, 23) years and there was a 
median (IQR) lag period of 3 (1, 11) years between the onset of the first criteria 
for diagnosis until four ACR criteria were met.  All patients satisfied 4/11 of the 
1997 ACR criteria and 101 (55%) satisfied more than four criteria.  The most 
common manifestation was an immunological abnormality although 
documentation of a positive antinuclear antibody was not available in 18 (10%) 
of patients.  Thirty-eight (21%) patients had biopsy-proven renal disease. See 
Table 66 for the prevalence of features of the 1997 ACR criteria amongst the 
SLE patients.   
 
Table 6 Prevalence of ACR criteria features   
 
 
 
 
 
 
 
 
 
 
Immunological profile was repeated at the time of the study assessment 
and the autoantibody profile is summarised in Table 77.  Approximately a 
 
Clinical Features 
 
n (%) patients 
1.   Malar Rash 100 (55) 
2.   Discoid rash 20 (11) 
3.   Photosensitivity 102 (56) 
4.   Oral Ulcers 96 (53) 
5.   Arthritis                                    124 (68) 
6.   Serositis                                   67 (37) 
7.   Renal disorder                         38 (21) 
8.   Neurological disorder               18 (10) 
9.   Haematological disorder          87 (48) 
10.Immunologic disorder             155 (85) 
11. Antinuclear antibody  164 (90) 
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quarter of patients had some immunological evidence of disease activity with a 
low C4 or high titre of anti-dsDNA antibody.   
Table 7 Immunological features of SLE patients 
  
  
  
  
  
 
 
 
 
 
 
10.1.3 Disease activity and damage scores 
SLE patients were selected from an outpatient setting and therefore in 
general had low disease activity.  The median SLEDAI score was 2 (0, 5) and in 
addition to the immunological components of the SLEDAI as highlighted in 
Table 77,  21% of patients had active arthritis, 15% had evidence of an 
inflammatory rash, 13% had a leucopoenia and 11% had mouth ulcers at the 
time of assessment. Eighteen (10%) patients had a SLEDAI score greater than 
8. Figure 10 summarises the SLEDAI scores at the time of the assessment. 
Similar to the SLEDAI scores, the key BILAG items suggest some disease 
activity within the mucocutaneous, musculoskeletal and haematological 
systems (Table 8). Fifty-five patients reported previous or current fatigue, an 
Immunological features at time of assessment n (%) patients 
Anti – Ro antibody  36 (23) 
Anti – La antibody 22 (12) 
Anti – Sm antibody 2 (1) 
Anti – RNP antibody 16 (9) 
Anti - cardiolipin antibody d                                  40 (22) 
Lupus anticoagulant                                   53 (29) 
Low C3 a                       5 (3) 
Low C4 b               46 (25) 
High anti - dsDNA antibody c      42 (23) 
 
a
 using local laboratory cut-off 0.62 g/L at time of study assessment  
b 
using local laboratory cut-off 0.14 g/L  at time of study assessment 
c 
using local laboratory cut-off 25 IU/ml at time of study assessment 
d
 using local laboratory cut-off for IgM anti-cardiolipin antibody 20     
IU/ml & IgG  anti-cardiolipin antibody 10  IU/ml 
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item not incorporated in the SLEDAI, and therefore contributed to the „general‟ 
category of the BILAG grades.   
 
Figure 10 SLEDAI score distribution in SLE 
Table 8 Distribution of BILAG scores and components 
 
 
 
 
 
 
 
 
 
The median damage index as measured using the SLICC damage index (SDI) 
was 1 (0, 2). The most prevalent items of the SDI were scarring alopecia 
occurring in 31 (17%) of patients, cataract in 27 (15%) and cerebrovascular 
accident 20 (11%). The prevalence of SDI items amongst this cohort is 
BILAG item 
% of SLE patients with grade 
A B C D E 
General 2 4 26 - 68 
Mucocutaneous 2 13 27 0.5 57.5 
Neurological - 1 6 - 93 
Musculoskeletal - 16 25 - 59 
Cardiorespiratory - 1 9 - 90 
Vasculitis 0.5 1 21 - 77.5 
Renal - 5 - - 95 
Haematological 0.5 12 55.5 - 32 
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summarised in Error! Reference source not found.9. Fifteen (9%) of patients 
gave a past history of  
 malignancy and 6 of those patients specified carcinoma of the breast.    
 Table 9 Prevalence of SDI items 
SDI item  n (%) patients 
Ocular  
Cataract  27 (15) 
Retinal damage  9 (5) 
Neuropsychiatric   
   Cognitive impairment     7 (4) 
   Seizures                  4 (2) 
  Cerebrovascular accident      20 (11) 
   Neuropathy 5 (9) 
   Transverse myelitis  2 (1) 
Renal   
 GFR< 50%  4 (2) 
 Proteinuria >3.5g/24/ESRF 4 (2) 
Pulmonary  
 Pulmonary hypertension 0 
 Pulmonary fibrosis 4 (2) 
 Shrinking lung 4 (2) 
 Pleural fibrosis 2 (1) 
 Pulmonary infarction  0 
Cardiovascular disease  
 Angina/CABG 9 (5) 
 Myocardial infarction 5 (3) 
 Cardiomyopathy 2 (1) 
 Valvular heart disease 2 (1) 
 Pericarditis /pericardectomy 5 (3) 
Peripheral vascular disease  
 Claudication  2 (1) 
 Minor tissue loss 0 
 Major tissue loss 2 (1) 
 Venous thrombosis/stasis 13 (7) 
Gastrointestinal disease   
 Organ infarction/resection 9 (5) 
 Mesenteric insufficiency 0 
 Chronic peritonitis 0 
 Stricture/GIT surgery  4 (2) 
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10.1.4 Lifestyle factors of SLE patients  
Seventeen patients (9%) of patients were current smokers and the median 
number of cigarettes smoked per day was 9 (4.5, 20). Seventy-nine (43%) of 
patients admitted to alcohol consumption and the average number of units 
consumed was 2 (0, 8) with 16 patients admitting to an alcohol consumption of 
greater than the recommended 14 units for women.  More than half the patients 
were post menopausal (103 patients) with an average age of menopause of 48 
(41, 51) years. Thirty patients had a prior history of hysterectomy at an average 
age of 39 (35, 43) years. Ninety-three percent (169 individuals) of patients had 
a previous live birth. Lifestyle factors were ascertained via direct interview and 
pre-visit questionnaire. Table 10 summarises the lifestyle characteristics of SLE 
patients. 
SDI item continued  % patients 
Musculoskeletal   
 Muscular atrophy/weakness 2 (1) 
 Deforming/erosive arthritis  13 (7) 
 Osteoporotic fracture  4 (2) 
 Avascular necrosis  2 (1) 
 Osteomyelitis  2 (1) 
Skin   
 Chronic scarring alopecia  31 (17) 
 Extensive scarring  7 (4) 
 Skin ulceration 2 (1) 
Premature gonadal failure  15 (8) 
Diabetes 9 (5) 
Malignancy  16 (9) 
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Table 10 Lifestyle factors of SLE patients  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
10.1.5 Treatment factors  
Three quarters of patients of patients (76%) had used corticosteroids (CS) 
during their disease course and 45% were using CS during the study period. 
Current and previous CS dosages were moderately low. See Table 11 for details 
of SLE therapy.  
 
Social factor 
 
n (%) patients 
Smoker – ever  78 (43) 
 Current smoker 16 (9) 
 Ex-smoker 62 (34) 
Alcohol consumption  78 (43) 
College or university education                                     102 (56) 
Hormone contraception use  31 (17) 
Post menopausal                                    103 (57) 
Hysterectomy   29 (16) 
HRT use - ever               60 (33) 
Pregnancy  149 (82) 
 1 or more live birth 139 (93) 
 1 or more miscarriage   40 (27) 
 1 or more termination  25 (17) 
Marital status   
 Single  24 (13) 
 Married/common law wife 124 (68) 
 Separated /divorced 24 (13) 
 Widowed 7 (4) 
101 
 
 
Table 11 Details of therapy of SLE patients  
 
 
 
 
Treatment 
 
 
Steroid – ever  139 (76) 
 Current steroid  82 (45) 
 Current daily steroid dose : median (IQR) mg 8 (5, 10) 
 Past steroid use  67 (37) 
 Past daily steroid dose : median (IQR) mg 10 (5, 15) 
Anti-malarial current  87 (48) 
Anti-malarial (any) – past     25 (14) 
Hydroxychloroquine – current  71 (39) 
Hydroxychloroquine – past  21 (12) 
Azathioprine – current 35 (19) 
Azathioprine – past  18 (10) 
Mycophenolate – current   17 (9) 
Mycophenolate – past  8 (4) 
Cyclophosphamide – current 5 (3) 
Cyclophosphamide – past  9 (5) 
Methotrexate – current  14 (8) 
Methotrexate – past   9 (5) 
Cyclosporin – current  3 (20) 
Cyclosporin – past  2 (1)  
  
All values n (%) unless other stated  
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10.2 Description of control population  
10.2.1 Demographics of controls  
A total of 70 control females were recruited with a median (IQR) age of 51 (39, 60) 
(39, 60) years and 46% were under the age of 50 years. The age distribution of control 
control participants is described in  
Figure 11. Similar to the patient population, the majority of controls were of 
White-Caucasian ethnicity and 8% were of Afro-Caribbean or Asian ethnicity.  
See Figure 12 for distribution of ethnicities.    
 
 
 
 
 
 
 
 
 
Figure 11 Age distribution of controls 
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10.2.2 Lifestyle factors of controls   
SLE patients and controls were reasonably well matched with regard to 
social factors. Overall 50% of controls had ever smoked however a slightly 
higher percentage of controls remained current smokers (20%) were current 
smokers and the median number of cigarettes smoked per day was 15 (7, 9). 
Sixty-two (89%) controls admitted to alcohol consumption and the average 
number of units consumed was 8 (4, 10) with 10 (14%) of controls admitting to 
an alcohol consumption of greater than the recommended 14 units for women.  
Just less than half of the controls were post menopausal (31 individuals) with an 
average age of menopause of that was very similar to the SLE patients of 47 
(40, 51) years. Ten controls had a prior history of hysterectomy at an average 
age of 40 (38, 43) years. Sixty percent (42 individuals) had a previous live birth. 
Table 12 summarises the lifestyle characteristics of the control population.  
Table 12 Lifestyle factors of controls 
 
 
 
 
 
 
 
 
 
 
Social factor   
 
% controls 
 
Smoker – ever  35 (50) 
 Current smoker 21 (30) 
 Ex-smoker 14 (20) 
Alcohol consumption  62 (89) 
College or university education                                     44 (63) 
Hormone contraception use  46 (66) 
Post menopausal                                    31 (44) 
Hysterectomy   10 (14) 
HRT use - ever               17 (24) 
Pregnancy  46 (66) 
 1 or more live birth 28 (60) 
 1 or more miscarriage   17 (36) 
 1 or more termination  2 (4) 
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10.2.3 Discussion  
SLE patients were recruited from existing databases in the Northwest of 
the UK and are representative of the ethnicity of that population. The majority of 
SLE patients (127/182) were recruited from a cohort of patients that participated 
in a previous study assessing factors contributing to carotid atherosclerosis and 
therefore recruited „older‟ patients. As a results, the majority of the SLE patients 
included in this study were older than 55 years and therefore postmenopausal, 
in comparison to the control population which had a more even spread of 
participants across the age-range. This will limit the sample size of analyses of 
younger patients. Age-adjusted statistical analyses will be taken undertaken 
when comparisons are made with controls to account for the age differences. In 
keeping with other studies, all patients satisfied the 1997 ACR classification 
criteria for SLE. The SLE patients appear to be representative of a European 
cohort of SLE patients with respect to clinical features and antibody profiles. 
Cervera et al. previously reported the prevalence of clinical features in 1000 
patients and observed arthritis in 84%, pleurisy in 36% and skin disease in 58% 
of patients. The reported prevalence of renal (39%) and neurological disease 
(27%) was slightly higher and oral ulceration (24%) slightly lower than observed 
in this cohort [59]. Previous studies have reported the expected frequency of 
anti-Ro to be 20-60%, anti-La 15-40%, anti-Sm 3-30% and anti-RNP 10-30% [5, 
302].   ANA was not re-tested during the study period but historical information 
was gathered from hospital record review. The platform measuring anti-
cardiolipin antibody titres was changed during the study period; as a result 
different titres were not comparable between patients. Anti-cardiolipin antibody 
was therefore classified as a positive or negative result according to the 
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suggested laboratory cut-off rather than defined as medium or high titres as 
specified in the classification of the APS.  Lupus anticoagulant was not 
measured in all participants owing to prescription of medications that would 
interfere with the result. Lupus anticoagulant was therefore not used as a 
variable in the analyses.  
The disease activity score is low as would be expected in patients 
recruited from an outpatient setting. The majority of patients had established 
disease with a median duration of 13 years and the average SDI of 1 (0, 2) is as 
would be expected. A mean (SD) SDI of 1.19 (1.59) at 10 years of disease 
duration and 1.9 (1.99) at 15 years has previously been reported [124]. We 
observed a higher rate of malignancies in this cohort at 9% compared to the 
estimates of 4-5% previously reported a Hungarian and an international cohort 
and this may represent geographical differences [28, 337]. Breast cancer was 
present in 6 (3%) of patients and this is slightly higher than a prevalence of 
1.7% previously reported [29].   
Less than half the patients were taking corticosteroids at the time of the 
study (45%) and the average daily dose in these patients was low at 8 (5, 10) 
mg. A similar number of patients were taking anti-malarial drugs but as 
expected in a cohort with low disease activity, less than 1/5 of patients were 
taking immunosuppressants such as azathioprine, mycophenolate and 
cyclophosphamide. Our findings are therefore unlikely to be an effect of disease 
severity or high inflammatory burden and more likely to be representative of a 
wider SLE population   
Control subjects were chosen from a historical database or recruited from 
amongst friends and family of patients from the same geographical area, in an 
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attempt to limit demographic and lifestyle factors.  Nonetheless, as might be 
expected, the prevalence of smoking, alcohol intake and hormone contraception 
use was increased in the control patients. Those factors that are less likely to be 
related to medications or medical advice such as further or higher education, 
prevalence of hysterectomies or miscarriages/terminations were remarkably 
similar between the groups (see Table 10 and Table 12). 
The prevalence of cardiovascular risk factors is discussed below. 
 
10.3 Cardiovascular risk factors, subclinical atherosclerosis and 
cardiovascular disease   
10.3.1 Cardiovascular risk factors in SLE patients   
A number of cardiovascular risk factors were assessed. Definitions are 
summarised in the methods chapter (section 9.4.1). Fasting blood glucose and 
lipid profiles were measured on the day of the visit. The comparison of 
cardiovascular risk factors between SLE patients and controls is summarised in 
Table 13. Definitions of high lipid levels are based on The Third Report of the 
National Cholesterol Education Program (Adult Treatment Panel III) [1]. As 
none of the measured values of triglycerides were very high i.e. above 4.5 
mmol/L, LDL cholesterol was calculated using the Friedewald formula [111]. 
See Figure 13.  
LDLc = total cholesterol – HDLc – (triglycerides/5) 
 Figure 13 Friedewald formula of LDL calculation 
There was a significant difference between SLE patients and healthy controls 
with regard to age; therefore all further analyses are adjusted for age. The 
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proportion with hypertension, as defined by a blood pressure greater than 
140/90 or current anti-hypertensive medications was significantly higher in the 
SLE patients. The proportion of individuals taking anti-lipid therapy was greater 
in the SLE group. Overall measures of total cholesterol and LDL cholesterol 
were higher in the control group. All these factors remained significantly 
associated after adjustment for age. Other traditional risk factors did not differ.  
Table 13 Comparison of cardiovascular risk factors in SLE patients and controls 
 
 
Cardiovascular risk factor 
 
SLE patients 
(n=182) 
Controls 
 (n=70) 
 
P 
value 
Age at assessment: med (IQR) years 53 (46, 61) 50 (39, 60) 0.01 
Hypertension: n (%) 66 (36%) 7 (10%) <0.001 
Systolic blood pressure: mean (SD) 129 (20) 124 (19) NS 
Diastolic blood pressure: mean (SD) 71 (10) 68 (16%) NS 
Hypercholesterolaemia: n (%) 74 (41%) 15 (21) 0.006 
Total cholesterol: mean (SD) 4.7 (0.9) 5.1 (1.0) 0.0013 
Anti-lipid therapy: n (%) 68 (37%) 5 (7%) 0.006 
Triglycerides: mean (SD) 1.2 (0.6) 1.1 (0.7) NS 
LDL : mean(SD) 2.7 (0.9) 3.2 (1.0) 0.0002 
HDL : mean(SD) 1.7 (0 .5) 1.7 (0.4) NS 
VLDL: mean(SD) 0.5 (0.3) 0.4 (0.3)` NS 
High cholesterol (>6.2 mmol/L): n (%) 9 (5%) 11 (16%) 0.004 
High LDL (>4.1 mmol/L): n (%) 12 (7%) 14 (21%) 0.001 
High triglycerides (>2.3 mmol/L): n (%) 8 (4%) 6 (9%) NS 
Low HDL (<1.03) 4 (2%) 0 NS 
Diabetes mellitus: n (%) 10 (5%) 1 (1%) NS 
Fasting blood glucose : med (IQR) 4.5 (4.2, 5.1) 4.7 ( 4.5,  4.9) NS 
Family history of CHD: n (%) 61 (34%) 21 (30) NS 
BMI: med (IQR) 26 (23, 31) 25 (23, 28) NS 
Waist circumference : med (IQR) 91 (81, 100) 86 (79, 95) NS 
Waist:hip ratio : med (IQR) 
0.88 (0.84, 
0.93) 
0.87 (0.82, 0.92) NS 
CRP 2.1 (0.8, 5.3) 1.9 (0.4, 3.9) NS 
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10.3.2 Cross sectional assessment of carotid IMT and plaque   
Control subjects had a trend towards a higher IMT compared to SLE 
patients (0.075 (0.122) vs. 0.062 (0 .014) cm, p=NS) and adjusting for age did 
not have a significant effect. A higher proportion of SLE patients had the 
presence of any carotid plaque compared to controls (45% vs. 23%, p=0.002). 
When adjusting for age controls remained less likely to have carotid plaque (OR 
0.34, 95%CI 0.16, 0.77, p=0.009). Further, a higher proportion of SLE patients 
had medium or large-sized plaque (9.6% vs. 6%) although this was not a 
statistically significant difference. The age of SLE participants with plaque was 
higher than those without (59.0 vs. 47.6 years, p<0.0001) and therefore all 
further analysis of plaque has been adjusted for age at assessment. There were 
6 controls and 26 SLE patients that were not of white Caucasian ethnicity but 
ethnicity did not have an association with carotid plaque.   
10.3.2.1 Univariable associations of carotid plaque in SLE  
 The association of cardiovascular risk factors, present at the time of 
assessment, with plaque within the SLE population is summarised in Table 14. 
Traditional cardiovascular risk factors significantly associated with carotid 
plaque within the SLE population were hypercholesterolaemia and smoking. 
HsCRP was associated with a small increase risk of carotid plaque (with a one-
unit increase in the hsCRP translating to a change in the odds for plaque of 
1.10). 
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Table 14 Univariable analysis of traditional CHD risk factors associated with 
carotid plaque in SLE 
 
 
 
 
 
 
 
 
 
 
 
A number of SLE-related factors were also considered and are 
summarised in Table 15. Factors analysed include the presence of any 
component of the ACR classification criteria and autoantibodies, at any time 
during the course of disease. Disease activity and damage indices analysed are 
as measured on the day of assessment. The uses of anti-malarials or 
immunosuppressants at any time of the disease course were also analysed.   
The current or past use of azathioprine was analysed separately in view of 
previous reports of an association with both subclinical and clinical 
atherosclerosis in SLE [7, 92, 143, 154]. 
Only two SLE patients had a prior history of vasculitis and therefore 
logistic regression using this variable was not possible.  Similarly only one 
patient was anti-Sm antibody positive and therefore this variable was not 
Cardiovascular risk factor   
Age-adjusted 
odds ratio 
95% 
confidence 
interval 
Hypertension (>140/90mmHG)/medication 1.57 0.75, 3.26 
Hypercholesterolemia  (>6.2mmol/L)/statin 2.13 1.01, 4.50* 
Smoking – ever  2.41 1.17, 5.00* 
Smoker – current  1.15    0.31, 4.23 
Family history of CHD 1.13 0.51, 2.52 
High BMI (>25 kg/m
2
)  1.55 0.74, 3.25 
Diabetes  2.20 0.31, 15.50 
hsCRP 1.10 1.01, 1.21* 
Systolic blood pressure 1.01 0.99, 1.03 
Total cholesterol  0.68 0.46, 1.02 
*factors significantly associated 
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analysed.  SLE- related factors were not significantly associated with carotid 
plaque in this analysis. 
Table 15 Univariable analysis of SLE-related factors associated with carotid 
plaque in SLE patients 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SLE-related risk factor   
Age-adjusted 
odds ratio  
95% 
confidence 
interval  
Clinical features    
Malar Rash 1 0.49, 2.05 
Discoid rash 0.36 0.10, 1.31 
Photosensitivity 0.41 0.44, 1.85 
Oral Ulcers 0.63 0.31, 1.30 
Arthritis                                    0.91 0.43, 1.94 
Serositis   0.70 0.34, 1.47 
Renal disorder                         1.93 0.80, 4.66 
Neurological disorder               0.75 0.24, 2.30 
Haematological disorder          0.71 0.35, 1.47 
Vasculitis - - 
Serology    
Anti – Ro antibody  0.53 0.23, 1.23 
Anti – La antibody 0.58 0.19, 1.76 
Anti – Sm antibody - - 
Anti – RNP antibody 0.78 0.23, 2.63 
Anti - cardiolipin antibody d*                                  0.77 0.29, 2.04 
Lupus anticoagulant                                   1.82 0.79, 4.13 
Measures of disease activity and damage  
Low C3 a*                       2.84 0.23, 38.77 
Low C4 b*               1.02 0.49, 2.09 
High anti - dsDNA antibody c*      1.89 0.46, 3.08 
SLEDAI score 0.97 0.89, 1.07 
SDI 1.09 0.87, 1.37 
Therapy    
Steroid ever 1.11 0.42, 2.91 
Steroid current 1.07 0.51, 2.22 
Anti-malarial use 0.65 0.31, 1.35 
Any immunosuppressant use 1.74 0.82, 3.68 
Azathioprine use  1.00 0.45,   2.26 
   
*a-d as defined in Table 77 
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10.3.2.2 Multivariable associations of carotid plaque in SLE patients  
Multivariable logistic regression was used to identify those factors 
independently associated with carotid plaque in SLE patients. Factors included 
in the stepwise regression model were those that were significantly associated 
in the univariable analysis namely, age at time of assessment, 
hypercholesterolemia, history of current or previous smoking and hsCRP.  
 
Table 16 Multivariable analysis of factors associated with carotid plaque in SLE 
patients 
 
 
 
 
 
 
 
The factors remaining in the regression model i.e. independently 
associated with plaque were age, smoking and hsCRP but all except smoking 
had a small effect on the odds of plaque. See Table 16 for detail. 
Risk factor Odds ratio 
95% 
confidence 
interval 
Age 1.15 1.09, 1.21* 
Hypercholesterolemia  1.77 0.81, 3.88 
Smoking – ever  3.34 1.49, 7.45* 
hsCRP 1.12 1.02, 1.23* 
*factors significantly associated   
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10.3.2.3 Univariable associations of carotid IMT (CIMT) in SLE  
Traditional risk factors associated with CIMT in the cross-sectional study 
are summarised in Table 17. A standardised coefficient β (SE) is utilised to 
assess the association of factors with CIMT. Please see section 10.4.1 for 
further details about the β coefficient and it‟s interpretation.  As would be 
expected, age and systolic blood pressure were significantly associated with 
CIMT but after correction for multiple testing, there was no significant 
association with other CHD risk factors.  
 
 
 
Table 17 Univariable analysis of traditional CHD risk factors associated with 
carotid IMT in SLE 
 
Baseline factors 
 
Unadjusted  
 
Age-adjusted 
 
β (SE) P value  β (SE) P value 
Age 
.4689399 
(.0000876) 
<0.0001 
- 
- 
Total cholesterol  
.1911229 
(.0011539) 
0.012 
.1169639 
(.0010553) 
0.096 
Hypercholesterolemia  
.0346571 
(.0022235) 
NS 
-.0872572 
(.0020598) 
NS 
Statin therapy  
.0181806 
( .002235) 
NS 
-.0803001 
(.0020536) 
NS 
Systolic blood pressure 
.3200345 
(.000051) 
<0.0001 
.1605941 
(.0000542) 
0.037 
Hypertension  
.0448302 
(.0022269) 
NS 
-.0471155 
(.0020676) 
NS 
Anti-hypertensive therapy  
.0473421 
(.0022085) 
NS 
-.048331 
(.002033) 
NS 
Fasting glucose 
.0891071 
(.001599) 
NS 
-.0110168 
(.0001685) 
NS 
Type 2 diabetes 
-.0489072 
(.0051871) 
NS 
-.1180383 
(.0046425) 
NS 
Smoking ever  
.1519777 
(.0021293) 
0.043 
.0956243 
(.0019392 ) 
NS 
Body mass index  
.057198 
(.0001851) 
NS 
-.0110168 
(.0001685) 
NS 
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Table 18 Univariable analysis of SLE-related factors associated with CIMT in SLE 
patients  
 
A number of SLE –related factors were analysed for associations with 
CIMT and are summarised in Table 18. Eighty-two (45%) patients were taking 
oral steroids at the time of the study. The average dose of steroid used was low 
at 8 (5, 10) mg/day. Current steroid use had a significant and negative 
 
Baseline factors 
 
Unadjusted  
 
Age-adjusted 
 
β (SE) P value  β (SE) P value 
Renal disease 
  .1204848 
(.0026112) 
NS 
-.0602664 
(.0023664) 
NS 
Creatinine  
-.0290138 
(.0000204) 
NS 
-.0699325 
(.0000265) 
NS 
SDI 
.0519586 
( .000656) 
NS 
-.0184051 
( .0006308) 
NS 
SLEDAI 
.0215067 
( .0003008 
NS 
.0198833 
( .0002734) 
NS 
C3 
.1208456 
(.0038758) 
NS 
.0511975 
( .0036754) 
NS 
Ro  
-.0536456 
(.0025316) 
NS 
-.0479568 
( .002284) 
NS 
La 
.0232183 
(.0033775) 
NS 
-.0009089 
( .0030917) 
NS 
Sm - NS - NS 
RNP 
-.0873208 
( .003616) 
NS 
-.0530032 
( .0034286) 
0.07 
Anti-cardiolipin antibody 
.0119319 
(.0030863) 
NS 
.0163385 
( .002772) 
NS 
Anti-malarial use 
.0119319 
(.0030863) 
NS 
.0163385 
( .002772) 
NS 
Immunosuppressant use  
-.1289854 
( .002149) 
NS 
-.0090888 
( .0020169) 
NS 
Azathioprine use 
-.1082384 
(.0023343) 
NS 
.0107513 
( .0021814) 
NS 
Steroid use current 
-.2291141 
(.0022072) 
0.003 
-.1450267 
( .0020464) 
0.041 
Steroid exposure ever 
-.0674298 
( .003058) 
NS 
.0033906 
( .0028292) 
NS 
Steroid dose  
.3414842 
(.0000698) 
0.002 
.2918351 
( .0000618) 
0.003 
Aspirin use 
-.0278989 
( .005908) 
NS 
.023949 
( .0053002) 
NS 
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correlation with CIMT suggesting that the use of low dose steroid may be 
beneficial with regard to CIMT.  However, current steroid dose had a significant 
and positive correlation suggesting higher doses of steroid may be detrimental 
to IMT. The influence of baseline factors on CIMT is of much interest and    
discussed below.    
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10.4 Longitudinal assessment of carotid IMT and plaque  
A number of SLE patients were followed longitudinally. A cohort of 200 
white SLE females was recruited to a previous study and had measurement of 
cardiovascular risk factors, SLE-related factors, carotid plaque and IMT. The 
clinical and serological features of these patients is summarised in Table 19.  
Table 19 Description of 200 SLE patients recruited to a previous study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    Adapted from Ahmad et al. [7] 
Of those 200 patients, 127 participated in the current study and therefore 
had a repeated measurement of carotid plaque and IMT by the same two 
carotid scanning technicians.  The 127 patients were followed longitudinally for 
a median (IQR) duration of 5.8 (5.2, 6.3) years, had a baseline median (IQR) 
Age: med (IQR)  yrs 48 (41.5–56) 
Age at diagnosis:  med (IQR)  yrs 36.4 (11.8) 
Disease duration:  med (IQR)  yrs 11.7 (9.4) 
Previous cerebrovascular event: n (%) 16 (8) 
Previous coronary event: n (%) 7 (3.5) 
Peripheral vascular disease: n (%) 1 (0.5) 
Ever ANA positive: n (%) 188 (94) 
Ever dsDNA positive: n (%) 115 (57.5) 
Ever aCL or LAC positive: n (%) 73 (37) 
Antiphospholipid syndrome: n (%) 21 (10.5) 
Current steroid therapy: n (%) 106 (53) 
SLEDAI-2K:  med (IQR)   1 (0–4) 
SLICC damage index:  med (IQR)   0 (0–4) 
Current anti-malarial therapy: n (%) 105 (52.5) 
Current immunosuppressive therapy: n (%) 74 (37) 
Postmenopausal: n (%) 94 (47) 
Current smoker: n (%) 40 (20) 
Ex-smoker: n (%) 57 (28.5) 
Family history of premature CHD: n (%) 53 (26.5) 
Total cholesterol:  med (IQR)  mmol/l 5.1 (4.3–6.0) 
Fasting plasma glucose:  med (IQR)  mmol/l 4.6 (4.3–4.9) 
Systolic blood pressure:  med (IQR)  mmHg 126 (116–140) 
Previous or current hypertension: n (%) 83 (41.5) 
BMI:  med (IQR)  kg/m2 26.0 (23.2–30.1) 
116 
 
age of 49 (44, 56) years and disease duration of 11(4, 18) years. Seventy-three 
of the 200 patients initially recruited did not participate in the follow up study and 
outcomes of these patients are described in Table 20.   One patient from the 
previous study did not fulfil SLE classification criteria and therefore did not 
qualify to participate in this study. Ten patients had died during the follow up 
period.  There was one suicide, one patient suffered a ruptured aortic 
aneurysm, one had a cerebral haemorrhage, one had a gastric bleed and 4 
patients had a malignancy (cervical, intracerebral, lung and liver). The cause of 
death was unknown in 2 patients.   
Table 20 Outcome of 200 patients form previous study 
 
 
 
 
 
 
Of the patients that declined participation, one had a throat cancer, one 
had bladder cancer and another had a cerebrovascular accident. A number of 
patients declined participation due to social reasons (sick relatives, child care 
and employment).  The patients that participated in the follow up study tended 
to be older but did not differ significantly to those that were not followed up with 
regards to age, disease duration, CHD risk factors or SLE-related factors. 
Outcome of 200 patients Number of patients 
Change of address / no current contact details  42 
Declined participation in follow up study 20 
Deceased  10 
Ineligible  1 
Participated in follow up study  127 
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A comparison of SLE patients followed up and those lost to follow up is 
summarised in Table 21. 
Table 21 Baseline features of SLE patients followed up compared to SLE patients 
lost to follow up 
 
10.4.1 Carotid IMT progression in SLE patients  
The average baseline and follow up carotid (C) IMT displayed skewed 
distributions and therefore the median and IQR are used to describe these 
outcomes in contrast to the change in CIMT over time and the follow up time 
which were normally distributed and therefore the mean and standard deviation 
are used. Table 22 summarises the change in CIMT observed over time in 127 
SLE patients. Whilst the majority of patients demonstrated some progression of 
IMT 8/127 had a regression of IMT. These 8 patients had a median baseline 
age of 53.5 (45, 60.5) years. 
Baseline factors 
SLE patients 
followed up 
N=127 
SLE patients 
lost to follow up 
N=73 
P 
value 
Age: median (IQR) yrs 49 (44, 56) 45 (37, 55) NS 
Disease duration : median (IQR) yrs 11 (4, 18) 7 (4, 16) NS 
Total cholesterol : mean (SD) mmol/L 5.1 (1.1) 5.3 (1.4) NS 
Systolic blood pressure: mean (SD) 
mmHg 
132 (20) 125 (19) 0.03 
Hypertension (%)  32 31 NS 
Fasting glucose: mean (SD) mmol/L 4.5 (0.8) 4.8 (0.9) NS 
Smoking ever (%) 43 56 NS 
CHD (%) 4 3 NS 
Family history of CHD (%) 27 27 NS 
Body mass index (kg/m2) 27 (6) 27 (6) NS 
Renal disease (%) 13 23 NS 
SDI: median (IQR)  0 (0, 1) 0 (0, 2) NS 
SLEDAI: median (IQR)  1 (0, 4) 0 (0, 2) NS 
Anti-cardiolipin antibody positive (%) 32 27 NS 
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Table 22 Rate of CIMT progression in SLE 
 
 
 
 
 
 
CIMT change increased with age when stratified by age groups (see Table 23).  
 
Table 23 Rate of change of CIMT in SLE stratified by age 
 
 
 
 
Table 24 summarises factors associated with CIMT progression in SLE.  
Since baseline factors are measured in different units, to allow a more direct 
comparison between the strength of associations, the coefficients have been 
standardised. The β coefficient is not measured in units of the baseline factor 
but rather in standard deviations. This transformation into standard scores prior 
to running the regression model allows comparison of strength of 
coefficient/association between the variables. Total cholesterol had a small 
negative association with CIMT change over time in SLE i.e. a one standard 
deviation decrease in total cholesterol would yield a 0.19 standard deviation 
increase in the predicted IMT change.  
 
  
Baseline  CIMT : median (IQR) cm 0.05 (0.04, 0.06) 
Follow up  Baseline  CIMT : median (IQR) cm 0.06 (0.05, 0.07) 
CIMT change : mean (SD) cm 0.012 (0.011) 
Follow up time  :  mean (SD) yrs 5.72 (0.89) 
Change in CIMT:  mean (SD) cm/yr 0.002 (0.001) 
Age : years Change in CIMT : mean (SD) cm 
<40 (n=6) 0.009 (0 .005) 
40.1 – 50 (n=26) 0.011(0.008) 
>50.1 (95) 0.013 (0.008) 
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Table 24 Univariable analysis of traditional CHD risk factors associated with 
CIMT progression in SLE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Factors other than lower cholesterol associated with IMT progression 
were lower systolic blood pressure and the presence of the metabolic syndrome 
(NCEP ATP III panel defined metabolic syndrome in women as the presence of 
three or more of the following, increased waist circumference (>88 cm); 
elevated triglycerides (≥150 mg/dl); low HDL cholesterol (<50 mg/dl in women); 
 
Baseline factors 
 
Age-
adjusted  
β (SE) 
P value 
Age 
0.0462949 
(0.0001032) 
NS 
Disease duration  
-0.0809026 
(0.0000996) 
NS 
Total cholesterol  
-0.1944166 
(0.0008191) 
0.03 
Hypercholesterolemia  
0.0748241 
(0.0028293) 
NS 
LDLc 
-0.0782959 
(2.9 x 10-6) 
NS 
Triglycerides  
-0.062034 
(2.0 x 10-6) 
NS 
Systolic blood pressure 
-0.1727444 
(0.0000467) 
0.06 
Hypertension  
-0.0423764 
(0.0020329) 
NS 
Fasting glucose 
-0.1098229 
(0.0012462) 
NS 
Type 2 diabetes 
-0.014464 
(0.0075498) 
NS 
Smoking ever  
0.0530166 
(0.0019157) 
NS 
CHD  
0.0118195 
(0.0015101) 
NS 
Family history of CHD 
-0.0723708 
(0.0021466) 
NS 
Body mass index  
-0.1102952 
(0.0001665) 
NS 
Metabolic syndrome  
0.1755169 
(0.0022396) 
0.05 
Waist circumference >88cm 
-.0553981 
( .0019987) 
NS 
HDL  
-.0720337 
(0.00002) 
NS 
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hypertension (≥130/≥85 mmHg); and impaired fasting glucose (≥110 mg/dl) 
[102]. Other traditional risk factors were not associated with IMT progression in 
this cohort of SLE patients. 
Table 25 Univariable analysis of SLE-related factors associated with CIMT 
progression 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Baseline factors 
 
Age-
adjusted  
β (SE) 
P value 
Renal disease 
0.0633667 
(0.001564) 
NS 
Creatinine  
0.0032491 
(0.0000163) 
NS 
SDI 
-0.1834327 
(0.0008044) 
0.04 
SLEDAI 
0.0623867 
(0.0004039) 
NS 
C3 
-0.0307353 
(0.0035119) 
NS 
C4  
-0.1736865 
(0 .0002623) 
0.05 
Ro  
-0.0040715 
(0.002221) 
NS 
La 
0.0498219 
(0.002762) 
NS 
Sm - - 
RNP 
0.0553044 
(0.0031001) 
NS 
Anti-cardiolipin antibody 
-0.0861927 
(0.0020555) 
NS 
Anti-malarial use 
-0.1204946 
(0.0027453) 
NS 
Anti-platelet use  
-0.0219427 
(0.0020783) 
NS 
Statin use 
 0.0511282 
(0.0031008) 
NS 
Steroid exposure ever 
-0.0430254 
(0.0022728) 
NS 
Average steroid dose 
0.108774  
(0.0001689) 
NS 
Total steroid dose 
-0.0017469 
(1.1 x 10-6) 
NS 
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Amongst SLE-related factors, a lower total SDI score was associated with 
IMT progression. Other SLE–related factors were not associated with carotid 
plaque.   
 
Table 26 Multivariable associations of IMT progression in SLE 
 
 
 
 
 
 
 
 
In the multivariable analysis, after adjusting for age and traditional risk 
factors at baseline, a SDI remained significantly and negatively associated with 
IMT progression; suggesting a higher SDI correlates with reduced IMT 
progression.  SeeTable 26. The items within the metabolic syndrome were 
examined further. IMT progression did not have a significant association with 
blood pressure criteria (age-adjusted β -.0622875, SE .0027712, p = NS), waist 
circumference as described above, high triglycerides (age-adjusted β -
.0884884, SE .0029132, p = NS) or impaired fasting glucose (age-adjusted β -
.0983361, SE .0062526, p = NS). Low HDLc did however have a significant 
association (age-adjusted β .246591, SE .0043239, p = 0.006) suggesting a low 
HDL correlates with increased IMT progression and is the major contributor to 
the metabolic syndrome association.   
 
Baseline factors 
 
Fully-
adjusted 
β (SE) 
P value 
Age 
0.2025859 
(0.0001119) 
0.04 
Systolic blood pressure  
-0.2252302 
(0.0000522) 
0.03 
Total cholesterol  
-0.189022 
(0.0008232)     
0.04 
Metabolic syndrome 
0.1840898 
(0.0021699) 
0.04 
C4 
-0.1513526 
(0.0002495)     
NS 
SDI 
-0.181023 
(0.000764) 
0.03 
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10.4.2 Carotid plaque progression in SLE 
 At the baseline assessment 34/127 (27%) of patients demonstrated at 
least one carotid plaque. At the follow up assessment 63/127 (50%) of patients 
demonstrated at least one plaque. Change in carotid plaque is summarised in 
Figure 14. Nearly half of the patients (59/127) had no plaque at either time point, 
4 patients had a lower plaque index at the follow up assessment consisting of 2 
patients that had one small plaque at the first assessment and no observable 
plaque at the second assessment and 2 patients that had one medium plaque 
(30-50 % of vessel diameter) at the first assessment and one small plaque 
(<30% of vessel diameter) at the second assessment.    
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Figure 14 Comparison of baseline and follow up carotid plaque in 127 SLE 
patients 
 
Thirty-three patients (26%) had no plaque at the baseline and had at least 
one plaque at the second assessment, 9 (7%) patients had a stable plaque 
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index and 22 (17.5%) had a higher plaque index at the second assessment.  
Figure 15 summarises the change of plaque index over time in those 22 patients 
that had an increased plaque index at the second time point. The majority of 
patients that demonstrated some plaque progression started with a grade 1 
(one small plaque) or grade 2 (one medium plaque or multiple small plaque) 
and progressed to more extensive plaque. 
 
 
 
 
Plaque 
index 
 
 
 
 
 
Figure 15 Change of carotid plaque index over time in SLE patients with a higher 
plaque index at the 2nd assessment 
 
 
Factors associated with plaque progression, defined as the onset of new 
plaque or a higher plaque index at the second assessment are summarised in 
Table 27. Baseline age was significantly associated with plaque progression (OR 
1.14, 95% CI 1.07, 1.20) and therefore all further analysis of plaque progression 
is adjusted for age.   
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Table 27 Univariable analysis of CHD risk factors: plaque progression (n=55) vs. 
no plaque (n=59) in SLE 
 
 
 
 
 
 
 
 
 
 
 
 
Four patients at the baseline assessment had a diagnosis of CHD and 
three of these patients were found to have a higher plaque index at the second 
assessment and one had a stable plaque index. Over the 5.8 (5.2, 6.3) years of 
follow up 4 patients developed a new CHD event. Of those 4 patients, 2 
developed a new plaque and 2 had a stable plaque index.  After adjustment for 
age baseline traditional CHD risk factors were not significantly associated with 
carotid plaque progression. 
 
 
Baseline factors 
 
Age-
adjusted 
odds ratio 
95% CI 
Disease duration  1.02 0.98, 1.06 
Total cholesterol  1.07 0.70, 1.46 
Hypercholesterolemia  4.87 0.98, 24.12 
LDLc 1.07 0.65, 1.78 
Triglycerides  1.45 0.71, 2.94 
Systolic blood pressure 1.02 0.99, 1.04 
Hypertension  0.99 0.38, 2.61 
Fasting glucose 0.92 0.40, 2.91 
Type 2 diabetes  0.64  0.03, 14.62 
Smoking ever  1.95 0.83, 4.56 
Family history of CHD 0.45 0.17, 1.18 
Body mass index  1.04 0.97, 1.12 
Metabolic syndrome 1.47 0.55, 4.02 
*p<0.05   
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Table 28 Univariable analysis of SLE-related factors: plaque progression (n=55) 
vs. no plaque (n=59) in SLE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SLE–related factors did not have a significant association with carotid plaque 
with the exception of the anti-Ro antibody which appeared to have a protective 
effect (p=0.012). The analysis was repeated comparing those with no plaque at 
both assessments to those with new onset of plaque at the second assessment.  
Baseline age was associated with a 12% increase in the odds of new plaque 
with each year increment and therefore all factors were again adjusted for age.    
 
 
 
 
Baseline factors 
 
Age-
adjusted 
odds ratio 
95% CI 
Renal disease 1.55 1.52, 1.99 
Creatinine  0.99 0.99,1.00 
SDI 1.26 0.89, 1.80 
SLEDAI 0.94 0.77, 1.13 
C3 2.13 0.51, 8.95 
C4  0.94 0.00, 6.41 
Ro  0.27   0.10, 0.75* 
La 0.34 0.15, 1.15 
Sm - - 
RNP 0.49 1.16, 2.05 
Anti-cardiolipin antibody 3.92 1.41, 10.91 
Anti-malarial use 0.36 0.09, 1.35 
Anti-platelet use  0.64 0.25, 1.61 
Statin use 8.38 0.99, 70.99 
Steroid exposure ever 1.14 0.42, 3.06 
Average steroid dose 1.01 0.94, 1.06 
Total steroid dose 1.00 0.99, 1.00 
*p<0.05   
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Table 29 Univariable analysis of risk factors:  new onset of plaque (n=33) vs. no 
plaque (n=59) in SLE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Baseline factors 
 
Age-
adjusted 
odds ratio 
95% CI 
Disease duration  0.99 0.94, 1.04 
Total cholesterol  0.90 0.38, 1.39 
Hypercholesterolemia  2.83 0.49, 16.49 
LDLc 1.01 0.56, 1.81 
Triglycerides  0.98 0.42, 2.30 
Systolic blood pressure 1.02 0.99, 1.05 
Hypertension  0.77 0.25, 2.31 
Fasting glucose 1.29 0.51, 3.21 
Type 2 diabetes  1.05 0.05, 22.22 
Smoking ever  1.13 0.43, 2.96 
Family history of CHD 0.45 0.15, 1.34 
Body mass index  1.04 0.97, 1.13 
Metabolic syndrome 0.90 0.28. 2.96 
Renal disease 0.49 0.11, 2.14 
Creatinine  0.98 0.94,1.02 
SDI 1.15 0.76, 1.75 
SLEDAI 0.95 0.78, 1.17 
C3 1.93 0.38, 9.77 
C4  0.93 0.00, 6.32 
Ro  0.27   0.09, 0.86* 
La 0.48 0.14, 1.72 
Sm - - 
RNP 0.21 1.02, 1.81 
Anti-cardiolipin antibody 3.23 1.06, 9.89* 
Anti-malarial use 0.38 0.09, 1.64 
Anti-platelet use  0.43 0.14, 1.31 
Statin use 3.51 0.33, 36.83 
Steroid exposure ever 0.88 0.31, 2.54 
Average steroid dose 0.97 0.89, 1.04 
Total steroid dose 1.00 0.99, 1.00 
*p<0.05   
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The Ro antibody was associated with a reduced risk of new onset of 
plaque (p=0.03) and the anti-cardiolipin antibody was associated with an 
increased risk of new plaque (p=0.04). After adjusting for age and traditional 
risk factors in a multivariable logistic regression model, these factors were no 
longer significantly associated with new onset of plaque.  
10.4.3 Discussion 
One-hundred and eighty-two patients with SLE and 70 healthy controls 
were recruited to a cross sectional study to examine carotid IMT and plaque.  
SLE patients have an increased age adjusted prevalence of hypertension 
compared to controls however, the average systolic blood pressure of SLE 
patients was within a normal range (129 [20] mmHg). Patients have lower total 
cholesterol and LDLc compared to controls and this is likely to be related to the 
use of statin drugs, reported in 41% of patients. The proportion of patients 
taking statins has increased significantly from 10% reported by Ahmad et al. 
previously and is likely to be due increased awareness of cardiovascular 
diseases in SLE, the older average age of the cohort and may be in part related 
to proposed guidelines for the management of risk factors  published in 2003 
[362]. The prevalence of diabetes in this cohort tended to be higher than in 
controls and was similar to that reported from the SLICC inception cohort [347].  
SLE patients and controls do not differ significantly with regards to carotid 
IMT in this study. Of the traditional risk factors only systolic blood pressure 
correlates with CIMT in the cross sectional study. The carotid IMT in SLE 
patients is 0.075 (0.122) cm and this is higher than previously reported in cross 
sectional studies. Roman et al. reported an IMT of 0.06 (0.012) cm in SLE 
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patients compared to a significantly lower IMT in controls however, the mean 
age of patients in the Roman study was 44 (13) years and controls was 44 (12) 
years [290]. In contrast, the median age of patients in this study is 53 (46, 61) 
years and controls 50 (39, 60) and the difference in age between these studies 
may explain the discrepancy in the IMT noted. However, consistent with our 
findings, several other groups have reported a similar IMT between SLE and 
controls [172, 332, 374]. The lack of IMT thickness in SLE compared to controls 
is perhaps surprising in view of the abundance of literature in the general 
population demonstrating that IMT is an independent predictor of coronary 
events. However IMT has also been shown to correlate with and predict 
traditional CHD risk factors in the general population  [61, 157] and the lack of 
correlation within SLE may be yet another reflection of the differences in 
aetiology of CHD within SLE. Of the disease related factors, only use of steroid 
was correlated to CIMT. Interestingly the use of any steroid was associated with 
a lower CIMT, however a higher dose was correlated to increased CIMT. This 
finding is in keeping with the theory that judicious use of steroids to control 
inflammation is beneficial but excessive use may lead to detrimental metabolic 
effects.   
Carotid plaque prevalence in the current study is significantly greater than 
in controls and this is in keeping with previous studies [290]. CHD risk factors 
associated with carotid plaque are age, high cholesterol, smoking history and 
hsCRP. SLE related factors did not correlate to the presence of carotid plaque 
in this study. Multivariable analysis demonstrated an association with age, 
smoking and hsCRP independent for other factors. The association with hsCRP 
is particularly interesting since CRP is classically within normal laboratory limits 
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in SLE patients. Low level rise in hsCRP may reflect „grumbling‟ subclinical 
inflammation better than currently used composite clinical scores used to detect 
disease activity.  Previous studies have demonstrated the association of 
hypertension, diabetes, SDI, prednisolone use and immunosuppressant use 
[290] with plaque as well as hypertension and C3 levels [220]. The differences 
in factors associated with carotid plaque may be due to the differential influence 
of risk factors with increasing age or geographical difference as both previous 
studies were of North American patients. The differences in results may also be 
the result of a smaller sample size in the current study.  
Two hundred SLE patients were followed longitudinal to assess the rate of 
progression and correlates of carotid atherosclerosis. Seventy-three of these 
patients were lost to follow and this may reduce the validity of the results, 
however as demonstrated in Table 21, that there are no significant differences 
with regard to age, CHD-related factors or SLE-related factors amongst the 
patients that were followed up and those that were not. We were not able to 
ascertain the cause of death in 2/10 patients however, of those where a cause 
of death was determined; none of the patients had a CHD event therefore 
reducing the risk of left censorship. Additionally, 20 patients declined 
participation in a follow up study due to a number of social or health related 
issues and none of these patients had a CHD event. The 127 patients that were 
followed up were assessed following a mean of 5.72 (0.89) years.  The mean 
change in IMT was 0.002 (0.001) cm/year and was greatest in patients over the 
age of 50 years. A large study within the general population has previously 
estimated common carotid IMT progression at 0.0010 cm/yr and the current 
study would therefore suggest a greater rate of IMT progression in SLE patients 
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than would be expected in this age group [161].   IMT progression in this study 
is similar to previous estimates of IMT progression in SLE (between 0.0011 – 
0.0039 cm/yr) [82, 289, 293]. However one recent controlled study has 
suggested that IMT progression in SLE is less than or similar to the control 
population [341]. In the current study, univariable factors associated with IMT 
change were total cholesterol, the metabolic syndrome, SDI and C4 levels. In 
the multivariable model, metabolic syndrome, and in particular the low HDLc 
component is associated with IMT progression.  
Paradoxically, SDI was negatively correlated with IMT progression 
suggesting a higher SDI correlates with less IMT progression. One possible 
explanation is a surviving cohort effect i.e. those with higher SDI have left the 
cohort or alternatively may be a reflection of the small number of patients 
included in the multivariable model.   Table 30 summarises previous longitudinal 
studies of carotid IMT and plaque progression.   Age at diagnosis and C3 have 
previously been shown to be associated with carotid IMT progression but these 
factors could not be verified in the current study. Other factors previously 
associated with IMT progression were homocysteine levels and C5a levels but 
these factors were not studied in the current study. 
Onset of new carotid plaque was observed in 26% of patients and a higher 
plaque index at the second assessment was observed in 17.5%. No plaque at 
either time point was observed in 46.5% and this is similar to previous studies 
within SLE. A general population-based study of women aged between 59 – 71 
years demonstrated plaque progressed in 18% over 4 years [388] and by this 
estimate the progression observed in the current study is greater than would be 
expected in the general population. Plaque regression was noted in 3% of 
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patients and this compares to a previous study that demonstrated regression in 
5% [341]. Those patients with plaque regression had a median (IQR) age of 
55.5 (42.5, 61) years at the baseline and disease duration of 18 (11, 28) years. 
Two of the four patients were taking aspirin at the baseline assessment and 
none were taking a statin drug. In those patients with a higher plaque index at 
the second assessment, the magnitude of change was at least double over time 
in the majority of patients. Baseline age was the only factor associated with 
plaque progression and the anti-Ro antibody was associated with reduced risk 
of new plaque and may represent patients with a „mild‟ phenotype. Interestingly, 
the point estimate for the anti-malarial use (0.38) was similar to the anti-Ro 
antibody estimate but did not reach significance.   Anti-cardiolipin antibodies, 
defined as the presence of 2 positive results at any time during the disease 
duration, are associated with plaque progression with an odds ratio of 3. This 
association has not been found in other longitudinal studies. Baseline steroid 
exposure, cumulative steroid dose or immunosuppressant uses were neither 
predictive nor protective of carotid plaque progression in the current study.  
 Age has been repeatedly associated with atherosclerosis progression and 
this may reflect a longer duration of exposure of various risk factors and their 
cumulative effect on the vasculature. Of interest, of the 4 patients that 
developed a new CHD event over the follow up period, 2 had plaque at baseline 
whilst 2 patients did not.  The very small number of patients with events restricts 
any comment about the predictive utility of carotid plaque in SLE.    
A number of limitations need to be considered when interpreting these 
findings. The sample size in the current study of 127 patients is relatively small 
and whilst the average follow up period of over 5 years is longer than previous 
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studies, this is still a relatively short period of follow up. Plaque progression was 
analysed as a dichotomised variable and therefore didn‟t allow use of all of the 
data most efficiently. There is some debate about which measure of plaque 
progression to use in longitudinal analyses. It should be noted that risk factors 
for disease incidence may be different to those for disease progression or 
severity. In this regard, the most appropriate comparison groups may be those 
with no plaque vs. those with new plaque over time. To obtain meaningful 
results from such analysis would require long-term follow up of a large cohort of 
patients.  The differences observed in this study with regard to IMT may reflect 
the differences in measurement as some previous studies have limited 
measurement to one part of the carotid artery [82]. Additionally, unlike previous 
studies, the current study was limited to white Caucasian females. In other 
studies up to 50% of patients were of none white Caucasian ethnicity and also 
included male patients. 
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 Table 30 Summary of longitudinal studies of carotid IMT and plaque progression 
 
Author 
Baseline 
age : mean 
(SD) years 
Average 
follow up 
period: years 
Sample 
size 
IMT progression: 
mean (SD) cm/yr 
Plaque progression over 
study period 
Factors associated with 
no plaque vs. new / more 
plaque or IMT* 
progression 
Roman et 
al.[289] 
- 2.8 (±0.75) 158 - 
No plaque      48.5% 
New plaque   15.8% 
More plaque  12.7% 
Age at diagnosis 
Disease duration 
Homocysteine level  
Thompson et al. 
[341] 
45.1 (10.3) 4.19 (±1.97) 217 0.0011 (0.003) New / more plaque 27% 
Higher serum C3 levels 
Immunosuppressant use 
Rua-Figueroa et 
al. [293] 
41.5 (11.7) 
2.03 (range 
1.49–2.82) 
101 0.0039 (0.004) New/more plaque 4% 
Age at diagnosis * 
Homocysteine* 
C3 and C5a* 
de Leeuw et al. 
[82] 
37 (14) 2.7(±0.58) 52 0.0012  (0.004) - Age * 
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The current study has highlighted the difficulty in identifying risk factors for 
carotid atherosclerosis progression and would suggest factors other than 
traditional CHD risk factors and commonly measured SLE–related factors are 
contributing to atherosclerosis progression but these factors, as yet, remain to 
be elucidated. The repeated observation that age contributes to atherosclerosis 
progression in SLE and that atherosclerosis occurs at a younger age than 
would be expected in the general population is particularly interesting and lends 
support to the hypothesis that age-related vasculature changes are particularly 
marked in SLE patients and may be related to reduced regenerative capacity of 
the vasculature in these patients.     
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10.5 Endothelial progenitor cells (EPC)  
Endothelial dysfunction has been shown to be an important trigger of 
atherosclerosis and maintenance of endothelial integrity is thought to be crucial 
to prevent atherosclerosis. Endothelial progenitor cells are bone marrow derived 
cells involved in repair and regeneration of the endothelium.    
The objectives of this chapter are to: 
a. Quantify EPC number in SLE 
b. Identify factors associated with EPC in SLE 
c. Describe relationship of EPC to atherosclerotic markers in SLE    
 
10.5.1 Endothelial progenitor cell (CD34+CD133+) quantification protocol   
10.5.1.1 Preparation of blood sample 
Peripheral venous blood (20 ml into EDTA containers) was drawn from 
study participants. An EPC isolation and enumeration protocol was adapted 
from a previously described technique [372] following a period of training at the 
protocol author‟s laboratory in Bonn, Germany. Fresh whole blood was diluted 
in a 1:1 ratio with phosphate buffer solution (PBS without calcium and 
magnesium x1, Lonza, Wokingham, UK).   Diluted blood was then layered onto 
Lymphoprep (Cambrex Biosciences, Wokingham, UK) in a 2:1 ratio and 
centrifuged at 2000 rpm for 30 min.  The PBMC layer was then harvested using 
a pastette as this population of cells contains the cells of interest.  The cells 
harvested using this gradient preparation contained several cell types other 
than mononuclear cells when viewed under a microscope.  In addition, a recent 
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publication would also suggest that cells harvested using Lymphoprep result in 
isolation of fewer CD34 positive cells compared to an alternative, Ficoll-paque 
PLUS (GE Healthcare, Little Chalfont, UK) [309].   Optimum results were 
obtained by layering diluted blood (as described above) onto Ficoll-paque (2:1) 
and centrifuging at 2400 rpm for 40 min, without breaks.  PBMC were then 
washed in PBS, counted and divided into 106 cell aliquots. 
 
10.5.1.2 Enumeration of circulating EPC using flow cytometry  
Mononuclear cells were labelled with conjugated antibodies to identify 
surface antigens specific to EPC and analysed using flow cytometry using 
conjugated antibodies for CD34, CD133 and KDR. Initially, 106 cells were 
stained consecutively with flourescein isothiocyanate (FITC)-conjugated anti-
human CD34 monoclonal antibody (mab) (Miltenyi Biotech, Germany), 
allophycocyanin (APC)-conjugated anti-human KDR mab (R & D Systems, 
USA) and phycoerythrin (PE)- conjugated  anti-human CD133 (Miltenyi Biotech, 
Germany) as described previously [372].  A 106 cell aliquot was also stained 
consecutively with isotype control antibodies (FITC-conjugated anti-mouse 
IgG2a antibody (Miltenyi Biotech, Germany), PE-conjugated anti-mouse IgG2b 
(Miltenyi Biotech, Germany) and APC-conjugated anti-mouse IgG1antibody (R 
& D Systems, USA) for comparison.  Unlabelled cells were also analysed to 
assess the autofluorescence of the cells.  Initial analysis using this protocol 
resulted in a high degree of non-specific binding. Density plot 1 of Figure 16 
demonstrates the characteristics of unlabelled cells.  Each dot represents a 
single cell or event on this two parameter histogram. The x-axis of this 
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histogram represents increasing levels of fluorescence detected.  The y-axis 
represents the amount of side-scattered light from each cell.    
 
 
 
 
 
Figure 16. Flow cytometry analysis of PBMC   
A series of experiments were carried out altering several factors 
consecutively in order to eliminate non-specific binding with all three antibodies 
separately.  Samples were incubated for 5, 10, 15 and 20 minutes in separate 
experiments. Samples were also incubated using differing volumes of antibody 
namely 5ul, 10ul and 15ul.  Optimal results for the CD34 and CD133 antibodies 
were obtained by making the following changes to the protocol:  
a. Pre-treating the sample with an Fc blocking agent (Miltenyi Biotech, 
Germany ) to saturate non-specific antibody binding sites (10ul for 
10 min) 
1. Flow cytometry analysis of 
unlabelled PBMC - very few events 
positive (in the boxed region) 
2. Flow cytometry analysis of PBMC 
stained with isotype controls – many 
cells staining non-specifically  
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b. Simultaneously incubating with antibodies ( for 10 min) rather than 
consecutively    
c. Staining with smaller volumes of antibody (5ul rather than 
manufacturer‟s recommended volumes)   
Simultaneously incubating with CD34 and CD133 antibodies did not 
change yield of cells enumerated using flow cytometry.  
Figure 17 shows a representative result of analysis on cells using an 
optimised protocol with several altered parameters and demonstrates very little 
difference between the unlabelled and isotype – control labelled cells, indicating 
that events detected using the positive conjugated-antibodies represent genuine 
cells with the surface antigen of interest.  
 
 
 
 
 
 
 
 
 
 
 
Figure 17 Flow cytometry of PBMC with optimised protocol for CD34 and CD133 
 
Flow cytometry analysis of 
unlabelled cells 
Flow cytometry analysis of 
cells labelled with isotype 
control antibody (FITC and 
PE) 
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A number of protocol modifications were made using the KDR antibody 
including differing the incubation time and temperature as well as the volume of 
antibody used. However, as demonstrated in Figure 18, results could not 
reliably and consistently identify antibody-labelled cells distinct from isotype 
control-labelled cells. At the time of the study conjugated anti-human KDR mab 
was not available from any other manufacturer and therefore KDR labelling was 
not used in further experiments.  
 
 
 
 
 
Figure 18 Flow cytometry analysis using KDR antibody after protocol 
modifications 
Flow cytometry analysis of 
cells labelled with isotype 
control antibody (APC) 
 
Flow cytometry analysis of 
cells labelled with APC-
conjugated KDR antibody 
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In addition, a number of events were detected with a very high degree of 
fluorescence (far right quadrant of density plot 2 of Figure 16).  These events 
are likely to represent clumped debris or dead cells.  Incubation of cells with 7 
amino-actinomycin D (Sigma Aldrich, UK), a DNA intercalater, which is 
excluded by viable cells (0.4ul incubated for 20 min), was carried out and 
enabled these cells to be excluded from the flow cytometry analysis.  
 
 
 
 
 
 
 
 
 
 
Figure 19 demonstrates density plots of cells labelled with antibodies with and 
without the addition of 7 AAD.  
  
Figure 19 demonstrates density plots of cells labelled with antibodies with 
and without the addition of 7 AAD.  The second density plot in Figure 20 
demonstrates fewer events in the extreme of the x-axis when cells that have 
stained with 7 AAD are accounted for.   All participant samples were aliquoted 
and 106 cells were stained with 2 antibodies separately (CD34 & CD133) as 
well as in dual combination to allow compensation of the wavelength of light 
detected with flow cytometry as well with isotypes (separately and dual 
combination) and compared to an unlabelled cell sample prior to enumeration of 
1. Cells labelled with fluorescent 
antibodies, no 7AAD  
2. Cells labelled with fluorescent 
antibodies and stained with 
7AAD  
 141 
 
CD34 + CD133 + cells. Flow cytometry analysis was undertaken within one 
hour of cell labelling.  All PBMC were analysed including the lymphocyte and 
monocyte populations as current literature would suggest that EPC have 
physical characteristics intermediate to these populations [296]. A comparison 
of numbers of EPC between SLE patients and age (within 10 years) and 
gender-matched non-SLE controls were undertaken assessing the numbers of 
CD34+ CD133+ cells. Figure 20 demonstrates analysis of participant (JB). The 
samples have been gated to exclude 7-AAD positive events and to include 
those cells identified within the gate of plot 2Plot 1 of Figure 20 demonstrates 
the autofluorescence of unlabelled cells; plot 2 demonstrates cells labelled with 
isotype control antibodies and plot 3 demonstrates cells labelled with both 
antibodies simultaneously.      
1. Unlabelled cells  
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Figure 20 Flow cytometry analysis of PBMC gated for 7-AAD negativity. R5 demonstrates 
CD34+CD133+ cells of interest  
2. Cells labelled with isotype control 
antibody (FITC and PE) 
3. Cells labelled with FITC-
conjugated CD34 mab and PE-
conjugated CD133 mab 
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The density plots of Figure 20 are able to show that the optimising steps 
have ensured that only cells positive for the surface markers of interest have 
been identified and enumerated.  CD34+ CD133+ cells are identified in the R5 
gate of plot 3.  The percentage of CD34+ CD133+ cells in R5 are used in the 
analysis.  
10.5.2 Endothelial cell colony-forming units protocol  
Endothelial cell number and function were assessed by quantifying the 
number of CFU formed in culture.  The protocol used was adapted from 
techniques described by Asahara [12] and Hill [152].  PBMC were separated 
from 20 ml of venous blood using a ficoll gradient as described above.  The 
recovered cells were washed once in PBS and once in supplemented 
endothelial media (EGM®-2 Endothelial Cell Growth Medium-2, Lonza). To 
avoid contamination with mature endothelial cells and other cell types, PBMC 
were pre-plated on a 12 well fibronectin-coated plate (Becton Dickinson 
Biosciences, UK) in 1ml of media. After 48 hours, 106 non-adherent cells were 
then washed in endothelial media and re-plated on a 24 well fibronectin-coated 
well (Becton Dickinson Biosciences, UK) in 500ul of supplemented media.  
Optimal results were obtained with media change every 3 days. Initial 
supplementation with 2% foetal bovine serum (FBS) resulted in suboptimal 
colony formation at day 7 (Figure 21). Supplementation with 20% FBS resulted 
in enhanced CFU formation (Figure 22). Colonies are counted manually at day 
7.  A colony is defined as a clump of cells with cells radiating from the 
peripheries [152].   
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Figure 21 CFU enumeration using 2% FBS supplementation to media 
 
 
 
Figure 22 Endothelial colony-forming units (CFU) at day 7 
 
CFU were characterised using immunohistochemistry to demonstrate 
origin from endothelial cells. Blue fluorescent DAPI (DAPI™ nucleic acid stain, 
Lonza) was used to stain nuclei as previously described [176]. CFU were 
stained with PE Mouse Anti-Human CD31 (PECAM-1, BD Biosciences) as 
Possible early colonies  
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CD31 is highly expressed on endothelial cells as well as platelets and 
neutrophils. CD31 is thought to play an important role in transendothelial 
migration of leukocytes in inflammatory responses [246, 252].  CFU were also 
stained with acetylated low density lipoprotein, labelled with 1,1\'-dioctadecyl – 
3,3,3\',3\'-tetramethyl-indocarbocyanine perchlorate (DiI-Ac-LDL). DiI-Ac-LDL 
labels vascular endothelial cells and macrophages.  Within labelled cells the 
lipoprotein is degraded by lysosomal enzymes and the DiI (fluorescent probe) 
accumulates in the intracellular membranes [126, 359]. Figure 23 demonstrates 
staining of CFU with DiI-Ac-LDL. Figure 24 and Figure 25 demonstrate positive 
staining with CD31.  
 
 
 
 
  
 
 
 
 
 
Figure 23 CFU stained positively with Dil-Ac-LDL (green) at day 7 (x20)
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a 
 
 
 
 
 
Figure 24 CFU with nuclei stained blue with DAPI (x20) 
a. CFU cells stained with control antibody (negative) 
b. CFU stained with CD31 antibody (positively stained red)  
 
 
 
 
  
 
 
 
 
Figure 25 CFU with nuclei stained blue with DAPI (x63)  
a. CFU cells stained with control antibody (negative) 
b. CFU stained with CD31 antibody (positively stained red)  
 
 
The isolation of PBMC prior to plating was used to exclude other cell types 
prior to culture.  Subsequent staining of CFU with both diI-Ac-LDL and CD31 
was accepted as evidence of endothelial cells origin.  
b 
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10.5.3 CD34+ CD133+ EPC number in SLE and controls  
EPC were quantified using the above protocol in 54 SLE patients and 49 
controls.  The characteristics of SLE patients and controls are summarised in 
Table 31. SLE patients were older than controls and therefore further analysis 
will be age-adjusted. The overall characteristics reflect those of the entire 
cohort.  
 
Table 31 Characteristics of SLE patients and controls included in EPC analysis 
 
The number of CD34+ CD133+ cells did not differ between SLE patients 
and controls (Figure 26).  CD34+ CD133+ cells did have a significant correlation 
to age with a small regression coefficient of 0.0006 (p=0.006). After adjusting 
for the difference in age  at the time of assessment , there was no significant 
difference between SLE patients and control with regard to number of 
CD34+CD133+ cells (R2 = -0.005, p=NS). Additionally, there was no difference 
in number of CD34+CD133+ cells in those participants under the age of 50 
years (Figure 27). 
 
 
SLE patients 
(n=54) 
Controls 
(n=49) 
P value 
Age at assessment: med (IQR) years 53 (47, 59) 50 (31, 59) 0.03 
Hypertension: n (%) 15 (28) 4 (9) 0.012 
Systolic blood pressure: mean (SD) 130 (22) 123 (20) NS 
Hypercholesterolaemia: n (%) 25 (46) 10 (20) 0.006 
Total cholesterol: mean (SD) 4.7 (1.1) 5.1 (1.0) NS 
Diabetes mellitus: n (%) 2 (3) 0 NS 
Fasting blood glucose : med (IQR) 4.8 (4.4, 5.2) 4.6 (4.5, 4.8) NS 
Family history of CHD: n (%) 18 (36) 14 (33) NS 
BMI: med (IQR) 26 (25, 31) 25 (23, 28) NS 
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Figure 26 No significant difference of CD34+ CD133+ cell number between SLE 
patients and controls 
 
Figure 27 No significant difference of CD34+ CD133+ cell number between SLE 
patients and controls less than age 50 yrs 
0 
.02 
.04 
.06 
.08 
.1 
 
SLE 
(N=19) 
Controls 
(N=49) 
p=NS 
SLE 
(N=54) 
Controls 
(N=49) 
p=NS 
% 
% 
.15 
.1 
.05 
0 
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10.5.3.1 Factors associated with EPC 
Factors associated with EPC in SLE were determined. Of interest, EPC 
number in controls was significantly correlated to age (β 0.33 (0.0002), p = 
0.02) in contrast to SLE patients, where there was no correlation (β 0.22 
(0.0004), p = 0.12).  
Table 32 Traditional risk factors associated with CD34/CD133+ EPC in SLE 
 
 
Hypertension and systolic blood pressure both correlated with EPC in the 
unadjusted analysis but were no longer associated when adjusted for age. 
Other traditional cardiovascular risk factors were not correlated to EPC number 
in SLE patients (Table 31).    
 
 
 
Baseline factors 
 
Unadjusted 
 
Age-adjusted 
 
β (SE) P value β (SE) P value 
Age 
.2187042 
(.0004348) 
NS 
- 
- 
Total cholesterol  
.0270632 
(.0028849) 
NS 
-.0390989 
( .0029037) 
NS 
Hypercholesterolemia  
.2484947 
(.0060021) 
0.01 
  .1664164 
(.006553) 
NS 
Statin therapy  
.0828812 
(.0100547) 
NS 
.0564684 
(.010117) 
NS 
Systolic blood pressure 
.2138145 
(.0001397) 
0.033 
.1074157 
( .0001556) 
NS 
Hypertension  
.1846548 
(.0075668) 
NS 
.1242826 
( .0076618) 
NS 
Anti-hypertensive therapy  
.16305 
(.0098648) 
NS 
.1344704 
(.0100758) 
NS 
Fasting glucose 
.1358739 
(.0042327) 
NS 
.0591029 
( .0043744) 
NS 
Type 2 diabetes 
-.0022219 
(.0233291) 
NS 
.0184777 
(.0235775) 
NS 
Smoking ever  
.1689538 
(.0058025) 
0.08 
.1468692 
( .0058145) 
NS 
Body mass index  
.0426935 
(.0005145) 
NS 
-.0301414 
( .0005203) 
NS 
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Table 33 Disease-related factors associated with EPC number in SLE 
 
 
SLE-related factors were not correlated with EPC number.  Furthermore, 
EPC did not correlate with aortic stiffness as measured by aortic pulse wave 
velocity β (SE) 0.011 (0.006), p=NS), CIMT (β (SE) -0.17 (0.51), p=NS) or 
plaque (β (SE) 0.09 (0.01), p=NS).  
 
 
Baseline factors 
 
Unadjusted 
 
Age-adjusted 
 
β (SE) P value β (SE) P value 
Renal disease 
.0475128 
(.0091376) 
NS 
.0555139 
( .0089372) 
NS 
Creatinine  
.0223855 
(.0000931) 
NS 
.0188541 
(.0000914) 
NS 
SDI 
.0116419 
(.0024569) 
NS 
.0422901 
(.0025584) 
NS 
SLEDAI 
.1316361 
(.0013507) 
NS 
.1472096 
(.0013569) 
NS 
C3 
-.1353044 
(.013717) 
NS 
-.1922454 
(.0145901) 
NS 
Ro  
.1239281 
(.008498) 
NS 
.0796516 
(.0084726) 
NS 
La 
.1040494 
(.0098589) 
NS 
.0826437 
(.0096874) 
NS 
Sm - NS - NS 
RNP 
-.1781443 
(.0149481) 
NS 
-.1772241 
(.0145911) 
0.07 
Anti-cardiolipin antibody 
.0920775 
(.0099209) 
NS 
.0773991 
(.0096769) 
NS 
Anti-malarial use 
.0641122 
(.0065244) 
NS 
.0038135 
(.0066523) 
NS 
Immunosuppressant use  
.2011236 
(.0063224) 
NS 
.1803834 
(.0063672) 
NS 
Azathioprine use 
.0635077 
(.008045) 
NS 
.0655233 
(.0079106) 
NS 
Steroid use current 
.1684823 
(.0073626) 
NS 
.1417321 
(.0072287) 
NS 
Steroid exposure ever 
.1756041 
(.0057666) 
NS 
.1574951 
(.0058799) 
NS 
Aspirin use  
-.0595755 
(.0150974) 
NS 
-.0478631 
(.01484) 
NS 
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10.5.4 CFU in SLE 
CFU were enumerated in 39 SLE patients with a median (IQR) age of 53 
(46, 58) years and 27 controls aged 43 (28, 55) years.  SLE patients formed 
significantly fewer CFU compared to healthy controls. The median (IQR) of CFU 
in SLE was 5.7 (2.3, 8.0) and in controls was 10.0 (5.7, 15.0); p= 0.0016 as 
demonstrated graphically in Figure 28.    
          
 
Figure 28 Mean CFU number lower in SLE compared to controls 
 
The difference in number of CFU between SLE patients and controls 
remained significant after adjusting for age; β (SE) 0.40 (2.49), p=0.002. The 
difference in the number of CFU was particularly marked amongst the 6 SLE 
patients and 12 controls under the age of 40 years; median CFU 4 (2, 8) vs. 
10.5 (7, 19), p= 0.03 and less marked in those over the age of 50 years     
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Figure 29 Mean CFU number lower in SLE compared to controls in those less 
than 40 years old 
 
Figure 30 Mean CFU number lower in SLE compared to controls in those more 
than 40 years old 
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The numbers of CFU with greater than 50 cells in the central cluster were 
enumerated. SLE patients formed an average of 0 (0, 2) large CFU compared 
to 3 (0, 10) formed by controls; p = 0.004. Furthermore 11/39 (28%) of SLE 
patients formed any large CFU compared with 17/27 (63%) of controls; p=0.02.  
10.5.4.1 Factors associated with CFU number in SLE patients  
Factors associated with CFU formation within the SLE population (n=39) 
were analysed. Traditional cardiovascular risk factors did not correlate with CFU 
formation. SLE-related factors including renal disease, antibody profile, disease 
activity, damage index and therapy did not correlate with CFU number (Table 
35). However the presence of anti-cardiolipin antibodies (aCL) was positively 
correlated with CFU number and remained significant when adjusted for age. 
One possible explanation for this is the use of aspirin however the correlation 
with aCL also remained positive when adjusted for aspirin therapy (β 
0.3580549, p = 0.023). Similarly the correlation of aspirin therapy with CFU 
number remained significant after adjustment for age and aCL (β 0.4139033, p 
= 0.011).  
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Table 34 Traditional risk factors associated with CFU formation in SLE 
 
 
 
 
 
 
 
 
 
 
 
Baseline factors 
 
Unadjusted  
 
Age-adjusted 
 
β (SE) P value  β (SE) P value 
Age 
.0393367 
(.0834571) 
NS 
- 
- 
Disease duration  
-.0615574 
(.0826601) 
NS 
-.0807062 
( .0877457) 
NS 
Total cholesterol  
.2240077 
(.8563361) 
NS 
.2186055 
(.8779495) 
NS 
Hypercholesterolemia  
.1945315 
(1.787787) 
NS 
.1732577 
(2.016818) 
NS 
LDLc 
.1105569 
(.9475673) 
NS 
.1051584 
(.9708252) 
NS 
Triglycerides  
-.0872086 
(1.356703) 
NS 
-.0721542 
(1.398444) 
NS 
Systolic blood pressure 
.125241 
( .044178) 
NS 
.1046377 
( .0467203) 
NS 
Hypertension  
.1142344 
(2.029275) 
NS 
.1031204 
( 2.081757) 
NS 
Fasting glucose 
.0233524 
(1.326692) 
NS 
.0129338 
( 1.370776) 
NS 
Type 2 diabetes 
.1442572 
(5.163697) 
NS 
.1418649 
( 5.267045) 
NS 
Smoking ever  
-.1502769 
(1.576456) 
NS 
-.1535755 
( 1.601833) 
NS 
Family history of CHD 
.0660778 
(1.918217) 
NS 
.0424189 
( 1.993597) 
NS 
Body mass index  
-.2637483 
(.1581398) 
NS 
-.263916 
( .1602434) 
NS 
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Table 35 Disease-related risk factors associated with CFU formation in SLE 
 
 
The average CFU number was greater in those taking aspirin compared to 
those not (7 [2, 18]) vs. (5 [2, 7]; p =0.045). The median CFU number was 
similar between those taking statins and those not.  
 
Baseline factors 
 
Unadjusted  
 
Age-adjusted 
 
β (SE) P value  β (SE) P value 
Renal disease 
-.0812705 
(2.142181) 
NS 
-.0978295 
(2.202384) 
NS 
Creatinine  
-.119968 
(.0139802) 
NS 
-.1240429 
(.0146683) 
NS 
SDI 
-.2582043 
(.4773714) 
NS 
-.2339211 
(.5252232) 
NS 
SLEDAI 
.1016079 
(.2458143) 
NS 
.1458744 
(.2585666) 
NS 
C3 
.1497136 
(2.97865) 
NS 
.2821646 
(3.505684) 
NS 
C4  
.0861817 
(15.09932) 
NS 
.1421088 
(16.1829) 
NS 
Ro  
.1451259 
(2.126536) 
NS 
.1344198 
(2.215996) 
NS 
La 
.1040958 
(2.703892) 
NS 
.1029149 
(2.773674) 
NS 
Sm -  -  
RNP 
-.1716301 
(3.049402) 
NS 
-.1792056 
(3.107327) 
NS 
Anti-cardiolipin antibody 
.3629715 
(2.595709) 
0.03 
.3859076 
(2.658597 
0.02 
Anti-malarial use 
-.0084068 
(1.699944) 
NS 
-.0207861 
(1.84168) 
NS 
Immunosuppressant use  
-.1560263 
(1.741649) 
NS 
-.1746781 
(1.850143) 
NS 
Azathioprine use 
-.1553937 
(1.728435) 
NS 
-.170063 
(1.776749) 
NS 
Steroid use current 
-.0127074 
(1.781797) 
NS 
-.0290727 
(1.832436) 
NS 
Steroid exposure ever 
.0016071 
(1.742038) 
NS 
.0295924 
(1.801269) 
NS 
Statin use 
.2754097 
(1.717979) 
NS 
.2714922 
(1.819499) 
NS 
Aspirin use  
.3225228 
(2.163891) 
0.045 
.3384277 
(2.248571) 
0.045 
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The correlation of CFU number and markers of subclinical atherosclerosis 
were assessed. Aortic stiffness was measured by the aortic pulse wave velocity 
(APWV) and the median (IQR) APWV amongst the 39 SLE patients was 
5.7(3.8, 8.6) m/s. CIMT was 0.062 (0.053, 0.070) cm and 12 (31%) patients had 
one or more plaque. CFU number did not correlate with APWV, CIMT or carotid 
plaque in this group of patients. One patient had a history of myocardial 
infarction and this patient did not form any CFU in culture.  
 
Table 36 CFU and markers of atherosclerosis in SLE 
 
 
 
 
 
 
 
 
 
 
Baseline factors 
 
Unadjusted  
 
Age-adjusted 
 
β (SE) P value  β (SE) P value 
APWV 
-.1054126 
(.1319949) 
NS 
-.1098138 
(.134661) 
NS 
CIMT 
.1865284 
(92.18052) 
NS 
.2925301 
(101.626) 
NS 
Carotid plaque 
-.1694966 
(1.788406) 
NS 
-.1351411 
(-.1351411) 
NS 
Carotid plaque progression 
-.2583806 
(2.338805) 
NS 
-.2207638 
(2.527775) 
NS 
CIMT progression  
.2144084 
(125.3675) 
NS 
.1811628 
(133.1052) 
NS 
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10.5.4.2 Discussion  
CD34+CD133+ EPC in SLE 
EPC were quantified in 54 SLE patients and 49 healthy controls using flow 
cytometry. This group of patients were chosen at random and were 
representative of the overall cohort as demonstrated in Table 311. Whilst a 
statistically significant higher proportion of SLE patients were hypertensive the 
systolic blood pressure indicates that these patients had well controlled blood 
pressure.  Similarly, whilst a higher proportion of patients had a diagnosis of 
hypercholesterolaemia and were therefore more likely to be on statin therapy, 
there was no significant difference in the overall cholesterol titre.  
CD34, CD133 and KDR were chosen as surface markers to identify EPC 
based on previous literature [12, 112, 263, 331]. However, following several 
experiments to optimise the use of the KDR antibody and personal 
communication with other groups, it was decided that this antibody could not be 
reliably utilised. EPC were therefore defined as CD34+CD133+ cells. CD34 is a 
marker expressed on bone marrow-derived haematopoietic cells  and mature 
endothelial cells in contrast to CD133 which has been shown to be expressed 
on haematopoietic progenitor cells but not on mature endothelial cells [119, 
263, 317] indicating that CD34+CD133+ cells are identifying an immature 
subpopulation of EPC.  
There was no significant difference in the number of CD34+CD133+ cells 
between SLE patients and controls. Of interest age was correlated to 
CD34+CD133+ cells within  the control population but not within the SLE group. 
This may in part be due the narrow age group of SLE patients studied (IQR 47 – 
59 years) in comparison to the control group (IQR 31 – 59 years). Traditional 
 158 
 
risk factors did not correlate with EPC number in this study. Seven (13%) of 
patients were taking statin therapy and 16 (30%) were taking an anti-
hypertensive medication. Statin or anti-hypertensive therapy use did not 
correlate with EPC number. EPC number did not correlate to markers of 
atherosclerosis including APVW, CIMT or carotid plaque. Disease-related 
factors also did not correlate to EPC number in this study including the clinical 
phenotype of patients, measures of disease activity or damage, antibody profile 
or therapies. Since the commencement of this study, 3 other groups have 
reported on EPC in SLE. One previous study has demonstrated a reduction of 
CD34+KDR+ EPCs in 15 SLE patients compared with 15 healthy controls [373] 
and another of  30 patients with SLE compared with 14 healthy controls 
reported a reduction of CD34+/CD133+/VEGFR2+ EPCs in patients with SLE.  
EPC level in the latter study was correlated with SLEDAI but not age or 
Framingham score [87]. Lastly Moonen et al. reported a reduction in 
CD34+CD133+ EPC in 20 SLE patients compared to 20 healthy controls [242]. 
Possible explanations for the discrepancy of the findings between different 
studies may be related to small sample sizes or due to the differences within the 
study population such as ethnicity, therapies, disease activity or differences in 
disease phenotype.  Furthermore, previous studies have identified cells with a 
different combination of surface markers and therefore may have identified a 
different subpopulation of EPC. The group that measured CD34+CD133+ cells 
studied a population of patients with a mean age 40 ± 12 years [242]. Our 
patients were on average a decade older and it is possible that the discrepancy 
in EPC number between SLE and controls is less marked with advancing age.  
One other important difference in the methodology used by different groups is 
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the quantification of cells.  Some groups have included absolute counts per 
volume of blood (e.g. [373] whilst others have measured percentage of the 
mononuclear cell population [135] as in this study. Lymphopenia amongst 
patients may possibly result in an underestimation of EPC in our population 
since a 1/3 (n = 18) of our patients had a lymphocyte count of less than 1.0. 
However, we did not observe a significant correlation between lymphocyte 
count and EPC number in our study (β – 0.07 (3.29), p =NS). It is also possible 
that lymphopenia may result in bone marrow stimulation and in which case 
relatively more progenitor cells may be detectable. More recent studies of EPC 
in SLE are in keeping with the findings of the current study and have 
demonstrated no significant difference of number of EPC measured using flow 
cytometry in SLE patients compared to controls or even a slight excess of EPC 
in SLE [93, 135].  
The lack of EPC deficiency in SLE is in contrast to other chronic conditions 
resulting in excess CHD e.g. diabetes or rheumatoid arthritis where EPC 
number has been shown to be reduced [134, 339]. One possible contributing 
factor is the relative lack of CRP response in SLE. A previous study using blood 
from healthy males has demonstrated increased apoptosis of EPC in culture 
when treated with CRP at concentrations > 15 µg/mL. Similarly, patients with 
type 2 diabetes with a high hsCRP have been shown to have reduced number 
of EPC compared to those with low hsCRP [192, 355]. Furthermore, absolute 
numbers of EPC may be less important in SLE. The EPC present in SLE may 
be functionally impaired and therefore the total number of „effective‟ EPC in SLE 
would therefore be reduced. SLE patients have been shown to have 
accelerated atherosclerosis and increased endothelial dysfunction [95, 290] 
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compared to controls and it may be that an EPC number comparable to healthy 
controls is not able to effectively regenerate and maintain the vasculature. It 
must be considered that cells identified using these surface markers using flow 
cytometry may in fact not be EPC but another population of cells also arising 
from the haematopoietic stem cell lineage. Of interest, whilst CD34+CD133+ 
cells were not different between patients and controls, they did show a positive 
correlation with CFU (R2 0.30, p =0.01) which was not attenuated following 
adjustment for age.  
CFU in SLE 
CFU formation was assessed in 39 SLE patients and 27 healthy controls. 
CFU formation is likely to reflect a composite marker indicating both the number 
of EPC and also functional ability to migrate to a cluster of cells and adhere to 
fibronectin. SLE patients were found to form significantly fewer CFU compared 
to controls and the difference was particularly marked in the younger age 
groups.  
Ablin et al. reported no significant difference in CFU number of 28 SLE 
patients and 50 controls [3]. A number of differences between those patients 
and the current cohort need to be considered when interpreting their findings. 
SLE patients were on average 37.7 ± 14.7 years old and controls 43.3 ± 18.2 
years old and included males. Patients with a prior history of high dose steroid, 
cyclophosphamide or MMF use were excluded suggesting the group studied 
were of a less severe phenotype. Fewer patients had a diagnosis of 
hypertension (12.9%) or hypercholesterolaemia (6.5%) compared to the current 
study. Ablin and colleagues did note an impaired adhesion of cells to fibronectin 
in SLE patients which was interpreted as a marker of impaired function. CFU 
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number or adhesion scores did not vary with disease activity. Grisar et al. also 
reported on CFU number in 13 SLE patients and 12 controls. The ages of these 
patients were not reported but the overall population of 31 SLE patients were 
aged 35 ± 2 years.  CFU number was similar between the 2 groups but they too 
reported a reduction in migratory and adhesive properties in SLE patients. 
Small sample size and several differences in the study populations as 
highlighted above may account for the discrepancy in number of CFU noted in 
these 2 studies compared to current study.   
Comparable with our findings, 2 other recent studies have reported 
reduced CFU number in SLE compared to controls. Moonen et al.  quantified 
CFU in 10 SLE patients and 10 healthy controls. The author noted, as we did, 
that the morphology of the CFU were very different amongst SLE patients. 
Figure 31 demonstrates the morphological differences of CFU in SLE patients 
and controls from my study.  
 
 
 
 
 
 
 
 
 
Figure 31 Examples of CFU (x50) a. typical CFU from a control. b. typical  
CFU from an SLE patient 
 
a
. 
b
. 
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SLE patients included in the study by Moonen et al.  had quiescent 
disease and demonstrated a reduced number of CFU compared to controls but 
noted adhesion and migratory properties were similar between the two groups. 
Lee et al.  reported on 70 SLE patients with an average age of 35 (27-45) years 
and 31 healthy controls aged 36 (26.5-44) years. The SLE population included 
males and 2/3 of patients were non-white Caucasian. They found SLE patients 
had significantly fewer CFU than controls but no correlation of CFU to traditional 
cardiovascular risk factors or SLE-related factors. Of particular interest, this 
group found CFU depletion was particularly marked in those patients with high 
Type I interferon (IFN-I) levels. Further they demonstrated that IFN-I inhibited 
EPC proliferation in culture and that IFN-I was also associated with endothelial 
dysfunction on SLE. The authors suggested endothelial dysfunction is mediated 
via IFN-I actions on EPC. IFN levels have previously been shown to correlate to 
disease activity and damage in SLE and this proposed contribution to 
atherosclerosis is of much interest [25].   
Studies with a small sample have not commented on clinical factors 
related to EPC/CFU number. The largest study to date was reported by Lee et 
al. and included 70 patients with SLE. No significant correlation was detected 
between CFU and CHD-related or disease-related factors.  Age and traditional 
CHD risk factors were not associated with CFU in our study (Table 34). Aspirin 
use, however did have a correlation with CFU number (R2 = 0.10, p = 0.045) 
which was not attenuated after age-adjustment. This relationship remained 
unchanged after adjusting for the presence of aCL which itself was correlated 
with CFU (R2 = 0.15, p = 0.02). Seven patients (18%) were taking aspirin at the 
time of the study and many of these patients were taking additional anti-
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hypertensive medications which may also be confounding factors. The 
association of aspirin with CFU number may support the debate for anti-platelet 
primary prevention of CHD in SLE but requires further investigation.  The 
association of aCL with CFU is interesting as the overall role of aCL in CHD risk 
is unclear. Previous studies have suggested aCL contribute to the initiation and 
instability of plaque [120, 188] whilst others have suggested some subtypes of 
aCL may be atheroprotective [253]. A positive correlation with CFU would 
support an atheroprotective effect of aCL.  
CFU did not correlate with aortic stiffness, CIMT or plaque in this study.  
APWV and carotid plaque did however indicate a negative association albeit 
non-significant. A larger sample size may have elucidated a significant 
relationship.  Alternatively CFU abnormalities can potentially be assumed to be 
an early risk for atherosclerosis in SLE since it was not associated with other 
markers of atherosclerosis in this study such as carotid plaque.  
Studies with larger sample sizes are required to clarify these initial 
findings. Whilst these small and perhaps preliminary in vitro studies provide an 
interesting potential mechanism for the excess of CHD observed in SLE, further 
larger studies will be necessary both in patients and animal models to establish 
a true reflection of in vivo actions of endothelial progenitor cells.    
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10.6 Telomere length in SLE 
SLE patients have been shown to have a premature onset of subclinical 
atherosclerosis and clinical CHD. The early onset of atherosclerosis may be 
related to premature biological ageing of cells.  A premature senescent 
phenotype may also be contributing to endothelial cell abnormalities observed. 
The objectives of this chapter are to  
1. Determine if there is evidence of premature biological ageing of 
peripheral blood cells from SLE patients   
2. Determine factors associated with senescent cells 
3. Describe association of senescent cells with markers of  
atherosclerosis 
   
10.6.1 Telomere length measurement  
All participants had a 5ml sample of blood taken at the time of the clinical 
assessment which was frozen at -80 degrees until DNA extraction. Genomic 
DNA was extracted from whole blood using an 8LX Automated DNA Extractor.  
DNA was measured using a NanoDrop ND-1000 UV – vis spectrophotometer, 
normalised to a 10 ng/ μL concentration and stored at -80 degrees.  Mean 
telomere length was measured using a fluorescence-based quantitative real 
time polymerase chain reaction adapted from the protocol previously described 
[57]  comparing telomere repeat sequence copy number to single-copy gene 
(RNAseP) copy number in a given sample using his improved primer set (Tel2a 
and Tel2b) and 36B4 as the single copy control gene as previously described 
[45].  The following primer sequences (5‟- 3‟) were used: 
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Tel1b CGGTTTGTTTGGGTTTGGGTTTGGGTTTGGGTTTGGGTT 
Tel2b GGCTTGCCTTACCCTTACCCTTACCCTTACCCTTACCCT 
36B4F CAGCAAGTGGGAAGGTGTAATCC 
36B4R CCCATTCTATCATCAACGGGTACAA  
Telomere (T) and 36B4 (S) runs were performed separately.  Master 
mixes for both were made up at the same time to ensure the same SYBR green 
and qPCR mix was used.  The T run was performed for the samples followed 
immediately by the S run, to keep conditions uniform. Each S sample was 
plated in the well in the identical corresponding position as the T sample. Each 
plate included 3 no template control (NTC) samples. 
DNA samples were amplified in triplicate in parallel 10.2 μL PCR 
reactions.  Each reaction consisted of: 
1. 3μl (30 ng) of DNA sample 
2. 5 μl of 2 x mastermix (SensiMix NoRef DNA kit, Quantace, Cat No 
QT505-20) 
3. 0.2 μl  SYBR Green (DNA kit, Quantace, Cat No QT505-20)   
4. 1μl Tel2a (600nM final concentration) or 36B4F (300nM final 
concentration)   
5. 1μl Tel2b (600nM final concentration) or 36B4R (500nM final 
concentration)   
  
All PCR were undertaken with the LightCycler 480 real time PCR machine 
(Roche Diagnostics, UK) with the following cycling conditions: 
T  95C for 10min followed by 30 cycles of 95C for 15 sec and 58C for 1min 
 
S  95C for 10min followed by 30 cycles of 95C for 15 sec and 58C for 1min 
 
All reactions were followed by a 10 second cooling period at 40˚C 
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10.6.2 Telomere length analysis 
To determine the telomere length, the amount of product produced in the 
telomere assay was compared to the amount of product produced from the 
36B4 assay.  LightCycler 480 software was used to calculate the second 
derivative of the real-time amplification curve. The peak of the second derivative 
curve represents the maximum exponential growth of the product. The point 
80% back from the peak is defined as the takeoff point, and the amplification 
efficiency calculated from the section of curve between these two points. The 
product is calculated for samples in this way. All samples were run in parallel 
with the same reference sample (from a control participant).  Samples were 
directly compared to the reference sample. The ratio of telomere and 36B4 
products is proportional to the average telomere length. The telomere length is 
therefore expressed as T relative conc / S relative conc (T/S). See Appendix 11 
for excel sheet calculation of relative telomere length.   
The NTC wells appeared to form some product within the PCR reactions 
and this is likely to be due to the formation of primer product. Primer products 
appeared at a much later cycle than the PCR product of interest and therefore 
were easily distinguished as demonstrated in Figure 32 and Figure 33.  
. 
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Figure 32 Amplification curve for PCR using telomere primers a. DNA sample in 
triplicate showing tight replication b. NTC amplifying at much later cycle 
 
 
 
Figure 33 Amplification curve for PCR using 36B4 primers a. DNA sample in 
triplicate showing tight replication b. NTC amplifying at much later cycle 
 
a  b 
a  b  
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10.6.3 Telomere length measurement validation  
DNA from each individual was plated in triplicate and samples showed 
very little variance within the triplicates (Figure 34).  
 
   
 
 
 
 
 
 
 
Figure 34 Schematic of PCR plate layout and graph demonstrating little variation 
of product between triplicate samples 
 
 
Thirty-five randomly chosen samples were also repeated at a second time-
point to ensure repeatability. Figure 36 and Figure 36 demonstrate good 
repeatability between measurements at different time points.   
 
 
 
 
 
 
 
Mean difference 
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Figure 35 Relative telomere length measured at 2 separate time points show good 
correlation  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 36 Bland Altman plot of difference between telomere length 
measurements at 2 time points (measurements outside shaded area excluded 
from analysis) 
 
 
 
Difference between 2 
measurements  
Telomere length 
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10.6.4 Telomere length association with age  
Telomere length measurement had an overall negative correlation with 
age with R2 of -0.01, p = 0.09.  The correlation was similar between SLE patients 
and controls (Figure 37). 
 
 
 
Figure 37 Correlation of telomere length in 63 SLE (R2 -0.005, p=NS) and 63 
controls (R2 -0.003, p=NS); y-axis represents relative telomere length 
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10.6.5 Telomere length in SLE and controls 
Telomere length was measured in 63 SLE patients and 63 age matched 
controls. The median (IQR) telomere length amongst SLE patients and controls 
was 0.97 (0.47, 1.57) and 1.53 (0.82, 2.29) respectively. SLE patients had 
significantly shorter relative telomere length (Figure 38). 
 
 
 
 
Figure 38 Telomere length in SLE patients and healthy controls; y-axis 
represents relative telomere length 
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10.6.6 Factors associated with telomere length in SLE    
Telomere length (TL) was measured in a larger cohort of 164 SLE patients 
with a median (IQR) age 53 (45, 60) years. The median (IQR) telomere length 
in this group was 1.23 (0.64, 1.86). Traditional CHD risk factors associated with 
TL is summarised in Table 37.  Age did not have a significant correlation with 
TL in this cohort. Triglycerides had a small but significant positive correlation 
with TL. Body mass index was also significantly positively correlated to TL with 
a stronger β coefficient and R2 of 0.25. Previous history of smoking was not 
associated with TL; however current smoking had a small significant correlation.  
Creatinine had a small positive correlation although history of renal disease and 
eGFR did not (β 0.109, (0. 531), p=NS). Increasing C3 and the presence of anti-
Ro antibody was also positively correlated with TL. Current steroid use also had 
a positive correlation with TL. Eighty (49%) of patients were taking oral 
corticosteroids at the time of the assessment and average dose was 8 (5, 10) 
mg. Other immunosuppressants and hydroxychloroquine, which was taken by 
102 (62%) of patients was not related to telomere length.  
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Table 37 CHD risk factors associated with telomere length in SLE 
 
Baseline factors 
 
Unadjusted Age-adjusted 
β (SE) P value  β (SE) P value 
Age 
.0286394 
(.0066339) 
NS 
- 
- 
Disease duration  
.003198 
(.0079396) 
NS 
-.0059501 
( .0083011) 
NS 
Total cholesterol  
.0347914 
(.0787449) 
NS 
.0283767 
(.0809326) 
NS 
Hypercholesterolemia  
.127029 
( .149541) 
NS 
.1301897 
( .1570589) 
NS 
LDLc 
-.025934 
(.0868653) 
NS 
-.0296583 
( .0889616) 
NS 
Triglycerides  
.269633 
(.1216939) 
0.001 
.1216939 
( .124337) 
0.001 
Systolic blood pressure 
.1006017 
(.0036394) 
NS 
.0828519 
( .0041404) 
NS 
Hypertension  
.1061452 
(.1475966) 
NS 
.0949059 
(.1537545) 
NS 
Fasting glucose 
.1165156 
(.1065638) 
NS 
.1065638 
(.1114359) 
NS 
Type 2 diabetes 
-.0247151 
(.3307528) 
NS 
-.0273742 
( .336669) 
NS 
Family history of CHD 
-.0672614 
(.1617464) 
NS 
-.0769809 
(.1651086) 
NS 
Body mass index  
.4999786 
(.0109257) 
<0.001 
.5045071 
(.011186) 
<0.001 
Smoking ever  
.0814292 
(.1488044) 
NS 
.075942 
(.1540154) 
NS 
Current smoking 
.1656675 
(.2411204) 
0.04 
.1629132 
(.2433388) 
0.04 
Statin use  
.039926 
(.1567863) 
NS 
.0376489 
(.1621877) 
NS 
Aspirin use  
-.0379615 
(.3930576) 
NS 
-.0369708 
(.3968273) 
NS 
hsCRP  
.1505296 
(.0152335) 
0.054 
.1346012 
(.0156504) 
0.091 
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Table 38 Disease-related factors associated with telomere length in SLE 
 
 
The correlation of TL and atherosclerosis was also assessed. Eleven (7%) 
of patients had a history of CHD (7 patients with MI and 4 patients with angina). 
The presence of carotid plaque had a small positive correlation with TL 
suggesting that those patients that had a clinical coronary event had longer 
telomeres than those did not. Similar results were seen when MI was analysed 
 
Baseline factors 
 
Unadjusted Age-adjusted 
β (SE) P value  β (SE) P value 
Renal disease 
.1232055 
(.1770499) 
NS 
.1277395 
(.1797314) 
NS 
Creatinine  
.1025418 
(.0013306) 
NS 
.1663254 
(.0019361) 
0.04 
SDI 
.1306735 
(.0428572) 
NS 
.12404 
(.0465613) 
NS 
SLEDAI 
-.055734 
(.0192574) 
NS 
-.0574061 
(.0196509) 
NS 
C3 
.3212446 
(.2452132) 
<0.001 
.3148529 
(.2590098) 
<0.001 
Ro  
-.2351623 
(.1734059) 
0.002 
-.2389531 
(.17638) 
0.002 
La 
-.0575649 
(.2418631) 
NS 
-.0546219 
(.2499176) 
NS 
Sm 
-.0646274 
(.9466094) 
NS 
-.0643486 
(.9522798) 
NS 
RNP 
-.095034 
(.2411683) 
NS 
-.0636681 
(.2573586) 
NS 
Anti-cardiolipin antibody 
-.0444031 
(.215287) 
NS 
-.0496692 
(.2172628) 
NS 
Anti-malarial use 
-.0286531 
(.1797815) 
NS 
-.003802 
(.1866773) 
NS 
Immunosuppressant use  
.1001962 
(.1754039) 
NS 
.1232227 
(.1860104) 
NS 
Azathioprine use 
-.0047449 
(.1595307) 
NS 
.0084572 
(.1664905) 
NS 
Steroid use current 
.1455769 
(.155517) 
0.07 
.1603626 
(.1587567) 
0.054 
Steroid exposure ever 
.0966537 
(.1902879) 
NS 
.0845827 
(.1946587) 
NS 
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separately (adjusted β 0.091 (0.152), p=NS).  When dividing the telomere 
length into 3 equal tertiles and comparing the mean APWV, CIMT and 
prevalence plaque, similar results are observed.  
  
Table 39 Telomere length in SLE atherosclerosis 
 
Table 40 Measures of atherosclerosis associated with tertiles of telomeres  
in SLE 
 
 
 
 
 
 
 
*Comparing low tertile to high tertile  
Relative telomere length had a significant age-adjusted correlation with 
CFU number in SLE patients (R2 0.1, p = 0.05) but in not in controls (R2 
0.01,p=NS).   
 
Baseline factors 
 
Unadjusted Age-adjusted 
β (SE) P value  β (SE) P value 
APWV 
-.0293293 
(.0088168) 
NS 
-.0156208 
(.0089319) 
NS 
CIMT 
-.0161027 
(5.150632) 
NS 
-.0711242 
( 5.797241) 
NS 
Carotid plaque 
.1973369 
(.1486059) 
0.013 
.2031888 
(.1772831) 
0.032 
Carotid plaque progression 
.2062594 
(.1481292) 
0.04 
.2195023 
(.1723362) 
0.062 
CIMT progression  
-.1178704 
(7.453621) 
NS 
-.1014365 
(7.5347) 
NS 
MI or angina  
.1546401 
(.2932337) 
0.051 
.1524812 
(.3035895) 
0.064 
Marker of 
atherosclerosis 
Low Middle High P value 
Plaque (%) 33 38 61 0.02* 
Intima media thickness: 
mean (SD) 
0.06 (0.02) 0.06 (0.01) 0.06 (0.01) NS 
Pulse wave velocity : 
mean (SD) 
10 (7) 7 (6) 11 (9) NS 
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10.6.7 Discussion  
We measured relative telomere length of PBMC from 64 patients with SLE 
using qPCR. Consistent with our hypothesis, we demonstrate a significant 
reduction, of approximately 1/3, in telomere length in SLE patients compared to 
64 age–matched controls.  Further we measured telomere length in a larger 
study of 164 SLE patients and analysed associated factors. There is no 
significant correlation of age with TL in our study. This may be a reflection of the 
small sample size. However it should be noted the IQR of age of our patients is 
45 – 60 and previous reports have suggested that telomere length does not 
show a marked inverse correlation between these ages [15].  
  CHD risk factors that are associated with telomere length in the age-
adjusted analysis are triglycerides, BMI and current smoking. It is possible that 
these factors present low level oxidative stress and a subsequent response to 
lengthen telomeres. Telomere length demonstrated an inverse correlation with 
aortic stiffness which failed to reach statistical significance.   Paradoxically, 
carotid plaque correlates with telomere length suggesting those patients with 
the longest telomeres are more likely to have plaque. Similarly, there is a 
correlation with clinical CHD events. When analysing the data by dividing length 
of telomeres into tertiles, a higher proportion of those with the longest telomeres 
are found to have carotid plaque. This may be a refection of some censorship 
i.e. those patients with the shortest telomeres and carotid plaque are deceased 
and therefore not captured in a cross-sectional study.   
SLE related factors that correlated with telomere length were anti-Ro 
antibody, C3 complement and current use of steroids. The correlation of 
telomere length with the anti-Ro antibody is interesting as this antibody was 
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also associated with reduced carotid atherosclerosis progression. It is possible 
that this antibody reflects those patients with a less severe disease phenotype 
or those patients of the Sjogren‟s disease spectrum.  An alternative explanation 
is that this antibody affords some atheroprotection. The correlation with C3 and 
current steroid therapy may suggest that reduced inflammatory burden results 
in a beneficial effect on telomere length.  However other measures of 
inflammation such as CRP or SLEDAI do not demonstrate an inverse 
correlation. Our study is similar to those previously reported that have shown a 
reduction in telomere length in SLE compared to controls [271, 274].  Similar to 
previous studies, we did not find a correlation of telomere length to lymphocyte 
count (β 0 .01, SE 0.04, p = NS) or disease activity, suggesting that telomere 
length is not simply a reflection of immune cell turnover. It should be noted in 
this regard that the majority our patients had low disease activity.          
Our study is a cross-sectional analysis and therefore we are unable to 
determine if our associations with telomere length are the cause or 
consequence of telomere length reduction. One theory is that disease states 
lead to accelerated telomere attrition whilst others believe an overall senescent 
phenotype will result in a propensity for certain diseases. The exact contribution 
of genetic factors on length of telomere also remains of much interest. 
Additionally, given the wide variation of telomere length between individuals, a 
cross-sectional measurement may be less valuable than serial measurements 
allowing a rate of attrition to be determined. The utility of telomere length as a 
biomarker has to be questioned in view of the wide variation between 
individuals and slow rate of change. Rather, it may provide an insight into 
mechanism underlying disease and present a potential therapeutic target.  
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We used real-time qPCR to measure telomere length as this method is 
more time efficient and requires smaller amounts of DNA [18]. Additionally, 
previous studies have shown a good correlation between measurement with 
qPCR and Southern blotting [45]. There has been some debate about whether 
PBMC, a heterogenous group of cells, are the ideal population of cells to study. 
To date several groups have used PBMC in SLE and in cardiovascular studies 
and demonstrated PBMC telomere length is a good a marker of disease (please 
see section 6.7.3 for more details). In addition, small studies have not 
demonstrated any differences in the telomere length of subpopulations of white 
cells between SLE and controls. We demonstrate a correlation between PBMC 
telomere length and mean CFU formation in SLE but not in controls which may 
suggest that a senescent phenotype contributes to abnormal endothelial repair. 
However, it is argued that cells from the target organ of interest should be 
analysed and to this end we have measured telomere length from endothelial 
cells. In a preliminary study we cultured CFU for 7 days using the protocol 
described above (section 10.5.2) for 5 SLE patients aged 51 (49, 56) years and 
5 controls aged 46 (41, 50) years. We isolated CFU at day 7 of culture and 
harvested DNA using phenol-chloroform extraction. We then quantified 
telomere length using qPCR as described in section 10.6.1. Relative telomere 
length tended to be shorter in SLE CFU compared to control CFU (0.41 [0.23, 
0.97] vs. 0.93 [0.41, 2.07]; p = NS). See Figure 39.  
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Figure 39 telomere length of CFU in SLE vs. controls 
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11 Conclusions  
We described carotid atherosclerosis progression in a UK cohort of white 
females with SLE. We designed a study to test the hypothesis that patients with 
SLE have premature cellular ageing and that this contributes to abnormal 
endothelial repair and subsequent atherosclerosis.   
We have demonstrated carotid plaque progression occurs in 17.5% of 
SLE patients over an average of 5 years and that baseline traditional CHD risk 
factors do not contribute to this risk.  We demonstrate reduced PBMC telomere 
length in patients with SLE compared to age-matched controls suggesting 
premature cellular ageing in our patients. We demonstrate a correlation of 
PBMC telomere length and CFU number, a measure of endothelial progenitor 
cell number and function.  We also demonstrate an overall reduction of CFU 
formation in SLE compared to healthy controls suggesting abnormal endothelial 
repair in SLE. Lastly, we demonstrate a trend to increased cellular ageing of 
SLE endothelial cells compared to controls.  Anti-cardiolipin antibody in our 
study is associated with carotid plaque progression and with CFU number and 
this may suggest endothelial cells are stimulated in response to aCL in an 
attempt to repair the vasculature. 
Our study is the largest to date of telomere length in SLE and we have 
utilised statistical testing to maximise the use of data points e.g. by using 
variables in a continuous manner where possible. Nonetheless, the sample size 
remains relatively low and is a weakness of the project. We have conducted 
cross-sectional studies to examine telomere length and endothelial progenitor 
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cells and as such are not able to determine if associations are a cause or effect 
of the variables examined.  
 
11.1 Future directions  
Many questions and suggestions are raised by the findings of this study. 
Firstly, future larger studies are required to verify our results. Studies would 
need to consist of a large sample size to allow robust conclusions to be drawn, 
particularly to ascertain the influence of drugs such as statins.  Given the low 
prevalence of SLE; it is likely that multi centre collaborations would be required.  
Our group and others have demonstrated reduced endothelial progenitor 
cells as measured by culture methods in SLE, however precise characterisation 
of EPC require further clarification and the mechanisms underpinning 
abnormalities in endothelial cell function e.g. homing signals to sites of 
damaged endothelium requires further investigation. The observation of a trend 
to shorter CFU telomeres in SLE is interesting and a larger sample size is 
required. To date, studies have compared SLE patients to healthy controls. 
However a more relevant comparison group may be a cohort with another 
chronic inflammatory condition to elucidate the relative contribution to 
atherosclerosis in SLE. Prospective studies are required to determine the 
consequence of low EPC number and to determine whether low EPC number 
does lead to an excess of CHD.    
It is unclear if telomere length is a „summary marker‟ of replicative and 
stress induced senescence or is involved in the pathogenesis of atherosclerotic 
disease. The influence of telomeres on the development of SLE and the 
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potential effect on clinical phenotype is interesting. Measuring the length of 
telomeres of patients in a large inception cohort such as the SLICC inception 
cohort would afford some clarification with regards to this.  Ideally, telomere 
length would be measured in a cohort study to determine if telomere attrition or 
disease states appear first and initiatives such as The European Prospective 
Investigation of Cancer (EPIC) – Norfolk, may provide a setting for such a 
study. Prospective follow up of our cohort is required to determine the 
consequence of short telomeres.   
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Appendix 2 Study promotion  
 186 
 
 
Appendix 3 Example of Patient information sheet 
   
 
 
(Version 3 August 2006) 
 
Patient Information Sheet - new participant 
(SLE)  
Accelerated atherosclerosis in SLE: Lupus factors, telomere shortening and progression 
of atherosclerosis 
 
Accelerated atherosclerosis and premature senescence in SLE. 
 
Systemic lupus erythematosus (SLE) is a chronic autoimmune illness that occurs in 
about 1/2000 women in the UK. It can affect many parts of the body initiated firstly by 
inflammation and then further complicated by organ damage in some patients. Women 
with SLE also have approximately a 5-8 fold increased risk of heart disease caused by 
atherosclerosis (hardening of the arteries). Our research is focused on understanding 
this process better. 
 
We have found in an initial study that a range of factors are likely to contribute to this 
increased risk of atherosclerosis and some of these factors included typical risk factors 
such as smoking and blood pressure as well as the type of lupus a patient has and 
certain antibodies associated with SLE also seemed to be important. It is also likely 
that some of the risk is driven by genetic markers associated with SLE and in particular 
we are interested in measuring telomere length and activity as one such marker. 
Telomere length is believed to be related to how quickly a cell ages and may be a 
better marker of cellular age. Since atherosclerosis occurs earlier in SLE we aim to 
determine whether the cells of SLE patients age at a quicker rate and if this relates to 
the higher risk of atherosclerosis seen.  As we are particularly interested in arteries 
(blood vessels) we also wish to study how the cells lining blood vessels (endothelial 
cells) age and how they are replaced naturally in the circulation. 
 
You are being asked to take part in this study because you have SLE and we wish to 
assess how factors associated with SLE alter the risk of atherosclerosis over time. This 
will be done by assessing SLE at baseline and also studying the thickness of the lining 
of the major blood vessel in the neck (carotid artery) to look for signs of early 
atherosclerosis as well as measurement of blood vessel stiffness.   A repeat “stiffness” 
scan will also be performed every 6 months and the neck scan will be performed 2 
years after the initial scan to assess progression of atherosclerosis and how SLE 
factors including telomere length may affect this. 
 
What will I have to do if I take part? 
If you agree to take part you will be asked to visit the Wellcome Trust Clinical Research 
Facility and to have fasted for 12 hours and avoided alcohol for 48 hours prior to this 
visit. We will take a medical history and examine you. This will help us to assess the 
current level of activity of your SLE.  A 60ml (approximately 10 tea spoons) blood 
sample will be taken to measure the level of inflammation in your system as well as 
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measure your cholesterol, blood glucose and other factors that may influence the risk 
of heart disease including lupus associated antibodies.  A DNA sample will also be 
taken from this blood sample.  A small urine sample (10ml) will also be frozen and 
stored to measure inflammation markers. 
 
The clinical assessment will be at the Wellcome Trust Clinical Research and this will 
include a history and examination as well as completing two Quality of Life 
questionnaires (SF36 and LupusQOL) and a short lifestyle questionnaire.  Your 
treatment will also be recorded including current dose of steroids, immunosuppressive 
agents and anti malarial drugs.   
 
You will also have two scans performed. The first (carotid scan) will be done using a 
small ultrasound probe placed on the surface of the neck and does not involve any 
needles. The scan will examine the main artery in your neck on both sides (carotid 
arteries) this will assess if there is any evidence of early atherosclerosis.  This scan is 
painless and does not involve any discomfort 
 
In addition to the carotid scan a second scan will also be performed.  The second 
(pulse wave velocity) involves placing a small ultrasound probe at the base of your 
neck, above the collar bone to measure the wave-form.  It does not involve any 
needles.  A second measurement is also taken from the blood vessel at the top of your 
leg (femoral artery) using the same device.  The distance between the 2 probes is then 
measured. This scan compares the pulsation in your neck with that in the artery at the 
top of your leg (femoral artery).  Again, this is a painless procedure and no needles are 
involved.  We will repeat this scan every 6 months for 2 years. 
 
The genetic sample will be used to measure telomere length. This is the length of 
the small protein „caps‟ at the end of each DNA strand.  These are believed to shorten 
gradually as we age.  It will also be used to study other genes.  Such genes include 
genes that alter proteins involved in SLE inflammation, for example, mannose-binding 
lectin, complement genes and E-selectin, also genes that control cholesterol such as 
apolipoprotein E.  Some of the blood sample will also be used to measure the type 
(„new‟ cells involved in repair vs „old‟ that have become detached from the blood 
vessel) and age of endothelial cells. Some of these tests may be done in different 
laboratories in Europe or the USA.  When your sample is sent to these collaborators, it 
will be coded and they will not be able to identify you. 
Overall the visit to the Lupus Research Clinic will take about 1 hour and can be 
arranged to coincide with your routine clinic appointment if necessary.  
We will reimburse you travel expenses by public transport or private car to attend 
any visits that are in addition to your usual clinic visits. 
 
What are the possible risks of taking part? 
Taking the blood sample may cause bruising and scan involves no risk. There is 
however a chance that we will discover some blood test or scan abnormalities that you 
were unaware of and are clinically relevant. If we find any unexpected abnormalities in 
the blood tests or scans a member of the study team will advise you of these and 
arrange with your agreement any additional tests or referrals that may be appropriate. 
 
This kind of genetic testing does not have any implications for other members of 
your family and it will not affect your chances of getting life insurance, mortgages etc.  
 
Are there any possible benefits? 
As a result of this study we will have detailed information of several important risk 
factors for heart disease. A member of the research team will discuss all the results 
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with you when they are available. With your permission they will communicate clinically 
relevant results to your general practitioner and your own Consultant where 
appropriate.  The results of the genetic tests will remain confidential.  
  
Do I have to take part? 
No, taking part is voluntary. If you prefer not to take part you do not have to give 
a reason. You can also withdraw at any time and again no reason is necessary. 
Refusal to take part will in no way affect the treatment you receive now or in the future. 
If at any time you decide that you no longer wish to be included in the genetic part of 
the study, this sample will be destroyed and not used further in the study.  
 
All information gathered as a result of this study will be treated in the strictest 
confidence and no publication or reporting of these results will personally identify you in 
any way. 
 
We would want to inform your GP that you are taking part, with your permission.  
 
What will happen to the blood and genetic samples? 
This sample will be a gift to medical research, and will be stored in a secure laboratory.  
Only authorised personnel associated with this study will have access to the sample. At 
the end of the study we would like to retain the samples. This may be valuable in future 
research so we would like to keep it as a coded sample. We will however only use your 
sample in future research after we have been granted further ethical approval.  
 
What do I do now? 
The doctor or study nurse organising this study will contact you to discuss 
whether you wish to take part and make the necessary arrangement for you. 
 
Thank you for considering taking part in this research. Please do not hesitate to 
discuss this information with your family, friends or GP if you wish. 
 
For further advice regarding this study you can contact: 
Dr Ian Bruce, 
Reader and Consultant Rheumatologist 
or 
Sr Joanna Shelmerdine 
University of Manchester 
Rheumatism Research Centre, 
Central Manchester and Manchester Children’s University Hospitals NHS 
Trust, 
Oxford Road, 
Manchester, M13 9WL. 
 
Telephone: 0161 276 6841. 
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Appendix 4 GP information letter 
 
Accelerated atherosclerosis in SLE: Lupus factors, telomere shortening and 
progression of atherosclerosis  
 
 
GENERAL PRACTITIONER INFORMATION LETTER 
 
 
5
th
 October 2009 
 
Dear «Title» «GPName», 
 
Re: «PatName» «PatSurname» («PatDOB») «PatAddress» «PatArea» «PatTown» «PatPost» 
 
I am writing to inform you that your patient indicated above is currently taking part in 
the above study.  This is a multi-centre study looking at the progression of 
atherosclerosis in SLE and whether or not this is associated with telomere shortening 
(premature ageing) and abnormal endothelial turnover.  We aim to compare 
changes/progression in subclinical atherosclerosis in a well defined population of 
patients with SLE followed over a 3-5 year period with that seen in a control population. 
 
Your patient has agreed to take part in this study (either as a patient or healthy control) 
and we therefore plan to review their medical notes, take a medical history and 
examine them.  We will take a 60ml blood sample to look at your patient‟s level of 
inflammation as well as to measure their cholesterol, blood glucose and other factors 
that may influence the risk of heart disease including lupus associated antibodies.  A 
DNA sample will also be taken from this blood sample and a 10ml urine sample will be 
frozen and stored to measure inflammation markers. Finally, your patient will undergo 
an ultrasound scan of the carotid artery. 
 
Should the blood tests or scan identify any unexpected clinically relevant abnormalities, 
your patient will be advised of any additional tests or referrals that may be relevant. 
 
If you require any further information regarding this study please do not hesitate to contact me. 
 
With best wishes 
Yours sincerely 
 
 
 
 
Dr I N Bruce 
Senior Lecturer and Consultant Rheumatologist 
 
Dr S Haque 
Clinical Research Fellow 
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Appendix 5 Clinic data collection form 
CENTRE NAME:     PATIENT INITIALS:  
  
 
CENTRE NO:      PATIENT ID NO:  
  
 
ASSESSMENT DATE: / /  
                        d       m        y  
 
For follow – up patients please update any changes since last visit 
 
DEMOGRAPHIC DATA 
 
 
Date of birth:   /  /  Date of diagnosis of SLE:    /
  /        
      d        m       y            d        m        
y 
      Date of 1st symptom:             / 
 /      
 
ACR criteria for diagnosis (tick as appropriate): 
 
□  Malar rash   □  Arthritis   □  Haematalogic disorder 
□  Discoid rash  □  Photosensitivity  □  Immunologic disorder 
□  Oral ulcers   □  Renal disorder  □  ANA 
□  Serositis   □  Neurologic disorder 
 
Other features: 
 
□ Raynauds □ Fatigue □ Polymyositis □ Last DXA scan □ Fractures 
 
Marital Status (circle as appropriate): 
 
1 = Single   4 = Divorced 
2 = Married   5 = Separated 
3 = Widowed   6 = Common law 
 
 
Education: 
 
Number of years prior to college/university:    
Number of years at college/ university:     
 
 
Occupation (specify):                       
           
  
 
 
FAMILY HISTORY AND LIFESTYLE 
 
Alcohol consumption: units per week        or   ml per week 
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Cigarette smoking (delete as appropriate): 
Current       Yes / No  If yes, number per day    
Ex-smoker       Yes / No  If no, number of years smoking   
     and date stopped     /
  /  
              d         m        
y 
 
Lifestyle questionnaire completed by patient (delete as appropriate): Yes/No 
   
CLINICAL DATA 
Height: cm  Weight (shoes and coat off): kg  BMI:
   
Waist/hip ratio:  cm /       cm Blood pressure (systolic/diastolic):        /
      
Antihypertensive therapy (delete as appropriate): 
Current Yes / No If yes, specify type (circle as appropriate): 
0 = Diuretics   5 = Calcium antagonists 
1 = Adrenergic inhibitors 6 = Angiotensin-converting enzyme inhibitors 
2 = Central and agonists         
3 = Beta blockers  7 = Other 
4 = Direct vasodilators  8 = Combination 
 
In the past Yes / No If yes, specify type (circle as appropriate): 
0 = Diuretics    5 = Calcium antagonists 
1 = Adrenergic inhibitors  6 = Angiotensin-converting  
2 = Central and agonists        enzyme inhibitors 
3 = Beta blockers   7 = Other 
4 = Direct vasodilators   8 = Combination 
Myocardial infarction (circle as appropriate): 
In the past  Yes / No    If yes, specify date(s):     /
  /           
     d          m        y         
           /  /
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                  d          m        
y 
 
Angina (circle as appropriate): 
 
Current  Yes / No If yes, specify date of diagnosis:   /
  /  
               d          m        
y         
            /
  /  
              d          m        
y 
 
In the past  Yes / No If yes, specify date of diagnosis:   /
  /  
               d          m        
y         
            /
  /  
              d          m        
y 
 
Congestive heart failure (circle as appropriate): 
 
Current  Yes / No If yes, specify date(s):    /
  /  
               d          m        
y         
            /
  /  
              d          m        
y 
 
In the past  Yes / No If yes, specify date(s):    /
  /  
               d          m        
y         
            /
  /  
              d          m        
y 
 
 
 
Angioplasty (circle as appropriate): 
Ever   Yes / No If yes, specify date(s):    /
  /  
               d          m        
y         
            /
  /  
              d          m        
y 
 
Bypass surgery(circle as appropriate): 
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Ever   Yes / No If yes, specify date:     /
  /  
               d          m        
y   
 
PREVIOUS SLE CARDIAC MANIFESTATIONS 
 
Pericardiditis:  Yes / No If yes, specify date(s):    /
  /  
               d          m        
y        
            /
  /  
              d          m        
y 
 
Myocarditis:  Yes / No If yes, specify date(s):    /
  /  
               d          m        
y      
            /
  /  
              d          m        
y 
 
Endocarditis:  Yes / No If yes, specify date(s):    /
  /  
               d          m        
y         
            /
  /  
              d          m        
y 
 
PERIPHERAL VASCULAR 
 
Intermittent claudication (circle as appropriate): 
 
Current  Yes / No If yes, specify date(s):    /
  /  
               d          m        
y         
            /
  /  
              d          m        
y 
In the past  Yes / No If yes, specify date(s):    /
  /  
              d          m        y         
            /
  /  
              d          m        
y 
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CEREBROVASCULAR 
 
Transient ischemic attack (circle as appropriate):  Yes / No 
 
 
If yes, specify date(s):    /  /  
               d          m        
y                    /
  /  
              d          m        
y 
 
Stroke (circle as appropriate): Yes / No 
 
If yes, specify date(s):  /  /  
               d          m        
y         
            /
  / 
              d          m        
y 
 
Type (if known): 1 = Hemorrhagic  2 = Thrombotic 
 
HYPERLIPIDEMIA THERAPY 
 
Current  Yes / No If current, specify type (circle as appropriate): 
     0 = None   4 = Fibrates 
     1 = Statins   5 = Combinations 
     2 = Sequestrants  6 = Other 
     3 = Nicotinic acid  
 
In the past  Yes / No If in the past, specify type (circle as 
appropriate): 
     0 = None   4 = Fibrates 
     1 = Statins   5 = Combinations 
     2 = Sequestrants  6 = Other 
     3 = Nicotinic acid  
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HORMONAL FACTORS 
 
Ovarian function (circle all which apply): 
 
1 = Menstruating  5 = Pre-menopausal hysterectomy 
2 = Premenarche  6 = Post-menopausal hysterectomy 
3 = Postmenopausal  7 = Pre-menopausal hysteroophorectomy  
4 = Amenorrhea 
 
Age at menopause _______ 
 
Oral contraceptive 
 
Current  Yes / No  If yes, specify number of years: 
  
 
In the past  Yes / No  If yes, specify number of years: 
  
 
Hormone replacement therapy: 
 
Current  Yes / No  If current, specify type (circle as 
appropriate): 
      1 = Estrogen (specify):  
  
      2 = Estrogen + progesterone 
  
      3 = Progesterone only 
      4 = Other (specify):   
  
 
      Current course start date:   / 
  /   
              d          m        
y 
 
In the past  Yes / No  If in the past, specify type (circle as 
appropriate):  
      1 = Estrogen (specify):  
  
      2 = Estrogen + progesterone 
  
      3 = Progesterone only 
      4 = Other (specify):   
  
 
Are you currently pregnant? (circle as appropriate):  Yes / No 
 
Gravida / Para:   /    Miscarriage (No):  
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ENDOCRINE 
 
Hypothyroidism: 
 
Current  Yes / No 
 
Ever   Yes / No 
 
 
Diabetes:  Yes / No If yes, specify date of diagnosis:  /   / 
  
                         d       m        y 
 
  Specify type (delete as appropriate): Type 1 / Type 2 
 
RENAL 
Active nephritis: 
 
Current   Yes / No 
 
In the past  Yes / No 
 
Nephrotic syndrome: 
 
Current  Yes / No 
 
In the past  Yes / No       
 
Past medical history:         
   
 
           
   
 
 
 
 
 
If follow up patient complete page 9 instead of this page 
 
THERAPY 
 
Steroids: 
 
Current   Yes / No If yes, specify course start date:   /   / 
  
                 d      m        y 
     and average daily dose:   mg   
 
In the past  Yes / No If yes, number of previous courses: 
  
     And average daily dose:  mg 
 
Number of previous courses of IV steroids (and details):    
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Number of courses in 6 months before event:     
   
 
Anti-malarials:  
Current Yes / No If yes, specify type (circle as appropriate): 
    1 = Chloroquine  3 = Hydroxychloroquine 
    2 = Atabrine   4 = Other (specify): 
   
      
    If yes, specify course start date:   /   /   
                d      m        y 
    and average daily dose:  mg   
 
In the past Yes / No If yes, specify type (circle as appropriate): 
    1 = Chloroquine  3 = Hydroxychloroquine 
    2 = Atabrine   4 = Other (specify): 
   
     
 
Immunsuppressives: 
Current Yes / No If yes, specify type (circle as appropriate): 
    1 = Azathioprine  4 = Cyclosporin 
    2 = Cyclophosphamide PO 5 = Mycophenolic acid 
    3 = Cyclophosphamide IV 6 = Methotrexate 
        7 = Other (specify): 
   
 
In the past Yes / No If yes, specify type (circle as appropriate): 
    1 = Azathioprone  4 = Cyclosporin 
    2 = Cyclophosphomide PO 5 = Mycophenolic acid 
    3 = Cyclophosphomide IV 6 = Methotrexate 
   
        7 = Other (specify): 
   
 
Current medications:         
   
 
 
QUALITY OF LIFE: 
Lupus QOL 
  Physical  Pain Planning Intimate Burden  Emotional Body Fatigue 
DOMAIN health   relationship to others  health image  
SCORE                 
 
SF36 
  Physical  Role Bodily General Vitality  Social Role Mental 
DOMAIN function physical pain health   function emotional health 
SCORE                 
 
Appendix 6 Carotid ultrasonography protocol  
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The right and left common carotid artery (CCA), carotid bulb and the first 
1.5 cm of the internal and external carotid arteries were examined in longitudinal 
and cross-sectional planes using the Philips HDI 5000.  Intima-medial thickness 
(IMT) was measured as previously described and validated [319]. Briefly, 
measurements were made in a longitudinal plane at a point of maximum 
thickness on the far wall of the CCA along a 1 cm section of the artery proximal 
to the carotid bulb. Measurements were repeated three times on each side, 
unfreezing the image on each occasion and relocating the maximal IMT, the 
average of six measurements were then used to calculate the mean IMT. 
Carotid plaque was defined if two of the following three conditions were met: (i) 
a distinct area of protrusion >50% compared with the surrounding area into the 
vessel lumen, (ii) increased echogenicity than the adjacent boundaries and (iii) 
IMT >0.15 cm [209].   
The degree of plaque was graded using the plaque index outlined below  
as previously described and validated [330].  
Table 41  Plaque index  
Grades Description 
0 No observable plaque 
1 One small plaque (< 30% of vessel diameter ) 
2 
One medium plaque (30-50 % of vessel diameter ) or multiple small 
plaque 
3 
One large plaque (>50% of vessel diameter) or multiple plaque with 
al least one medium sized plaque  
Adapted from [330] 
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Inter-observer variability  
Carotid scans were performed by one of two experienced vascular 
technicians blinded to the all other patients details. Measurements taken by 
each technician on 10 different subjects has shown a good level of agreement   
 
 
 
 
 
 
 
 
 
 
 
Figure 40 Bland Altman plot of difference between 2 operators (vertical axis) and mean of 
2 operators (horizontal axis) 
 
Dashed green line represents the mean difference (- 0.001) and bold blue line 
represents the 95% limits of agreement (-0.0098, 0.0078) and indicate good 
agreement between operators. 
Difference 
(Operator 1 – 
Operator 2) 
-.01 
-.005 
0 
.00
5 
.0
1 
.04 .075 
Mean of operators‟ measurements  
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Appendix 7  Aortic pulse wave velocity measurement 
Participants were supine for >5 minutes before recording. All 
measurements ere undertaken in a temperature-regulated room. Carotid-
femoral APWV was determined using the Micro Medical Pulse Wave Velocity 
machine by sequentially recording ECG-gated carotid and femoral artery 
waveforms. Distances from sternal notch to the femoral was measured as a 
straight line between the points on the body surface using a tape measure.  A 
4Mhz Doppler pencil probe was placed at 45° to the skin surface of the artery 
and measured with the probe facing towards the flow direction (towards the 
heart).  
 
 
Figure 41 Bland Altman plot of difference between 2 operators (vertical axis) and mean of 
2 operators (horizontal axis) 
 
Dashed green line represents the mean difference and bold blue line represents 
the 95% limits of agreement and indicates little variation between operators.   
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Appendix 8 BILAG Index 
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Appendix 9 SLE Disease Activity Index 
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Appendix 10 SLICC Damage Index 
 205 
 
 
 206 
 
 
 207 
 
 
 208 
 
 209 
 
 
 
Appendix 11 Example of telomere length calculation 
           
Pos Nam
e/study_id 
TelC
p 
Avera
ge Cp 
TELOMERE 
Pos Nam
e 
36B4
Cp  
Avera
ge Cp 36B4 
C
T

CT 
(RELATIVE 
TO TV4)
RELA
TIVE 
TELOMERE 
LENGTH  
A1 15 13.56 13.25
666667 
A1 15 20.72 20.62
666667 
-7.37 1.043
33 
0.485
206237 
A2 15 13.16  A2 15 20.62     
A3 15 13.05  A3 15 20.54     
A5 41 12.56 12.58
333333 
A5 41 20.29 20.38
333333 
-7.8 0.613
33 
0.653
686134 
A6 41 12.55  A6 41 20.44     
A7 41 12.64  A7 41 20.42     
A9 65 12.51 12.49
666667 
A9 65 20.57 20.51
666667 
-8.02 0.393
33 
0.761
370195 
A10 65 12.48  A10 65 20.46     
A11 65 12.5  A11 65 20.52     
A13 94 11.72 11.74
5 
A13 94 20.43 20.54
333333 
-
8.79833333
3 
-
0.38500333
3 
1.305
862804 
A14 94   A14 94 20.54     
A15 94 11.77  A15 94 20.66     
B1 16 12.32 12.2 B1 16 20.25 20.33
666667 
-
8.13666666
7 
0.276
663333 
0.825
498024 
B2 16 12.22  B2 16 20.32     
B3 16 12.06  B3 16 20.44     
 210 
 
 
Reference List 
 
 1.  AnonymousThird Report of the National Cholesterol Education Program 
(NCEP) Expert Panel on Detection, Evaluation, and Treatment of 
High Blood Cholesterol in Adults (Adult Treatment Panel III) Final 
Report. Circulation 2002; 106 (25):3143 
 2.  http://news.bbc.co.uk/1/hi/health/6216468.stm. BBC News| Health . 25-2-
2007. 25-2-2007. (GENERIC) 
Ref Type: Internet Communication 
 3.  Ablin JN, Boguslavski V, Aloush V, Elkayam O, Paran D, Levartovski D, 
Caspi D, George J. Enhanced adhesive properties of endothelial 
progenitor cells (EPCs) in patients with SLE. Rheumatol.Int. 2010;  
 4.  Abu-Shakra M, Shoenfeld Y. Azathioprine therapy for patients with 
systemic lupus erythematosus. Lupus 2001; 10 (3):152-153 
 5.  Abuaf N, Johanet C, Chretien P, Absalon BI, Homberg JC, Buri JF. 
Detection of autoantibodies to Sm antigen in systemic lupus 
erythematosus by immunodiffusion, ELISA and immunoblotting: 
variability of incidence related to assays and ethnic origin of 
patients. Eur.J Clin.Invest 1990; 20 (4):354-359 
 6.  Adaikalakoteswari A, Balasubramanyam M, Ravikumar R, Deepa R, 
Mohan V. Association of telomere shortening with impaired 
glucose tolerance and diabetic macroangiopathy. Atherosclerosis 
2007; 195 (1):83-89 
 7.  Ahmad Y, Shelmerdine J, Bodill H, Lunt M, Pattrick MG, Teh LS, 
Bernstein RM, Walker MG, Bruce IN. Subclinical atherosclerosis 
in systemic lupus erythematosus (SLE): the relative contribution of 
classic risk factors and the lupus phenotype. Rheumatology 2007; 
46 (6):983-988 
 8.  Aoki J, Serruys PW, van Beusekom H, Ong ATL, McFadden EP, Sianos 
G, van der Giessen WJ, Regar E, de Feyter PJ, Davis HR, 
Rowland S, Kutryk MJB. Endothelial Progenitor Cell Capture by 
Stents Coated With Antibody Against CD34: The HEALING-FIM 
(Healthy Endothelial Accelerated Lining Inhibits Neointimal 
Growth-First In Man) Registry. Journal of the American College of 
Cardiology 2005; 45 (10):1574-1579 
 9.  Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, Dennis GJ, 
James JA, Harley JB. Development of autoantibodies before the 
clinical onset of systemic lupus erythematosus. N Engl J Med 
2003; 349 (16):1526-1533 
 211 
 
 10.  Armstrong L, Lako M, Lincoln J, Cairns PM, Hole N. mTert expression 
correlates with telomerase activity during the differentiation of 
murine embryonic stem cells. Mech.Dev. 2000; 97 (1-2):109-116 
 11.  Artlett CM, Black CM, Briggs DC, Stevens CO, Welsh KI. Telomere 
reduction in scleroderma patients: a possible cause for 
chromosomal instability. Br.J.Rheumatol. 1996; 35 (8):732-737 
 12.  Asahara T, Murohara T, Sullivan A, Silver M, van der ZR, Li T, 
Witzenbichler B, Schatteman G, Isner JM. Isolation of putative 
progenitor endothelial cells for angiogenesis. Science 1997; 275 
(5302):964-967 
 13.  Asahara T, Takahashi T, Masuda H, Kalka C, Chen D, Iwaguro H, Inai Y, 
Silver M, Isner JM. VEGF contributes to postnatal 
neovascularization by mobilizing bone marrow-derived endothelial 
progenitor cells. EMBO J. 1999; 18 (14):3964-3972 
 14.  Asanuma Y, Oeser A, Shintani AK, Turner E, Olsen N, Fazio S, Linton 
MF, Raggi P, Stein CM. Premature coronary-artery 
atherosclerosis in systemic lupus erythematosus. N Engl J Med 
2003; 349 (25):2407-2415 
 15.  Aubert G, Lansdorp PM. Telomeres and aging. Physiol Rev 2008; 88 
(2):557-579 
 16.  Aubry MC, Maradit-Kremers H, Reinalda MS, Crowson CS, Edwards 
WD, Gabriel SE. Differences in atherosclerotic coronary heart 
disease between subjects with and without rheumatoid arthritis. 
J.Rheumatol. 2007; 34 (5):937-942 
 17.  Bahlmann FH, De GK, Spandau JM, Landry AL, Hertel B, Duckert T, 
Boehm SM, Menne J, Haller H, Fliser D. Erythropoietin regulates 
endothelial progenitor cells. Blood 2004; 103 (3):921-926 
 18.  Baird DM. New developments in telomere length analysis. Exp.Gerontol. 
2005; 40 (5):363-368 
 19.  Banchereau J, Pascual V. Type I interferon in systemic lupus 
erythematosus and other autoimmune diseases. Immunity. 2006; 
25 (3):383-392 
 20.  Bansilal S, Farkouh ME, Fuster V. Role of Insulin Resistance and 
Hyperglycemia in the Development of Atherosclerosis. The 
American Journal of Cardiology 2007; 99 (4, Supplement 1):6-14 
 21.  Baranova I, Vishnyakova T, Bocharov A, Chen Z, Remaley AT, Stonik J, 
Eggerman TL, Patterson AP. Lipopolysaccharide down regulates 
both scavenger receptor B1 and ATP binding cassette transporter 
A1 in RAW cells. Infect.Immun. 2002; 70 (6):2995-3003 
 212 
 
 22.  Beier F, Balabanov S, Amberger CC, Hartmann U, Manger K, Dietz K, 
Kotter I, Brummendorf TH. Telomere length analysis in monocytes 
and lymphocytes from patients with systemic lupus erythematosus 
using multi-color flow-FISH. Lupus 2007; 16 (12):955-962 
 23.  Benetos A, Gardner JP, Zureik M, Labat C, Xiaobin L, Adamopoulos C, 
Temmar M, Bean KE, Thomas F, Aviv A. Short telomeres are 
associated with increased carotid atherosclerosis in hypertensive 
subjects. Hypertension 2004; 43 (2):182-185 
 24.  Benetos A, Okuda K, Lajemi M, Kimura M, Thomas F, Skurnick J, Labat 
C, Bean K, Aviv A. Telomere Length as an Indicator of Biological 
Aging : The Gender Effect and Relation With Pulse Pressure and 
Pulse Wave Velocity. Hypertension 2001; 37 (2):381-385 
 25.  Bengtsson AA, Sturfelt G, Truedsson L, Blomberg J, Alm G, Vallin H, 
Ronnblom L. Activation of type I interferon system in systemic 
lupus erythematosus correlates with disease activity but not with 
antiretroviral antibodies. Lupus 2000; 9 (9):664-671 
 26.  Bernal-Mizrachi L, Jy W, Fierro C, Macdonough R, Velazques HA, Purow 
J, Jimenez JJ, Horstman LL, Ferreira A, de Marchena E, Ahn YS. 
Endothelial microparticles correlate with high-risk angiographic 
lesions in acute coronary syndromes. International Journal of 
Cardiology 2004; 97 (3):439-446 
 27.  Bernal-Mizrachi L, Jy W, Jimenez JJ, Pastor J, Mauro LM, Horstman LL, 
de Marchena E, Ahn YS. High levels of circulating endothelial 
microparticles in patients with acute coronary syndromes. 
American Heart Journal 2003; 145 (6):962-970 
 28.  Bernatsky S, Boivin JF, Joseph L, Rajan R, Zoma A, Manzi S, Ginzler E, 
Urowitz M, Gladman D, Fortin PR, Petri M, Edworthy S, Barr S, 
Gordon C, Bae SC, Sibley J, Isenberg D, Rahman A, Aranow C, 
Dooley MA, Steinsson K, Nived O, Sturfelt G, Alarcon G, Senecal 
JL, Zummer M, Hanly J, Ensworth S, Pope J, El-Gabalawy H, 
McCarthy T, St PY, Ramsey-Goldman R, Clarke A. An 
international cohort study of cancer in systemic lupus 
erythematosus. Arthritis Rheum. 2005; 52 (5):1481-1490 
 29.  Bernatsky S, Clarke A, Ramsey-Goldman R, Joseph L, Boivin JF, Rajan 
R, Moore AD, Leung MH, Allen A, Gordon C. Hormonal exposures 
and breast cancer in a sample of women with systemic lupus 
erythematosus. Rheumatology (Oxford) 2004; 43 (9):1178-1181 
 30.  Bessant R, Duncan R, Ambler G, Swanton J, Isenberg DA, Gordon C, 
Rahman A. Prevalence of conventional and lupus-specific risk 
factors for cardiovascular disease in patients with systemic lupus 
erythematosus: A case-control study. Arthritis Rheum. 2006; 55 
(6):892-899 
 213 
 
 31.  Bhatia VK, Yun S, Leung V, Grimsditch DC, Benson GM, Botto MB, 
Boyle JJ, Haskard DO. Complement C1q reduces early 
atherosclerosis in low-density lipoprotein receptor-deficient mice. 
Am.J Pathol. 2007; 170 (1):416-426 
 32.  Bischoff C, Petersen HC, Graakjaer J, ndersen-Ranberg K, Vaupel JW, 
Bohr VA, Kolvraa S, Christensen K. No association between 
telomere length and survival among the elderly and oldest old. 
Epidemiology 2006; 17 (2):190-194 
 33.  Bjorkbacka H, Kunjathoor VV, Moore KJ, Koehn S, Ordija CM, Lee MA, 
Means T, Halmen K, Luster AD, Golenbock DT, Freeman MW. 
Reduced atherosclerosis in MyD88-null mice links elevated serum 
cholesterol levels to activation of innate immunity signaling 
pathways. Nat.Med 2004; 10 (4):416-421 
 34.  Blacher J, Demuth K, Guerin AP, Safar ME, Moatti N, London GM. 
Influence of biochemical alterations on arterial stiffness in patients 
with end-stage renal disease. Arterioscler.Thromb.Vasc.Biol. 
1998; 18 (4):535-541 
 35.  Bland JM, Altman DG. Statistical methods for assessing agreement 
between two methods of clinical measurement. Lancet 1986; 1 
(8476):307-310 
 36.  Blasco MA. Mice with bad ends: mouse models for the study of 
telomeres and telomerase in cancer and aging. EMBO J. 2005; 24 
(6):1095-1103 
 37.  Blasco MA, Lee HW, Hande MP, Samper E, Lansdorp PM, DePinho RA, 
Greider CW. Telomere shortening and tumor formation by mouse 
cells lacking telomerase RNA. Cell 1997; 91 (1):25-34 
 38.  Block SR, Winfield JB, Lockshin MD, D'Angelo WA, Christian CL. Studies 
of twins with systemic lupus erythematosus. A review of the 
literature and presentation of 12 additional sets. Am.J Med 1975; 
59 (4):533-552 
 39.  Bodnar AG, Ouellette M, Frolkis M, Holt SE, Chiu CP, Morin GB, Harley 
CB, Shay JW, Lichtsteiner S, Wright WE. Extension of life-span by 
introduction of telomerase into normal human cells. Science 1998; 
279 (5349):349-352 
 40.  Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. 
Derivation of the SLEDAI. A disease activity index for lupus 
patients. The Committee on Prognosis Studies in SLE. Arthritis 
Rheum. 1992; 35 (6):630-640 
 41.  Borchers AT, Naguwa SM, Shoenfeld Y, Gershwin ME. The 
geoepidemiology of systemic lupus erythematosus. 
Autoimmun.Rev 2010; 9 (5):A277-A287 
 214 
 
 42.  Boring L, Gosling J, Cleary M, Charo IF. Decreased lesion formation in 
CCR2-/- mice reveals a role for chemokines in the initiation of 
atherosclerosis. Nature 1998; 394 (6696):894-897 
 43.  Broccoli D, Smogorzewska A, Chong L, de LT. Human telomeres contain 
two distinct Myb-related proteins, TRF1 and TRF2. Nat.Genet. 
1997; 17 (2):231-235 
 44.  Brouilette S, Singh RK, Thompson JR, Goodall AH, Samani NJ. White 
cell telomere length and risk of premature myocardial infarction. 
Arterioscler.Thromb.Vasc.Biol. 2003; 23 (5):842-846 
 45.  Brouilette SW, Moore JS, McMahon AD, Thompson JR, Ford I, Shepherd 
J, Packard CJ, Samani NJ. Telomere length, risk of coronary heart 
disease, and statin treatment in the West of Scotland Primary 
Prevention Study: a nested case-control study. The Lancet 2007; 
369 (9556):107-114 
 46.  Brown DA, Breit SN, Buring J, Fairlie WD, Bauskin AR, Liu T, Ridker PM. 
Concentration in plasma of macrophage inhibitory cytokine-1 and 
risk of cardiovascular events in women: a nested case-control 
study. Lancet 2002; 359 (9324):2159-2163 
 47.  Bruce IN, Burns RJ, Gladman DD, Urowitz MB. Single photon emission 
computed tomography dual isotope myocardial perfusion imaging 
in women with systemic lupus erythematosus. I. Prevalence and 
distribution of abnormalities. J.Rheumatol. 2000; 27 (10):2372-
2377 
 48.  Bruce IN, Urowitz MB, Gladman DD, Hallett DC. Natural history of 
hypercholesterolemia in systemic lupus erythematosus. 
J.Rheumatol. 1999; 26 (10):2137-2143 
 49.  Bruce IN, Urowitz MB, Gladman DD, Ibanez D, Steiner G. Risk factors 
for coronary heart disease in women with systemic lupus 
erythematosus: the Toronto Risk Factor Study. Arthritis Rheum. 
2003; 48 (11):3159-3167 
 50.  Bryan TM, Englezou A, Gupta J, Bacchetti S, Reddel RR. Telomere 
elongation in immortal human cells without detectable telomerase 
activity. EMBO J. 1995; 14 (17):4240-4248 
 51.  Bucciarelli S, Espinosa G, Cervera R. The CAPS Registry: morbidity and 
mortality of the catastrophic antiphospholipid syndrome. Lupus 
2009; 18 (10):905-912 
 52.  Bulkley BH, Roberts WC. The heart in systemic lupus erythematosus and 
the changes induced in it by corticosteroid therapy. A study of 36 
necropsy patients. Am.J.Med. 1975; 58 (2):243-264 
 215 
 
 53.  Buono C, Come CE, Witztum JL, Maguire GF, Connelly PW, Carroll M, 
Lichtman AH. Influence of C3 deficiency on atherosclerosis. 
Circulation 2002; 105 (25):3025-3031 
 54.  Canizo MC, Lozano F, Gonzalez-Porras JR, Barros M, Lopez-Holgado 
N, Briz E, Sanchez-Guijo FM. Peripheral endothelial progenitor 
cells (CD133 +) for therapeutic vasculogenesis in a patient with 
critical limb ischemia. One year follow-up. Cytotherapy. 2007; 9 
(1):99-102 
 55.  Castrillo A, Joseph SB, Vaidya SA, Haberland M, Fogelman AM, Cheng 
G, Tontonoz P. Crosstalk between LXR and toll-like receptor 
signaling mediates bacterial and viral antagonism of cholesterol 
metabolism. Mol.Cell 2003; 12 (4):805-816 
 56.  Cawthon RM. Telomere length measurement by a novel monochrome 
multiplex quantitative PCR method. Nucleic Acids Res. 2009; 37 
(3):e21 
 57.  Cawthon RM, Smith KR, O'Brien E, Sivatchenko A, Kerber RA. 
Association between telomere length in blood and mortality in 
people aged 60 years or older. Lancet 2003; 361 (9355):393-395 
 58.  Cederholm A, Svenungsson E, Jensen-Urstad K, Trollmo C, Ulfgren AK, 
Swedenborg J, Fei GZ, Frostegard J. Decreased binding of 
annexin v to endothelial cells: a potential mechanism in 
atherothrombosis of patients with systemic lupus erythematosus. 
Arterioscler.Thromb.Vasc.Biol. 2005; 25 (1):198-203 
 59.  Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, 
Aydintug AO, Jedryka-Goral A, de RE, Fernandez-Nebro A, 
Galeazzi M, Haga HJ, Mathieu A, Houssiau F, Ruiz-Irastorza G, 
Ingelmo M, Hughes GR. Morbidity and mortality in systemic lupus 
erythematosus during a 5-year period. A multicenter prospective 
study of 1,000 patients. European Working Party on Systemic 
Lupus Erythematosus. Medicine (Baltimore) 1999; 78 (3):167-175 
 60.  Cervera R, Piette JC, Font J, Khamashta MA, Shoenfeld Y, Camps MT, 
Jacobsen S, Lakos G, Tincani A, Kontopoulou-Griva I, Galeazzi 
M, Meroni PL, Derksen RH, De Groot PG, Gromnica-Ihle E, 
Baleva M, Mosca M, Bombardieri S, Houssiau F, Gris JC, Quere I, 
Hachulla E, Vasconcelos C, Roch B, Fernandez-Nebro A, Boffa 
MC, Hughes GR, Ingelmo M. Antiphospholipid syndrome: clinical 
and immunologic manifestations and patterns of disease 
expression in a cohort of 1,000 patients. Arthritis Rheum. 2002; 46 
(4):1019-1027 
 61.  Chambless LE, Heiss G, Folsom AR, Rosamond W, Szklo M, Sharrett 
AR, Clegg LX. Association of coronary heart disease incidence 
with carotid arterial wall thickness and major risk factors: the 
 216 
 
Atherosclerosis Risk in Communities (ARIC) Study, 1987-1993. 
Am.J.Epidemiol. 1997; 146 (6):483-494 
 62.  Chang E, Harley CB. Telomere length and replicative aging in human 
vascular tissues. Proc.Natl.Acad.Sci.U.S.A 1995; 92 (24):11190-
11194 
 63.  Chen JZ, Zhang FR, Tao QM, Wang XX, Zhu JH, Zhu JH. Number and 
activity of endothelial progenitor cells from peripheral blood in 
patients with hypercholesterolaemia. Clin.Sci.(Lond) 2004; 107 
(3):273-280 
 64.  Cheng J, Baumhueter S, Cacalano G, Carver-Moore K, Thibodeaux H, 
Thomas R, Broxmeyer HE, Cooper S, Hague N, Moore M, Lasky 
LA. Hematopoietic defects in mice lacking the sialomucin CD34. 
Blood 1996; 87 (2):479-490 
 65.  Cherif H, Tarry JL, Ozanne SE, Hales CN. Ageing and telomeres: a 
study into organ- and gender-specific telomere shortening. Nucleic 
Acids Res. 2003; 31 (5):1576-1583 
 66.  Chin L, Artandi SE, Shen Q, Tam A, Lee SL, Gottlieb GJ, Greider CW, 
DePinho RA. p53 Deficiency Rescues the Adverse Effects of 
Telomere Loss and Cooperates with Telomere Dysfunction to 
Accelerate Carcinogenesis. Cell 1999; 97 (4):527-538 
 67.  Chiu CP, Dragowska W, Kim NW, Vaziri H, Yui J, Thomas TE, Harley 
CB, Lansdorp PM. Differential expression of telomerase activity in 
hematopoietic progenitors from adult human bone marrow. Stem 
Cells 1996; 14 (2):239-248 
 68.  Chong L, van SB, Broccoli D, Erdjument-Bromage H, Hanish J, Tempst 
P, de LT. A human telomeric protein. Science 1995; 270 
(5242):1663-1667 
 69.  Chung CP, Avalos I, Oeser A, Gebretsadik T, Shintani A, Raggi P, 
Michael SC. High prevalence of the metabolic syndrome in 
patients with systemic lupus erythematosus: association with 
disease characteristics and cardiovascular risk factors. Ann 
Rheum Dis 2007; 66 (2):208-214 
 70.  Clancy R, Marder G, Martin V, Belmont HM, Abramson SB, Buyon J. 
Circulating activated endothelial cells in systemic lupus 
erythematosus: further evidence for diffuse vasculopathy. Arthritis 
Rheum. 2001; 44 (5):1203-1208 
 71.  Clowse ME, Magder LS, Witter F, Petri M. The impact of increased lupus 
activity on obstetric outcomes. Arthritis Rheum. 2005; 52 (2):514-
521 
 217 
 
 72.  Cohen AS, Reynolds W, Franklin EC. Preliminary criteria for the 
classification of SLE. Bulletin of the Rheumatic Diseases 1971; 
21:643-645 
 73.  Cooper GS, Wither J, Bernatsky S, Claudio JO, Clarke A, Rioux JD, 
Fortin PR. Occupational and environmental exposures and risk of 
systemic lupus erythematosus: silica, sunlight, solvents. 
Rheumatology (Oxford) 2010; 49 (11):2172-2180 
 74.  Coulter WH. High speed automatic blood cell counter and 
cell size analyzer. [Abstract]. Proc Natl Electronics Conf 
1956; 12:1034-1040 
 75.  Crispin JC, Liossis SN, Kis-Toth K, Lieberman LA, Kyttaris VC, Juang 
YT, Tsokos GC. Pathogenesis of human systemic lupus 
erythematosus: recent advances. Trends Mol.Med 2010; 16 
(2):47-57 
 76.  Criswell LA. The genetic contribution to systemic lupus erythematosus. 
Bull.NYU.Hosp.Jt.Dis. 2008; 66 (3):176-183 
 77.  Culwell KR, Curtis KM, del Carmen CM. Safety of contraceptive method 
use among women with systemic lupus erythematosus: a 
systematic review. Obstet.Gynecol. 2009; 114 (2 Pt 1):341-353 
 78.  Cypiene A, Kovaite M, Venalis A, Dadoniene J, Rugiene R, Petrulioniene 
Z, Ryliskyte L, Laucevicius A. Arterial wall dysfunction in systemic 
lupus erythematosus. Lupus 2009; 18 (6):522-529 
 79.  Davignon J, Ganz P. Role of endothelial dysfunction in atherosclerosis. 
Circulation 2004; 109 (23 Suppl 1):III27-III32 
 80.  de LT. Protection of mammalian telomeres. Oncogene 2002; 21 (4):532-
540 
 81.  de LT. Shelterin: the protein complex that shapes and safeguards human 
telomeres. Genes Dev. 2005; 19 (18):2100-2110 
 82.  de LK, Smit AJ, de GE, van Roon AM, Kallenberg CG, Bijl M. 
Longitudinal study on premature atherosclerosis in patients with 
systemic lupus erythematosus. Atherosclerosis 2009; 206 (2):546-
550 
 83.  Deapen D, Escalante A, Weinrib L, Horwitz D, Bachman B, Roy-Burman 
P, Walker A, Mack TM. A revised estimate of twin concordance in 
systemic lupus erythematosus. Arthritis Rheum. 1992; 35 (3):311-
318 
 84.  Demissie S, Levy D, Benjamin EJ, Cupples LA, Gardner JP, Herbert A, 
Kimura M, Larson MG, Meigs JB, Keaney JF, Aviv A. Insulin 
resistance, oxidative stress, hypertension, and leukocyte telomere 
 218 
 
length in men from the Framingham Heart Study. Aging Cell 2006; 
5 (4):325-330 
 85.  Deng Y, Tsao BP. Genetic susceptibility to systemic lupus 
erythematosus in the genomic era. Nat Rev Rheumatol. 2010; 6 
(12):683-692 
 86.  Denis CV. Molecular and cellular biology of von Willebrand factor. Int.J 
Hematol. 2002; 75 (1):3-8 
 87.  Denny M, Somers EC, Kaplan MJ. imbalance of endothelial 
damage/regeneration in SLE [Abstract]. Arthritis Rheum 2005; 
 88.  Denny MF, Thacker S, Mehta H, Somers EC, Dodick T, Barrat FJ, 
McCune WJ, Kaplan MJ. Interferon-{alpha} promotes abnormal 
vasculogenesis in lupus: a potential pathway for premature 
atherosclerosis. Blood 2007; 110 (8):2907-2915 
 89.  Diaz - Borjon A, Colmegna I, Fujii H, Schaefer L, Goronzy J, Weyand C. 
Impaired Clonogenic Potential and Shortened Telomeres of 
Haematopoietic Progenitor Cells in Rheumatoid Arthritis 
[Abstract]. Arthritis Rheum 2006; 
 90.  Dimmeler S, Aicher A, Vasa M, Mildner-Rihm C, Adler K, Tiemann M, 
Rutten H, Fichtlscherer S, Martin H, Zeiher AM. HMG-CoA 
reductase inhibitors (statins) increase endothelial progenitor cells 
via the PI 3-kinase/Akt pathway. J.Clin.Invest 2001; 108 (3):391-
397 
 91.  Ding D, Mehta H, McCune WJ, Kaplan MJ. Aberrant phenotype and 
function of myeloid dendritic cells in systemic lupus 
erythematosus. J Immunol 2006; 177 (9):5878-5889 
 92.  Doria A, Shoenfeld Y, Wu R, Gambari PF, Puato M, Ghirardello A, 
Gilburd B, Corbanese S, Patnaik M, Zampieri S, Peter JB, 
Favaretto E, Iaccarino L, Sherer Y, Todesco S, Pauletto P. Risk 
factors for subclinical atherosclerosis in a prospective cohort of 
patients with systemic lupus erythematosus. Ann Rheum Dis 
2003; 62 (11):1071-1077 
 93.  Ebner P, Picard F, Richter J, Darrelmann E, Schneider M, Strauer BE, 
Brehm M. Accumulation of VEGFR-2+/CD133+ cells and 
decreased number and impaired functionality of CD34+/VEGFR-
2+ cells in patients with SLE. Rheumatology (Oxford) 2010; 49 
(1):63-72 
 94.  Egerer K, Feist E, Rohr U, Pruss A, Burmester GR, Dorner T. Increased 
serum soluble CD14, ICAM-1 and E-selectin correlate with 
disease activity and prognosis in systemic lupus erythematosus. 
Lupus 2000; 9 (8):614-621 
 219 
 
 95.  El-Magadmi M, Bodill H, Ahmad Y, Durrington PN, Mackness M, Walker 
M, Bernstein RM, Bruce IN. Systemic lupus erythematosus: an 
independent risk factor for endothelial dysfunction in women. 
Circulation 2004; 110 (4):399-404 
 96.  Eppihimer MJ, Wolitzky B, Anderson DC, Labow MA, Granger DN. 
Heterogeneity of Expression of E- and P-Selectins In Vivo. Circ 
Res 1996; 79 (3):560-569 
 97.  Erridge C. The roles of Toll-like receptors in atherosclerosis. J 
Innate.Immun. 2009; 1 (4):340-349 
 98.  Erridge C, Burdess A, Jackson AJ, Murray C, Riggio M, Lappin D, 
Milligan S, Spickett CM, Webb DJ. Vascular cell responsiveness 
to Toll-like receptor ligands in carotid atheroma. Eur.J Clin.Invest 
2008; 38 (10):713-720 
 99.  Esdaile JM, Abrahamowicz M, Grodzicky T, Li Y, Panaritis C, du BR, 
Cote R, Grover SA, Fortin PR, Clarke AE, Senecal JL. Traditional 
Framingham risk factors fail to fully account for accelerated 
atherosclerosis in systemic lupus erythematosus. Arthritis Rheum. 
2001; 44 (10):2331-2337 
 100.  Espinosa G, Cervera R. Morbidity and mortality in the antiphospholipid 
syndrome. Curr.Opin.Pulm.Med 2009; 15 (5):413-417 
 101.  Ettinger WH, Goldberg AP, pplebaum-Bowden D, Hazzard WR. 
Dyslipoproteinemia in systemic lupus erythematosus. Effect of 
corticosteroids. Am.J.Med. 1987; 83 (3):503-508 
 102.  Expert Panel on Detection EaToHBCiA. Executive Summary of the Third 
Report of the National Cholesterol Education Program (NCEP) 
Expert Panel on Detection, Evaluation, and Treatment of High 
Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA: 
The Journal of the American Medical Association 2001; 285 
(19):2486-2497 
 103.  Fadini GP, Coracina A, Baesso I, Agostini C, Tiengo A, Avogaro A, de 
Kreutzenberg SV. Peripheral blood CD34+KDR+ endothelial 
progenitor cells are determinants of subclinical atherosclerosis in 
a middle-aged general population. Stroke 2006; 37 (9):2277-2282 
 104.  Falaschi F, Ravelli A, Martignoni A, Migliavacca D, Sartori M, Pistorio A, 
Perani G, Martini A. Nephrotic-range proteinuria, the major risk 
factor for early atherosclerosis in juvenile-onset systemic lupus 
erythematosus. Arthritis Rheum. 2000; 43 (6):1405-1409 
 105.  Fellstrom BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, 
Beutler J, Chae DW, Chevaile A, Cobbe SM, Gronhagen-Riska C, 
De Lima JJ, Lins R, Mayer G, McMahon AW, Parving HH, 
Remuzzi G, Samuelsson O, Sonkodi S, Sci D, Suleymanlar G, 
 220 
 
Tsakiris D, Tesar V, Todorov V, Wiecek A, Wuthrich RP, Gottlow 
M, Johnsson E, Zannad F. Rosuvastatin and cardiovascular 
events in patients undergoing hemodialysis. N Engl J Med 2009; 
360 (14):1395-1407 
 106.  Ferreira GA, Navarro TP, Telles RW, Andrade LE, Sato EI. Atorvastatin 
therapy improves endothelial-dependent vasodilation in patients 
with systemic lupus erythematosus: an 8 weeks controlled trial. 
Rheumatology (Oxford) 2007; 46 (10):1560-1565 
 107.  Fischer LM, Schlienger RG, Matter C, Jick H, Meier CR. Effect of 
rheumatoid arthritis or systemic lupus erythematosus on the risk of 
first-time acute myocardial infarction. Am.J Cardiol. 2004; 93 
(2):198-200 
 108.  Flesher DL, Sun X, Behrens TW, Graham RR, Criswell LA. Recent 
advances in the genetics of systemic lupus erythematosus. 
Expert.Rev Clin.Immunol 2010; 6 (3):461-479 
 109.  Forsyth NR, Wright WE, Shay JW. Telomerase and differentiation in 
multicellular organisms: turn it off, turn it on, and turn it off again. 
Differentiation 2002; 69 (4-5):188-197 
 110.  Freire BF, da Silva RC, Fabro AT, dos S. Is systemic lupus 
erithematosus a new risk factor for atherosclerosis? Arq 
Bras.Cardiol. 2006; 87 (3):300-306 
 111.  Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration 
of low-density lipoprotein cholesterol in plasma, without use of the 
preparative ultracentrifuge. Clin.Chem. 1972; 18 (6):499-502 
 112.  Friedrich EB, Walenta K, Scharlau J, Nickenig G, Werner N. CD34-
/CD133+/VEGFR-2+ endothelial progenitor cell subpopulation with 
potent vasoregenerative capacities. Circ.Res. 2006; 98 (3):e20-
e25 
 113.  Frostegard AG, Su J, von LP, Frostegard J. Effects of anti-cardiolipin 
antibodies and IVIg on annexin A5 binding to endothelial cells: 
implications for cardiovascular disease. Scand.J.Rheumatol. 
2010; 39 (1):77-83 
 114.  Fujii H, Shao L, Diaz - Borjon A, Colmegna I, Goronzy JJ, Weyand C. 
Defective Telomerase Activity as a Mechanism for Premature 
Immunosenescence in Rheumatoid Arthritis [Abstract]. Arthritis 
Rheum 2006; 
 115.  Fukumoto S, Tsumagari T, Kinjo M, Tanaka K. Coronary atherosclerosis 
in patients with systemic lupus erythematosus at autopsy. Acta 
Pathol.Jpn. 1987; 37 (1):1-9 
 221 
 
 116.  Gaeta G, De MM, Cuomo S, Guarini P, Foglia MC, Bond MG, Trevisan 
M. Arterial abnormalities in the offspring of patients with premature 
myocardial infarction. N.Engl.J.Med. 2000; 343 (12):840-846 
 117.  Gardner JP, Li S, Srinivasan SR, Chen W, Kimura M, Lu X, Berenson 
GS, Aviv A. Rise in Insulin Resistance Is Associated With 
Escalated Telomere Attrition. Circulation 2005; 111 (17):2171-
2177 
 118.  Gateva V, Sandling JK, Hom G, Taylor KE, Chung SA, Sun X, Ortmann 
W, Kosoy R, Ferreira RC, Nordmark G, Gunnarsson I, 
Svenungsson E, Padyukov L, Sturfelt G, Jonsen A, Bengtsson 
AA, Rantapaa-Dahlqvist S, Baechler EC, Brown EE, Alarcon GS, 
Edberg JC, Ramsey-Goldman R, McGwin G, Jr., Reveille JD, Vila 
LM, Kimberly RP, Manzi S, Petri MA, Lee A, Gregersen PK, 
Seldin MF, Ronnblom L, Criswell LA, Syvanen AC, Behrens TW, 
Graham RR. A large-scale replication study identifies TNIP1, 
PRDM1, JAZF1, UHRF1BP1 and IL10 as risk loci for systemic 
lupus erythematosus. Nat Genet. 2009; 41 (11):1228-1233 
 119.  Gehling UM, Ergun S, Schumacher U, Wagener C, Pantel K, Otte M, 
Schuch G, Schafhausen P, Mende T, Kilic N, Kluge K, Schafer B, 
Hossfeld DK, Fiedler W. In vitro differentiation of endothelial cells 
from AC133-positive progenitor cells. Blood 2000; 95 (10):3106-
3112 
 120.  George J, Harats D, Gilburd B, Afek A, Levy Y, Schneiderman J, 
Barshack I, Kopolovic J, Shoenfeld Y. Immunolocalization of 
beta2-glycoprotein I (apolipoprotein H) to human atherosclerotic 
plaques: potential implications for lesion progression. Circulation 
1999; 99 (17):2227-2230 
 121.  Gill M, Dias S, Hattori K, Rivera ML, Hicklin D, Witte L, Girardi L, Yurt R, 
Himel H, Rafii S. Vascular Trauma Induces Rapid but Transient 
Mobilization of VEGFR2+AC133+ Endothelial Precursor Cells. 
Circ Res 2001; 88 (2):167-174 
 122.  Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M, Bacon 
P, Bombardieri S, Hanly J, Hay E, Isenberg D, Jones J, Kalunian 
K, Maddison P, Nived O, Petri M, Richter M, Sanchez-Guerrero J, 
Snaith M, Sturfelt G, Symmons D, Zoma A. The development and 
initial validation of the Systemic Lupus International Collaborating 
Clinics/American College of Rheumatology damage index for 
systemic lupus erythematosus. Arthritis Rheum. 1996; 39 (3):363-
369 
 123.  Gladman DD, Urowitz MB. Morbidity in systemic lupus erythematosus. 
J.Rheumatol.Suppl 1987; 14 Suppl 13:223-226 
 222 
 
 124.  Gladman DD, Urowitz MB, Rahman P, Ibanez D, Tam LS. Accrual of 
organ damage over time in patients with systemic lupus 
erythematosus. J Rheumatol. 2003; 30 (9):1955-1959 
 125.  Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney 
disease and the risks of death, cardiovascular events, and 
hospitalization. N Engl J Med 2004; 351 (13):1296-1305 
 126.  Goldstein JL, Ho YK, Basu SK, Brown MS. Binding site on macrophages 
that mediates uptake and degradation of acetylated low density 
lipoprotein, producing massive cholesterol deposition. 
Proc.Natl.Acad.Sci.U.S.A 1979; 76 (1):333-337 
 127.  Gough A, Faint J, Salmon M, Hassell A, Wordsworth P, Pilling D, Birley 
A, Emery P. Genetic typing of patients with inflammatory arthritis 
at presentation can be used to predict outcome. Arthritis Rheum 
1994; 37 (8):1166-1170 
 128.  Graakjaer J, Bischoff C, Korsholm L, Holstebroe S, Vach W, Bohr VA, 
Christensen K, Kolvraa S. The pattern of chromosome-specific 
variations in telomere length in humans is determined by inherited, 
telomere-near factors and is maintained throughout life. 
Mech.Ageing Dev. 2003; 124 (5):629-640 
 129.  Graham KL, Utz PJ. Sources of autoantigens in systemic lupus 
erythematosus. Curr.Opin.Rheumatol. 2005; 17 (5):513-517 
 130.  Graham RR, Cotsapas C, Davies L, Hackett R, Lessard CJ, Leon JM, 
Burtt NP, Guiducci C, Parkin M, Gates C, Plenge RM, Behrens 
TW, Wither JE, Rioux JD, Fortin PR, Graham DC, Wong AK, Vyse 
TJ, Daly MJ, Altshuler D, Moser KL, Gaffney PM. Genetic variants 
near TNFAIP3 on 6q23 are associated with systemic lupus 
erythematosus. Nat Genet. 2008; 40 (9):1059-1061 
 131.  Greco TP, Conti-Kelly AM, Greco T, Jr., Doyle R, Matsuura E, Anthony 
JR, Lopez LR. Newer antiphospholipid antibodies predict adverse 
outcomes in patients with acute coronary syndrome. 
Am.J.Clin.Pathol. 2009; 132 (4):613-620 
 132.  Greenberg RA, Chin L, Femino A, Lee KH, Gottlieb GJ, Singer RH, 
Greider CW, DePinho RA. Short Dysfunctional Telomeres Impair 
Tumorigenesis in the INK4a[Delta]2/3 Cancer-Prone Mouse. Cell 
1999; 97 (4):515-525 
 133.  Greider CW, Blackburn EH. A telomeric sequence in the RNA of 
Tetrahymena telomerase required for telomere repeat synthesis. 
Nature 1989; 337 (6205):331-337 
 134.  Grisar J, Aletaha D, Steiner CW, Kapral T, Steiner S, Seidinger D, 
Weigel G, Schwarzinger I, Wolozcszuk W, Steiner G, Smolen JS. 
Depletion of endothelial progenitor cells in the peripheral blood of 
 223 
 
patients with rheumatoid arthritis. Circulation 2005; 111 (2):204-
211 
 135.  Grisar J, Steiner CW, Bonelli M, Karonitsch T, Schwarzinger I, Weigel G, 
Steiner G, Smolen JS. Systemic lupus erythematosus patients 
exhibit functional deficiencies of endothelial progenitor cells. 
Rheumatology 2008; 47 (10):1476-1483 
 136.  Gu L, Okada Y, Clinton SK, Gerard C, Sukhova GK, Libby P, Rollins BJ. 
Absence of Monocyte Chemoattractant Protein-1 Reduces 
Atherosclerosis in Low Density Lipoprotein Receptor-Deficient 
Mice. Molecular Cell 1998; 2 (2):275-281 
 137.  Guray U, Erbay AR, Guray Y, Yilmaz MB, Boyaci AA, Sasmaz H, 
Korkmaz S, Kutuk E. Levels of soluble adhesion molecules in 
various clinical presentations of coronary atherosclerosis. 
Int.J.Cardiol. 2004; 96 (2):235-240 
 138.  Hahn WC, Weinberg RA. Modelling the molecular circuitry of cancer. 
Nature Reviews.Cancer 2002; 2 (5):331-341 
 139.  Haider YS, Roberts WC. Coronary arterial disease in systemic lupus 
erythematosus; quantification of degrees of narrowing in 22 
necropsy patients (21 women) aged 16 to 37 years. Am.J Med 
1981; 70 (4):775-781 
 140.  Hall JC, Rosen A. Type I interferons: crucial participants in disease 
amplification in autoimmunity. Nat Rev Rheumatol. 2010; 6 (1):40-
49 
 141.  Han JW, Zheng HF, Cui Y, Sun LD, Ye DQ, Hu Z, Xu JH, Cai ZM, Huang 
W, Zhao GP, Xie HF, Fang H, Lu QJ, Xu JH, Li XP, Pan YF, Deng 
DQ, Zeng FQ, Ye ZZ, Zhang XY, Wang QW, Hao F, Ma L, Zuo 
XB, Zhou FS, Du WH, Cheng YL, Yang JQ, Shen SK, Li J, Sheng 
YJ, Zuo XX, Zhu WF, Gao F, Zhang PL, Guo Q, Li B, Gao M, Xiao 
FL, Quan C, Zhang C, Zhang Z, Zhu KJ, Li Y, Hu DY, Lu WS, 
Huang JL, Liu SX, Li H, Ren YQ, Wang ZX, Yang CJ, Wang PG, 
Zhou WM, Lv YM, Zhang AP, Zhang SQ, Lin D, Li Y, Low HQ, 
Shen M, Zhai ZF, Wang Y, Zhang FY, Yang S, Liu JJ, Zhang XJ. 
Genome-wide association study in a Chinese Han population 
identifies nine new susceptibility loci for systemic lupus 
erythematosus. Nat Genet. 2009; 41 (11):1234-1237 
 142.  Hansson GK. Inflammation, atherosclerosis, and coronary artery 
disease. N.Engl.J.Med. 2005; 352 (16):1685-1695 
 143.  Haque S, Gordon C, Isenberg D, Rahman A, Lanyon P, Bell A, Emery P, 
McHugh N, Teh LS, Scott DG, Akil M, Naz S, Andrews J, Griffiths 
B, Harris H, Youssef H, McLaren J, Toescu V, Devakumar V, Teir 
J, Bruce IN. Risk factors for clinical coronary heart disease in 
systemic lupus erythematosus: the lupus and atherosclerosis 
 224 
 
evaluation of risk (LASER) study. J Rheumatol. 2010; 37 (2):322-
329 
 144.  Harley CB, Futcher AB, Greider CW. Telomeres shorten during ageing of 
human fibroblasts. Nature 1990; 345 (6274):458-460 
 145.  Harris EN, Gharavi AE, Boey ML, Patel BM, kworth-Young CG, Loizou S, 
Hughes GR. Anticardiolipin antibodies: detection by 
radioimmunoassay and association with thrombosis in systemic 
lupus erythematosus. Lancet 1983; 2 (8361):1211-1214 
 146.  Hasunuma Y, Matsuura E, Makita Z, Katahira T, Nishi S, Koike T. 
Involvement of beta 2-glycoprotein I and anticardiolipin antibodies 
in oxidatively modified low-density lipoprotein uptake by 
macrophages. Clin.Exp.Immunol. 1997; 107 (3):569-573 
 147.  Hayflick L. The limited in vitro lifetime of human diploid cell strains. 
Exp.Cell Res. 1965; 37:614-636 
 148.  Herrera E, Samper E, Martin-Caballero J, Flores JM, Lee HW, Blasco 
MA. Disease states associated with telomerase deficiency appear 
earlier in mice with short telomeres. EMBO J. 1999; 18 (11):2950-
2960 
 149.  Hewagama A, Richardson B. The genetics and epigenetics of 
autoimmune diseases. J Autoimmun. 2009; 33 (1):3-11 
 150.  Hijmering ML, Stroes ES, Pasterkamp G, Sierevogel M, Banga JD, 
Rabelink TJ. Variability of flow mediated dilation: consequences 
for clinical application. Atherosclerosis 2001; 157 (2):369-373 
 151.  Hildbrand P, Cirulli V, Prinsen RC, Smith KA, Torbett BE, Salomon DR, 
Crisa L. The role of angiopoietins in the development of 
endothelial cells from cord blood CD34+ progenitors. Blood 2004; 
104 (7):2010-2019 
 152.  Hill JM, Zalos G, Halcox JP, Schenke WH, Waclawiw MA, Quyyumi AA, 
Finkel T. Circulating endothelial progenitor cells, vascular function, 
and cardiovascular risk. N.Engl.J.Med. 2003; 348 (7):593-600 
 153.  Hiyama K, Hirai Y, Kyoizumi S, Akiyama M, Hiyama E, Piatyszek MA, 
Shay JW, Ishioka S, Yamakido M. Activation of telomerase in 
human lymphocytes and hematopoietic progenitor cells. 
J.Immunol. 1995; 155 (8):3711-3715 
 154.  Ho KT, Ahn CW, Alarcon GS, Baethge BA, Tan FK, Roseman J, Bastian 
HM, Fessler BJ, McGwin G, Jr., Vila LM, Calvo-Alen J, Reveille 
JD, for the LUMINA Study Group. Systemic lupus erythematosus 
in a multiethnic cohort (LUMINA): XXVIII. Factors predictive of 
thrombotic events. Rheumatology 2005; 44 (10):1303-1307 
 225 
 
 155.  Hochberg MC. Updating the American College of Rheumatology revised 
criteria for the classification of systemic lupus erythematosus. 
Arthritis Rheum. 1997; 40 (9):1725 
 156.  Hoffmann MH, Trembleau S, Muller S, Steiner G. Nucleic acid-
associated autoantigens: pathogenic involvement and therapeutic 
potential. J Autoimmun. 2010; 34 (3):J178-J206 
 157.  Hollander M, Bots ML, Del Sol AI, Koudstaal PJ, Witteman JC, Grobbee 
DE, Hofman A, Breteler MM. Carotid plaques increase the risk of 
stroke and subtypes of cerebral infarction in asymptomatic elderly: 
the Rotterdam study. Circulation 2002; 105 (24):2872-2877 
 158.  Hollenbeck C, Reaven GM. Variations in insulin-stimulated glucose 
uptake in healthy individuals with normal glucose tolerance. J Clin 
Endocrinol Metab 1987; 64 (6):1169-1173 
 159.  Holmen C, Elsheikh E, Stenvinkel P, Qureshi AR, Pettersson E, Jalkanen 
S, Sumitran-Holgersson S. Circulating Inflammatory Endothelial 
Cells Contribute to Endothelial Progenitor Cell Dysfunction in 
Patients with Vasculitis and Kidney Involvement. J Am Soc 
Nephrol 2005; 16 (10):3110-3120 
 160.  Honda M, Mengesha E, Albano S, Nichols WS, Wallace DJ, Metzger A, 
Klinenberg JR, Linker-Israeli M. Telomere Shortening and 
Decreased Replicative Potential, Contrasted by Continued 
Proliferation of Telomerase-Positive CD8+CD28lo T Cells in 
Patients with Systemic Lupus Erythematosus. Clinical 
Immunology 2001; 99 (2):211-221 
 161.  Howard G, Sharrett AR, Heiss G, Evans GW, Chambless LE, Riley WA, 
Burke GL. Carotid artery intimal-medial thickness distribution in 
general populations as evaluated by B-mode ultrasound. ARIC 
Investigators. Stroke 1993; 24 (9):1297-1304 
 162.  Hu T, She Q, Jiang Y, Su L, Yin Y. Level of CD14+-endothelial 
progenitor cells is not associated with coronary artery disease or 
cardiovascular risk factors. Age (Dordr.) 2008; 30 (4):319-326 
 163.  Huffman KE, Levene SD, Tesmer VM, Shay JW, Wright WE. Telomere 
Shortening Is Proportional to the Size of the G-rich Telomeric 3'-
Overhang. J.Biol.Chem. 2000; 275 (26):19719-19722 
 164.  Hunt SC, Chen W, Gardner JP, Kimura M, Srinivasan SR, Eckfeldt JH, 
Berenson GS, Aviv A. Leukocyte telomeres are longer in African 
Americans than in whites: the National Heart, Lung, and Blood 
Institute Family Heart Study and the Bogalusa Heart Study. Aging 
Cell 2008; 7 (4):451-458 
 165.  Huong DL, Papo T, Beaufils H, Wechsler B, Bletry O, Baumelou A, 
Godeau P, Piette JC. Renal involvement in systemic lupus 
 226 
 
erythematosus. A study of 180 patients from a single center. 
Medicine (Baltimore) 1999; 78 (3):148-166 
 166.  Imanishi T, Hano T, Nishio I. Angiotensin II potentiates vascular 
endothelial growth factor-induced proliferation and network 
formation of endothelial progenitor cells. Hypertens.Res. 2004; 27 
(2):101-108 
 167.  Ingram DA, Mead LE, Moore DB, Woodard W, Fenoglio A, Yoder MC. 
Vessel wall-derived endothelial cells rapidly proliferate because 
they contain a complete hierarchy of endothelial progenitor cells. 
Blood 2005; 105 (7):2783-2786 
 168.  Isenberg DA, Rahman A, Allen E, Farewell V, Akil M, Bruce IN, D'Cruz D, 
Griffiths B, Khamashta M, Maddison P, McHugh N, Snaith M, Teh 
LS, Yee CS, Zoma A, Gordon C. BILAG 2004. Development and 
initial validation of an updated version of the British Isles Lupus 
Assessment Group's disease activity index for patients with 
systemic lupus erythematosus. Rheumatology 2005; 44 (7):902-
906 
 169.  Jeanclos E, Krolewski A, Skurnick J, Kimura M, Aviv H, Warram JH, Aviv 
A. Shortened telomere length in white blood cells of patients with 
IDDM. Diabetes 1998; 47 (3):482-486 
 170.  Jeanclos E, Schork NJ, Kyvik KO, Kimura M, Skurnick JH, Aviv A. 
Telomere Length Inversely Correlates With Pulse Pressure and Is 
Highly Familial. Hypertension 2000; 36 (2):195-200 
 171.  Jialal I, Devaraj S, Singh U, Huet BA. Decreased number and impaired 
functionality of endothelial progenitor cells in subjects with 
metabolic syndrome: implications for increased cardiovascular 
risk. Atherosclerosis 2010; 211 (1):297-302 
 172.  Jimenez S, Garcia-Criado MA, Tassies D, Reverter JC, Cervera R, 
Gilabert MR, Zambon D, Ros E, Bru C, Font J. Preclinical vascular 
disease in systemic lupus erythematosus and primary 
antiphospholipid syndrome. Rheumatology (Oxford) 2005; 44 
(6):756-761 
 173.  Johnson AE, Gordon C, Palmer RG, Bacon PA. The prevalence and 
incidence of systemic lupus erythematosus in Birmingham, 
England. Relationship to ethnicity and country of birth. Arthritis 
Rheum. 1995; 38 (4):551-558 
 174.  Kalka C, Masuda H, Takahashi T, Kalka-Moll WM, Silver M, Kearney M, 
Li T, Isner JM, Asahara T. Transplantation of ex vivo expanded 
endothelial progenitor cells for therapeutic neovascularization. 
PNAS 2000; 97 (7):3422-3427 
 227 
 
 175.  Kaposi M. Lupus vulgaris. On Diseases of the Skin including the 
Exanthemata 1875; VI 
 176.  Kapuscinski J. Interactions of nucleic acids with fluorescent dyes: 
spectral properties of condensed complexes. J 
Histochem.Cytochem. 1990; 38 (9):1323-1329 
 177.  Kasitanon N, Magder LS, Petri M. Predictors of survival in systemic lupus 
erythematosus. Medicine (Baltimore) 2006; 85 (3):147-156 
 178.  Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. 
Participation of p53 protein in the cellular response to DNA 
damage. Cancer Res. 1991; 51 (23 Pt 1):6304-6311 
 179.  Katayama Y, Kohriyama K. Telomerase activity in peripheral blood 
mononuclear cells of systemic connective tissue diseases. 
J.Rheumatol. 2001; 28 (2):288-291 
 180.  Kavai M. Immune complex clearance by complement receptor type 1 in 
SLE. Autoimmun.Rev 2008; 8 (2):160-164 
 181.  Kavanaugh AF, Solomon DH. Guidelines for immunologic laboratory 
testing in the rheumatic diseases: anti-DNA antibody tests. 
Arthritis Rheum. 2002; 47 (5):546-555 
 182.  Kawai T, Akira S. Pathogen recognition with Toll-like receptors. 
Curr.Opin.Immunol. 2005; 17 (4):338-344 
 183.  Khan SS, Solomon MA, McCoy JP, Jr. Detection of circulating 
endothelial cells and endothelial progenitor cells by flow 
cytometry. Cytometry B Clin.Cytom. 2005; 64 (1):1-8 
 184.  Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, 
Coviello GM, Wright WE, Weinrich SL, Shay JW. Specific 
association of human telomerase activity with immortal cells and 
cancer. Science 1994; 266 (5193):2011-2015 
 185.  Kim SH, Kaminker P, Campisi J. TIN2, a new regulator of telomere 
length in human cells. Nat.Genet. 1999; 23 (4):405-412 
 186.  Kirou KA, Lee C, George S, Louca K, Peterson MG, Crow MK. Activation 
of the interferon-alpha pathway identifies a subgroup of systemic 
lupus erythematosus patients with distinct serologic features and 
active disease. Arthritis Rheum. 2005; 52 (5):1491-1503 
 187.  Klapper W, Moosig F, Sotnikova A, Qian W, Schroder JO, Parwaresch R. 
Telomerase activity in B and T lymphocytes of patients with 
systemic lupus erythematosus. Ann Rheum Dis 2004; 63 
(12):1681-1683 
 228 
 
 188.  Kobayashi K, Kishi M, Atsumi T, Bertolaccini ML, Makino H, Sakairi N, 
Yamamoto I, Yasuda T, Khamashta MA, Hughes GR, Koike T, 
Voelker DR, Matsuura E. Circulating oxidized LDL forms 
complexes with beta2-glycoprotein I: implication as an atherogenic 
autoantigen. J Lipid Res. 2003; 44 (4):716-726 
 189.  Kondo T, Hayashi M, Takeshita K, Numaguchi Y, Kobayashi K, Iino S, 
Inden Y, Murohara T. Smoking cessation rapidly increases 
circulating progenitor cells in peripheral blood in chronic smokers. 
Arterioscler.Thromb.Vasc.Biol. 2004; 24 (8):1442-1447 
 190.  Kong D, Melo LG, Gnecchi M, Zhang L, Mostoslavsky G, Liew CC, Pratt 
RE, Dzau VJ. Cytokine-Induced Mobilization of Circulating 
Endothelial Progenitor Cells Enhances Repair of Injured Arteries. 
Circulation 2004; 110 (14):2039-2046 
 191.  Korkmaz H, Onalan O. Evaluation of endothelial dysfunction: flow-
mediated dilation. Endothelium 2008; 15 (4):157-163 
 192.  Koshikawa M, Izawa A, Tomita T, Kumazaki S, Koyama J, Shimodaira S, 
Ikeda U. Association between circulating endothelial progenitor 
cells and hs-CRP in patients with diabetes. The British Journal of 
Diabetes & Vascular Disease 2010; 10 (3):133-138 
 193.  Kostner KM. Activation of the complement system: a crucial link between 
inflammation and atherosclerosis? Eur.J Clin.Invest 2004; 34 
(12):800-802 
 194.  Kurosaka D, Ozawa Y, Yasuda J, Yokoyama T, Yamada A, Akiyama M, 
Saito S, Tajima N. Telomerase activity in peripheral blood 
mononuclear cells from patients with SLE. Ann Rheum Dis 2001; 
60 (12):1158-1159 
 195.  Kurosaka D, Yasuda J, Yoshida K, Yokoyama T, Ozawa Y, Obayashi Y, 
Kingetsu I, Saito S, Yamada A. Telomerase activity and telomere 
length of peripheral blood mononuclear cells in SLE patients. 
Lupus 2003; 12 (8):591-599 
 196.  Kurosaka D, Yasuda J, Yoshida K, Yoneda A, Yasuda C, Kingetsu I, 
Toyokawa Y, Yokoyama T, Saito S, Yamada A. Abnormal 
telomerase activity and telomere length in T and B cells from 
patients with systemic lupus erythematosus. J.Rheumatol. 2006; 
33 (6):1102-1107 
 197.  Lakka TA, Salonen R, Kaplan GA, Salonen JT. Blood pressure and the 
progression of carotid atherosclerosis in middle-aged men. 
Hypertension 1999; 34 (1):51-56 
 198.  Lateef A, Petri M. Biologics in the treatment of systemic lupus 
erythematosus. Curr.Opin.Rheumatol. 2010; 22 (5):504-509 
 229 
 
 199.  Laud PR, Multani AS, Bailey SM, Wu L, Ma J, Kingsley C, Lebel M, 
Pathak S, DePinho RA, Chang S. Elevated telomere-telomere 
recombination in WRN-deficient, telomere dysfunctional cells 
promotes escape from senescence and engagement of the ALT 
pathway. Genes Dev. 2005; 19 (21):2560-2570 
 200.  Laufs U, Urhausen A, Werner N, Scharhag J, Heitz A, Kissner G, Bohm 
M, Kindermann W, Nickenig G. Running exercise of different 
duration and intensity: effect on endothelial progenitor cells in 
healthy subjects. Eur.J.Cardiovasc.Prev.Rehabil. 2005; 12 
(4):407-414 
 201.  Lee PY, Li Y, Richards HB, Chan FS, Zhuang H, Narain S, Butfiloski EJ, 
Sobel ES, Reeves WH, Segal MS. Type I interferon as a novel 
risk factor for endothelial progenitor cell depletion and endothelial 
dysfunction in systemic lupus erythematosus. Arthritis Rheum. 
2007; 56 (11):3759-3769 
 202.  Lei M, Podell ER, Baumann P, Cech TR. DNA self-recognition in the 
structure of Pot1 bound to telomeric single-stranded DNA. Nature 
2003; 426 (6963):198-203 
 203.  Lei M, Podell ER, Cech TR. Structure of human POT1 bound to telomeric 
single-stranded DNA provides a model for chromosome end-
protection. Nat.Struct.Mol.Biol. 2004; 11 (12):1223-1229 
 204.  Lei M, Zaug AJ, Podell ER, Cech TR. Switching human telomerase on 
and off with hPOT1 protein in vitro. J.Biol.Chem. 2005; 280 
(21):20449-20456 
 205.  Leong KH, Koh ET, Feng PH, Boey ML. Lipid profiles in patients with 
systemic lupus erythematosus. J.Rheumatol. 1994; 21 (7):1264-
1267 
 206.  Leri A, Franco S, Zacheo A, Barlucchi L, Chimenti S, Limana F, Nadal-
Ginard B, Kajstura J, Anversa P, Blasco MA. Ablation of 
telomerase and telomere loss leads to cardiac dilatation and heart 
failure associated with p53 upregulation. EMBO J. 2003; 22 
(1):131-139 
 207.  Levy BI. Beneficial effects of circulating progenitor endothelial cells 
activated by angiotensin receptor antagonists. Hypertension 2005; 
45 (4):491-492 
 208.  Li B, Oestreich S, de LT. Identification of human Rap1: implications for 
telomere evolution. Cell 2000; 101 (5):471-483 
 209.  Li R, Duncan BB, Metcalf PA, Crouse JR, III, Sharrett AR, Tyroler HA, 
Barnes R, Heiss G. B-mode-detected carotid artery plaque in a 
general population. Atherosclerosis Risk in Communities (ARIC) 
Study Investigators. Stroke 1994; 25 (12):2377-2383 
 230 
 
 210.  Lin Y, Weisdorf DJ, Solovey A, Hebbel RP. Origins of circulating 
endothelial cells and endothelial outgrowth from blood. J 
Clin.Invest 2000; 105 (1):71-77 
 211.  Liuzzo G, Goronzy JJ, Yang H, Kopecky SL, Holmes DR, Frye RL, 
Weyand CM. Monoclonal T-cell proliferation and plaque instability 
in acute coronary syndromes. Circulation 2000; 101 (25):2883-
2888 
 212.  Llodra J, Angeli V, Liu J, Trogan E, Fisher EA, Randolph GJ. Emigration 
of monocyte-derived cells from atherosclerotic lesions 
characterizes regressive, but not progressive, plaques. 
Proc.Natl.Acad.Sci.U.S.A 2004; 101 (32):11779-11784 
 213.  Loayza D, De Lange T. POT1 as a terminal transducer of TRF1 telomere 
length control. Nature 2003; 423 (6943):1013-1018 
 214.  Love PE, Santoro SA. Antiphospholipid antibodies: anticardiolipin and 
the lupus anticoagulant in systemic lupus erythematosus (SLE) 
and in non-SLE disorders. Prevalence and clinical significance. 
Ann.Intern.Med. 1990; 112 (9):682-698 
 215.  Lundblad V, Blackburn EH. An alternative pathway for yeast telomere 
maintenance rescues est1- senescence. Cell 1993; 73 (2):347-
360 
 216.  Lundblad V, Szostak JW. A mutant with a defect in telomere elongation 
leads to senescence in yeast. Cell 1989; 57 (4):633-643 
 217.  MacGregor AJ, Dhillon VB, Binder A, Forte CA, Knight BC, Betteridge 
DJ, Isenberg DA. Fasting lipids and anticardiolipin antibodies as 
risk factors for vascular disease in systemic lupus erythematosus. 
Ann.Rheum.Dis. 1992; 51 (2):152-155 
 218.  Mach F, Sauty A, Iarossi AS, Sukhova GK, Neote K, Libby P, Luster AD. 
Differential expression of three T lymphocyte-activating CXC 
chemokines by human atheroma-associated cells. J Clin.Invest 
1999; 104 (8):1041-1050 
 219.  Madan M, Amar S. Toll-like receptor-2 mediates diet and/or pathogen 
associated atherosclerosis: proteomic findings. PLoS.One. 2008; 
3 (9):e3204 
 220.  Maksimowicz-McKinnon K, Magder LS, Petri M. Predictors of carotid 
atherosclerosis in systemic lupus erythematosus. J.Rheumatol. 
2006; 33 (12):2458-2463 
 221.  Mallat Z, Benamer H, Hugel B, Benessiano J, Steg PG, Freyssinet JM, 
Tedgui A. Elevated levels of shed membrane microparticles with 
procoagulant potential in the peripheral circulating blood of 
 231 
 
patients with acute coronary syndromes. Circulation 2000; 101 
(8):841-843 
 222.  Manger K, Kusus M, Forster C, Ropers D, Daniel WG, Kalden JR, 
Achenbach S, Manger B. Factors associated with coronary artery 
calcification in young female patients with SLE. Ann.Rheum.Dis. 
2003; 62 (9):846-850 
 223.  Manzi S, Meilahn EN, Rairie JE, Conte CG, Medsger TA, Jr., Jansen-
McWilliams L, D'Agostino RB, Kuller LH. Age-specific incidence 
rates of myocardial infarction and angina in women with systemic 
lupus erythematosus: comparison with the Framingham Study. 
Am.J.Epidemiol. 1997; 145 (5):408-415 
 224.  Manzi S, Selzer F, Sutton-Tyrrell K, Fitzgerald SG, Rairie JE, Tracy RP, 
Kuller LH. Prevalence and risk factors of carotid plaque in women 
with systemic lupus erythematosus. Arthritis Rheum. 1999; 42 
(1):51-60 
 225.  Martin-Ruiz CM, Gussekloo J, van HD, von ZT, Westendorp RG. 
Telomere length in white blood cells is not associated with 
morbidity or mortality in the oldest old: a population-based study. 
Aging Cell 2005; 4 (6):287-290 
 226.  Massa M, Rosti V, Ferrario M, Campanelli R, Ramajoli I, Rosso R, De 
Ferrari GM, Ferlini M, Goffredo L, Bertoletti A, Klersy C, Pecci A, 
Moratti R, Tavazzi L. Increased circulating hematopoietic and 
endothelial progenitor cells in the early phase of acute myocardial 
infarction. Blood 2005; 105 (1):199-206 
 227.  Masutomi K, Yu EY, Khurts S, Ben-Porath I, Currier JL, Metz GB, Brooks 
MW, Kaneko S, Murakami S, DeCaprio JA, Weinberg RA, Stewart 
SA, Hahn WC. Telomerase maintains telomere structure in normal 
human cells. Cell 2003; 114 (2):241-253 
 228.  Mattace-Raso FU, van der Cammen TJ, Hofman A, van Popele NM, Bos 
ML, Schalekamp MA, Asmar R, Reneman RS, Hoeks AP, Breteler 
MM, Witteman JC. Arterial stiffness and risk of coronary heart 
disease and stroke: the Rotterdam Study. Circulation 2006; 113 
(5):657-663 
 229.  McCarty DJ, Manzi S, Medsger TA, Jr., Ramsey-Goldman R, LaPorte 
RE, Kwoh CK. Incidence of systemic lupus erythematosus. Race 
and gender differences. Arthritis Rheum. 1995; 38 (9):1260-1270 
 230.  MCclintock B. Cytological observations of deficiencies involving genes, 
translocations and an inversion in Zea Mays [Abstract]. Missouri 
Agr.Exp.Sta.Res.Bull. 1931; 163:1-48 
 231.  McEvoy JW, Blaha MJ, Defilippis AP, Budoff MJ, Nasir K, Blumenthal 
RS, Jones SR. Coronary artery calcium progression: an important 
 232 
 
clinical measurement? A review of published reports. J 
Am.Coll.Cardiol. 2010; 56 (20):1613-1622 
 232.  McLeod AL, Uren NG, Wilkinson IB, Webb DJ, Maxwell SR, Northridge 
DB, Newby DE. Non-invasive measures of pulse wave velocity 
correlate with coronary arterial plaque load in humans. 
J.Hypertens. 2004; 22 (2):363-368 
 233.  McMahon M, Grossman J, FitzGerald J, hlin-Lee E, Wallace DJ, Thong 
BY, Badsha H, Kalunian K, Charles C, Navab M, Fogelman AM, 
Hahn BH. Proinflammatory high-density lipoprotein as a biomarker 
for atherosclerosis in patients with systemic lupus erythematosus 
and rheumatoid arthritis. Arthritis Rheum. 2006; 54 (8):2541-2549 
 234.  Mei F, Zhang B, Tang ZW, Hou L. Expression of a telomerase-
associated gene in normal, atrophic, and tumorous testes. Chin 
Med.Sci.J. 2005; 20 (3):217-220 
 235.  MERRELL M, SHULMAN LE. Determination of prognosis in chronic 
disease, illustrated by systemic lupus erythematosus. 
J.Chronic.Dis. 1955; 1 (1):12-32 
 236.  Michelsen KS, Wong MH, Shah PK, Zhang W, Yano J, Doherty TM, 
Akira S, Rajavashisth TB, Arditi M. Lack of Toll-like receptor 4 or 
myeloid differentiation factor 88 reduces atherosclerosis and alters 
plaque phenotype in mice deficient in apolipoprotein E. 
Proc.Natl.Acad.Sci.U.S.A 2004; 101 (29):10679-10684 
 237.  Milis L, Timmermans V, Morris CA, Pussell BA, Charlesworth JA. The 
value of complement measurements in the assessment of lupus 
activity. Aust.N Z.J Med 1992; 22 (4):338-344 
 238.  Min TQ, Zhu CJ, Xiang WX, Hui ZJ, Peng SY. Improvement in 
endothelial progenitor cells from peripheral blood by ramipril 
therapy in patients with stable coronary artery disease. 
Cardiovasc.Drugs Ther. 2004; 18 (3):203-209 
 239.  Mitchell JR, Wood E, Collins K. A telomerase component is defective in 
the human disease dyskeratosis congenita. Nature 1999; 402 
(6761):551-555 
 240.  Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, 
Derksen RH, De Groot PG, Koike T, Meroni PL, Reber G, 
Shoenfeld Y, Tincani A, Vlachoyiannopoulos PG, Krilis SA. 
International consensus statement on an update of the 
classification criteria for definite antiphospholipid syndrome (APS). 
J Thromb.Haemost. 2006; 4 (2):295-306 
 241.  Mok, C., Wong, C., To, C., Lai, J., and Lam, C. Effects of 
rosuvastatin on vascular biomarkers and carotid atherosclerosis in lupus: A 
 233 
 
double-blind randomized placebo-controlled trial. Arthritis Care Res. doi: 
10.1002/acr.20440. [Epub] 
 
 242.  Moonen JR, de LK, van S, X, Kallenberg CG, van Luyn MJ, Bijl M, 
Harmsen MC. Reduced number and impaired function of 
circulating progenitor cells in patients with systemic lupus 
erythematosus. Arthritis Res.Ther. 2007; 9 (4):R84 
 243.  Morla M, Busquets X, Pons J, Sauleda J, MacNee W, Agusti AGN. 
Telomere shortening in smokers with and without COPD. Eur 
Respir J 2006; 27 (3):525-528 
 244.  Moyzis RK, Buckingham JM, Cram LS, Dani M, Deaven LL, Jones MD, 
Meyne J, Ratliff RL, Wu JR. A Highly Conserved Repetitive DNA 
Sequence, (TTAGGG)n, Present at the Telomeres of Human 
Chromosomes. PNAS 1988; 85 (18):6622-6626 
 245.  Muller HJ.  The remaking of chromosomes. The Collecting Net 1938;  
(13):181-198 
 246.  Muller WA, Ratti CM, McDonnell SL, Cohn ZA. A human endothelial cell-
restricted, externally disposed plasmalemmal protein enriched in 
intercellular junctions. J Exp.Med 1989; 170 (2):399-414 
 247.  Mullick AE, Tobias PS, Curtiss LK. Modulation of atherosclerosis in mice 
by Toll-like receptor 2. J Clin.Invest 2005; 115 (11):3149-3156 
 248.  Munro JM, Pober JS, Cotran RS. Recruitment of neutrophils in the local 
endotoxin response: association with de novo endothelial 
expression of endothelial leukocyte adhesion molecule-1. Lab 
Invest 1991; 64 (2):295-299 
 249.  Muscari A, Bozzoli C, Puddu GM, Sangiorgi Z, Dormi A, Rovinetti C, 
Descovich GC, Puddu P. Association of serum C3 levels with the 
risk of myocardial infarction. Am.J Med 1995; 98 (4):357-364 
 250.  Muscari A, Massarelli G, Bastagli L, Poggiopollini G, Tomassetti V, Volta 
U, Puddu GM, Puddu P. Relationship between serum C3 levels 
and traditional risk factors for myocardial infarction. Acta Cardiol. 
1998; 53 (6):345-354 
 251.  Nepom GT. Major histocompatibility complex-directed susceptibility to 
rheumatoid arthritis. Adv.Immunol. 1998; 68:315-332 
 252.  Newman PJ. The biology of PECAM-1. J Clin.Invest 1997; 100 (11 
Suppl):S25-S29 
 253.  Nicolo D, Goldman BI, Monestier M. Reduction of atherosclerosis in low-
density lipoprotein receptor-deficient mice by passive 
 234 
 
administration of antiphospholipid antibody. Arthritis Rheum. 2003; 
48 (10):2974-2978 
 254.  Nordfjall K, Larefalk A, Lindgren P, Holmberg D, Roos G. Telomere 
length and heredity: Indications of paternal inheritance. 
Proc.Natl.Acad.Sci.U.S.A 2005; 102 (45):16374-16378 
 255.  O'Donnell CJ, Demissie S, Kimura M, Levy D, Gardner JP, White C, 
D'Agostino RB, Wolf PA, Polak J, Cupples LA, Aviv A. Leukocyte 
telomere length and carotid artery intimal medial thickness: the 
Framingham Heart Study. Arterioscler.Thromb.Vasc.Biol. 2008; 28 
(6):1165-1171 
 256.  O'Rourke MF, Kelly RP. Wave reflection in the systemic circulation and 
its implications in ventricular function. J.Hypertens. 1993; 11 
(4):327-337 
 257.  Oeseburg H, de Boer RA, van Gilst WH, van der HP. Telomere biology in 
healthy aging and disease. Pflugers Arch. 2010; 459 (2):259-268 
 258.  Ogami M, Ikura Y, Ohsawa M, Matsuo T, Kayo S, Yoshimi N, Hai E, 
Shirai N, Ehara S, Komatsu R, Naruko T, Ueda M. Telomere 
shortening in human coronary artery diseases. 
Arterioscler.Thromb.Vasc.Biol. 2004; 24 (3):546-550 
 259.  Oksjoki R, Kovanen PT, Pentikainen MO. Role of complement activation 
in atherosclerosis. Curr.Opin.Lipidol. 2003; 14 (5):477-482 
 260.  Okuda K, Bardeguez A, Gardner JP, Rodriguez P, Ganesh V, Kimura M, 
Skurnick J, Awad G, Aviv A. Telomere length in the newborn. 
Pediatr.Res. 2002; 52 (3):377-381 
 261.  Osler W. On the visceral complications of erythema exudativum 
multiforme. The American Journal of Medical Sciences 1895; 
110:629-646 
 262.  Panayiotou AG, Nicolaides AN, Griffin M, Tyllis T, Georgiou N, Bond D, 
Martin RM, Hoppensteadt D, Fareed J, Humphries SE. Leukocyte 
telomere length is associated with measures of subclinical 
atherosclerosis. Atherosclerosis 2010; 211 (1):176-181 
 263.  Peichev M, Naiyer AJ, Pereira D, Zhu Z, Lane WJ, Williams M, Oz MC, 
Hicklin DJ, Witte L, Moore MA, Rafii S. Expression of VEGFR-2 
and AC133 by circulating human CD34(+) cells identifies a 
population of functional endothelial precursors. Blood 2000; 95 
(3):952-958 
 264.  Pellegatta F, Bragheri M, Grigore L, Raselli S, Maggi FM, Brambilla C, 
Reduzzi A, Pirillo A, Norata GD, Catapano AL. In vitro isolation of 
circulating endothelial progenitor cells is related to the high density 
lipoprotein plasma levels. Int.J Mol.Med 2006; 17 (2):203-208 
 235 
 
 265.  Perez-Rivero G, Ruiz-Torres MP, Rivas-Elena JV, Jerkic M, ez-Marques 
ML, Lopez-Novoa JM, Blasco MA, Rodriguez-Puyol D. Mice 
Deficient in Telomerase Activity Develop Hypertension Because of 
an Excess of Endothelin Production. Circulation 2006; 114 
(4):309-317 
 266.  Persson L, Boren J, Robertson AK, Wallenius V, Hansson GK, Pekna M. 
Lack of complement factor C3, but not factor B, increases 
hyperlipidemia and atherosclerosis in apolipoprotein E-/- low-
density lipoprotein receptor-/- mice. Arterioscler.Thromb.Vasc.Biol. 
2004; 24 (6):1062-1067 
 267.  Petri M. Prospective study of systemic lupus erythematosus pregnancies. 
Lupus 2004; 13 (9):688-689 
 268.  Petri M, Perez-Gutthann S, Spence D, Hochberg MC. Risk factors for 
coronary artery disease in patients with systemic lupus 
erythematosus. Am.J.Med. 1992; 93 (5):513-519 
 269.  Petri M, Spence D, Bone LR, Hochberg MC. Coronary artery disease risk 
factors in the Johns Hopkins Lupus Cohort: prevalence, 
recognition by patients, and preventive practices. Medicine 
(Baltimore) 1992; 71 (5):291-302 
 270.  Petri MA, Kiani AN, Post W, Christopher-Stine L, Magder LS. Lupus 
Atherosclerosis Prevention Study (LAPS). Ann.Rheum.Dis. 2011; 
70 (5):760-765 
 271.  Phan TG, Wong RC, Adelstein S. Autoantibodies to extractable nuclear 
antigens: making detection and interpretation more meaningful. 
Clin.Diagn.Lab Immunol 2002; 9 (1):1-7 
 272.  Pickering MC, Botto M, Taylor PR, Lachmann PJ, Walport MJ. Systemic 
lupus erythematosus, complement deficiency, and apoptosis. 
Adv.Immunol. 2000; 76:227-324 
 273.  Pigott R, Dillon LP, Hemingway IH, Gearing AJH. Soluble forms of E-
selectin, ICAM-1 and VCAM-1 are present in the supernatants of 
cytokine activated cultured endothelial cells. Biochemical and 
Biophysical Research Communications 1992; 187 (2):584-589 
 274.  Pisoni CN, Karim Y, Cuadrado MJ. Mycophenolate mofetil and systemic 
lupus erythematosus: an overview. Lupus 2005; 14 Suppl 1:s9-11 
 275.  Poli A, Tremoli E, Colombo A, Sirtori M, Pignoli P, Paoletti R. 
Ultrasonographic measurement of the common carotid artery wall 
thickness in hypercholesterolemic patients. A new model for the 
quantitation and follow-up of preclinical atherosclerosis in living 
human subjects. Atherosclerosis 1988; 70 (3):253-261 
 236 
 
 276.  Pons-Estel GJ, Gonzalez LA, Zhang J, Burgos PI, Reveille JD, Vila LM, 
Alarcon GS. Predictors of cardiovascular damage in patients with 
systemic lupus erythematosus: data from LUMINA (LXVIII), a 
multiethnic US cohort. Rheumatology 2009; 48 (7):817-822 
 277.  Pradhan AD, Manson JE, Rossouw JE, Siscovick DS, Mouton CP, Rifai 
N, Wallace RB, Jackson RD, Pettinger MB, Ridker PM. 
Inflammatory biomarkers, hormone replacement therapy, and 
incident coronary heart disease: prospective analysis from the 
Women's Health Initiative observational study. JAMA 2002; 288 
(8):980-987 
 278.  Printseva OY, Peclo MM, Gown AM. Various cell types in human 
atherosclerotic lesions express ICAM-1. Further 
immunocytochemical and immunochemical studies employing 
monoclonal antibody 10F3. Am.J.Pathol. 1992; 140 (4):889-896 
 279.  Prowse KR, Greider CW. Developmental and tissue-specific regulation of 
mouse telomerase and telomere length. Proc.Natl.Acad.Sci.U.S.A 
1995; 92 (11):4818-4822 
 280.  Rahman P, Urowitz MB, Gladman DD, Bruce IN, Genest J, Jr. 
Contribution of traditional risk factors to coronary artery disease in 
patients with systemic lupus erythematosus. J.Rheumatol. 1999; 
26 (11):2363-2368 
 281.  Rajagopalan S, Somers EC, Brook RD, Kehrer C, Pfenninger D, Lewis E, 
Chakrabarti A, Richardson BC, Shelden E, McCune WJ, Kaplan 
MJ. Endothelial cell apoptosis in systemic lupus erythematosus: a 
common pathway for abnormal vascular function and thrombosis 
propensity. Blood 2004; 103 (10):3677-3683 
 282.  Ramos-Casals M, Cuadrado MJ, Alba P, Sanna G, Brito-Zeron P, 
Bertolaccini L, Babini A, Moreno A, D'Cruz D, Khamashta MA. 
Acute viral infections in patients with systemic lupus 
erythematosus: description of 23 cases and review of the 
literature. Medicine (Baltimore) 2008; 87 (6):311-318 
 283.  Ridker PM, Buring JE, Rifai N, Cook NR. Development and validation of 
improved algorithms for the assessment of global cardiovascular 
risk in women: the Reynolds Risk Score. JAMA 2007; 297 (6):611-
619 
 284.  Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. 
Inflammation, aspirin, and the risk of cardiovascular disease in 
apparently healthy men. N Engl J Med 1997; 336 (14):973-979 
 285.  Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and 
other markers of inflammation in the prediction of cardiovascular 
disease in women. N.Engl.J.Med. 2000; 342 (12):836-843 
 237 
 
 286.  Ridker PM, Rifai N, Pfeffer M, Sacks F, Lepage S, Braunwald E. 
Elevation of tumor necrosis factor-alpha and increased risk of 
recurrent coronary events after myocardial infarction. Circulation 
2000; 101 (18):2149-2153 
 287.  Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-
reactive protein and low-density lipoprotein cholesterol levels in 
the prediction of first cardiovascular events. N Engl J Med 2002; 
347 (20):1557-1565 
 288.  Ridker PM, Danielson E, Fonseca FAH, Genest J, Gotto AM, Jr., 
Kastelein JJP, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, 
Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ, the 
JUPITER Study Group. Rosuvastatin to Prevent Vascular Events 
in Men and Women with Elevated C-Reactive Protein. N Engl J 
Med 2008; 359 (21):2195-2207 
 289.  Roman MJ, Crow MK, Lockshin MD, Devereux RB, Paget SA, 
Sammaritano L, Levine DM, Davis A, Salmon JE. Rate and 
determinants of progression of atherosclerosis in systemic lupus 
erythematosus. Arthritis Rheum. 2007; 56 (10):3412-3419 
 290.  Roman MJ, Shanker BA, Davis A, Lockshin MD, Sammaritano L, 
Simantov R, Crow MK, Schwartz JE, Paget SA, Devereux RB, 
Salmon JE. Prevalence and correlates of accelerated 
atherosclerosis in systemic lupus erythematosus. N.Engl.J.Med. 
2003; 349 (25):2399-2406 
 291.  Ronnblom L, Elkon KB. Cytokines as therapeutic targets in SLE. Nat Rev 
Rheumatol. 2010; 6 (6):339-347 
 292.  Roskoski R, Jr. VEGF receptor protein-tyrosine kinases: structure and 
regulation. Biochem.Biophys.Res.Commun. 2008; 375 (3):287-
291 
 293.  Rua-Figueroa I, rencibia-Mireles O, Elvira M, Erausquin C, Ojeda S, 
Francisco F, Naranjo A, Rodriguez-Gallego C, Garcia-Laorden I, 
Rodriguez-Perez J, Rodriguez-Lozano C. Factors involved in the 
progress of preclinical atherosclerosis associated with systemic 
lupus erythematosus: a 2-year longitudinal study. Ann.Rheum.Dis. 
2010; 69 (6):1136-1139 
 294.  Rudolph KL, Chang S, Lee HW, Blasco M, Gottlieb GJ, Greider C, 
DePinho RA. Longevity, Stress Response, and Cancer in Aging 
Telomerase-Deficient Mice. Cell 1999; 96 (5):701-712 
 295.  Rufer N, Dragowska W, Thornbury G, Roosnek E, Lansdorp PM. 
Telomere length dynamics in human lymphocyte subpopulations 
measured by flow cytometry. Nat Biotechnol. 1998; 16 (8):743-747 
 238 
 
 296.  Rustemeyer P, Wittkowski W, Greve B, Stehling M. Flow-cytometric 
identification, enumeration, purification, and expansion of CD133+ 
and VEGF-R2+ endothelial progenitor cells from peripheral blood. 
J.Immunoassay Immunochem. 2007; 28 (1):13-23 
 297.  Samani NJ, Boultby R, Butler R, Thompson JR, Goodall AH. Telomere 
shortening in atherosclerosis. Lancet 2001; 358 (9280):472-473 
 298.  Sampson MJ, Winterbone MS, Hughes JC, Dozio N, Hughes DA. 
Monocyte Telomere Shortening and Oxidative DNA Damage in 
Type 2 Diabetes. Diabetes Care 2006; 29 (2):283-289 
 299.  Sandri M, Adams V, Gielen S, Linke A, Lenk K, Krankel N, Lenz D, Erbs 
S, Scheinert D, Mohr FW, Schuler G, Hambrecht R. Effects of 
exercise and ischemia on mobilization and functional activation of 
blood-derived progenitor cells in patients with ischemic 
syndromes: results of 3 randomized studies. Circulation 2005; 111 
(25):3391-3399 
 300.  Saran AM, DuBose TD, Jr. Cardiovascular disease in chronic kidney 
disease. Ther.Adv.Cardiovasc.Dis. 2008; 2 (6):425-434 
 301.  Sari RA, Taysi S, Erdem F, Yilmaz O, Kele S, Kiziltunc A, Odaba AR, 
Cetinkaya R. Correlation of serum levels of soluble intercellular 
adhesion molecule-1 with disease activity in systemic lupus 
erythematosus. Rheumatology International 2002; 21 (4):149-152 
 302.  Sawalha AH, Harley JB. Antinuclear autoantibodies in systemic lupus 
erythematosus. Curr.Opin.Rheumatol. 2004; 16 (5):534-540 
 303.  Schmidt-Lucke C, Rossig L, Fichtlscherer S, Vasa M, Britten M, Kamper 
U, Dimmeler S, Zeiher AM. Reduced number of circulating 
endothelial progenitor cells predicts future cardiovascular events: 
proof of concept for the clinical importance of endogenous 
vascular repair. Circulation 2005; 111 (22):2981-2987 
 304.  Schneider EL, Mitsui Y. The relationship between in vitro cellular aging 
and in vivo human age. Proc.Natl.Acad.Sci.U.S.A 1976; 73 
(10):3584-3588 
 305.  Schonbeck U, Varo N, Libby P, Buring J, Ridker PM. Soluble CD40L and 
cardiovascular risk in women. Circulation 2001; 104 (19):2266-
2268 
 306.  Schonland SO, Lopez C, Widmann T, Zimmer J, Bryl E, Goronzy JJ, 
Weyand CM. Premature telomeric loss in rheumatoid arthritis is 
genetically determined and involves both myeloid and lymphoid 
cell lineages. PNAS 2003; 100 (23):13471-13476 
 239 
 
 307.  Schur PH, Sandson J. Immunologic factors and clinical activity in 
systemic lupus erythematosus. N Engl J Med 1968; 278 (10):533-
538 
 308.  Sebastiani GD, Galeazzi M, Tincani A, Piette JC, Font J, Allegri F, 
Mathieu A, Smolen J, de Ramon GE, Fernandez-Nebro A, 
Jedryka-Goral A, Papasteriades C, Morozzi G, Bellisai F, De PO, 
Marcolongo R. Anticardiolipin and anti-beta2GPI antibodies in a 
large series of European patients with systemic lupus 
erythematosus. Prevalence and clinical associations. European 
Concerted Action on the Immunogenetics of SLE. Scand.J 
Rheumatol. 1999; 28 (6):344-351 
 309.  Seeger FH, Tonn T, Krzossok N, Zeiher AM, Dimmeler S. Cell isolation 
procedures matter: a comparison of different isolation protocols of 
bone marrow mononuclear cells used for cell therapy in patients 
with acute myocardial infarction. Eur Heart J 2007; 28 (6):766-772 
 310.  Seifert PS, Kazatchkine MD. The complement system in atherosclerosis. 
Atherosclerosis 1988; 73 (2-3):91-104 
 311.  Sella EM, Sato EI, Leite WA, Oliveira Filho JA, Barbieri A. Myocardial 
perfusion scintigraphy and coronary disease risk factors in 
systemic lupus erythematosus. Ann.Rheum.Dis. 2003; 62 
(11):1066-1070 
 312.  Shaffer RG, Greene S, Arshi A, Supple G, Bantly A, Moore JS, Mohler 
ER, III. Flow cytometric measurement of circulating endothelial 
cells: the effect of age and peripheral arterial disease on baseline 
levels of mature and progenitor populations. Cytometry B 
Clin.Cytom. 2006; 70 (2):56-62 
 313.  Sharp Collaborative Group. Study of Heart and Renal Protection 
(SHARP): randomized trial to assess the effects of lowering low-
density lipoprotein cholesterol among 9,438 patients with chronic 
kidney disease. Am.Heart J 2010; 160 (5):785-794 
 314.  Sherer Y, Zinger H, Shoenfeld Y. Atherosclerosis in systemic lupus 
erythematosus. Autoimmunity 2010; 43 (1):98-102 
 315.  Shintani S, Murohara T, Ikeda H, Ueno T, Honma T, Katoh A, Sasaki K, 
Shimada T, Oike Y, Imaizumi T. Mobilization of endothelial 
progenitor cells in patients with acute myocardial infarction. 
Circulation 2001; 103 (23):2776-2779 
 316.  Shintani S, Murohara T, Ikeda H, Ueno T, Sasaki Ki, Duan J, Imaizumi T. 
Augmentation of Postnatal Neovascularization With Autologous 
Bone Marrow Transplantation. Circulation 2001; 103 (6):897-903 
 317.  Shmelkov SV, St CR, Lyden D, Rafii S. AC133/CD133/Prominin-1. Int.J 
Biochem.Cell Biol. 2005; 37 (4):715-719 
 240 
 
 318.  Shokawa T, Imazu M, Yamamoto H, Toyofuku M, Tasaki N, Okimoto T, 
Yamane K, Kohno N. Pulse wave velocity predicts cardiovascular 
mortality: findings from the Hawaii-Los Angeles-Hiroshima study. 
Circ.J. 2005; 69 (3):259-264 
 319.  Sidhu PS, Desai SR. A simple and reproducible method for assessing 
intimal-medial thickness of the common carotid artery. Br J Radiol 
1997; 70 (829):85-89 
 320.  Slagboom PE, Droog S, Boomsma DI. Genetic determination of telomere 
size in humans: a twin study of three age groups. 
Am.J.Hum.Genet. 1994; 55 (5):876-882 
 321.  Smeenk R, Brinkman K, van den BH, Termaat RM, Berden J, Nossent H, 
Swaak T. Antibodies to DNA in patients with systemic lupus 
erythematosus. Their role in the diagnosis, the follow-up and the 
pathogenesis of the disease. Clin.Rheumatol. 1990; 9 (1 Suppl 
1):100-110 
 322.  Solomon DH, Kavanaugh AJ, Schur PH. Evidence-based guidelines for 
the use of immunologic tests: antinuclear antibody testing. Arthritis 
Rheum. 2002; 47 (4):434-444 
 323.  Somers EC, Mehta H, Lewis E, Kaplan MJ. increased endothelial cell 
apoptosis in SLE correlates with anatomical evidence of 
atherosclerosis: a biomarker for premature cardiovascular disease 
[Abstract]. Arthritis Rheum 2006; 
 324.  Somers EC, Thomas SL, Smeeth L, Schoonen WM, Hall AJ. Incidence of 
systemic lupus erythematosus in the United Kingdom, 1990-1999. 
Arthritis Rheum. 2007; 57 (4):612-618 
 325.  Stastny P. Association of the B-cell alloantigen DRw4 with rheumatoid 
arthritis. N.Engl.J.Med. 1978; 298 (16):869-871 
 326.  Steer SE, Williams FMK, Kato B, Gardner JP, Norman PJ, Hall MA, 
Kimura M, Vaughan R, Aviv A, Spector TD. Reduced telomere 
length in rheumatoid arthritis is independent of disease activity 
and duration. Ann Rheum Dis 2007; 66 (4):476-480 
 327.  Steinberg AD, Steinberg SC. Long-term preservation of renal function in 
patients with lupus nephritis receiving treatment that includes 
cyclophosphamide versus those treated with prednisone only. 
Arthritis Rheum. 1991; 34 (8):945-950 
 328.  Stewart SA, Weinberg RA. Telomerase and human tumorigenesis. 
Seminars in Cancer Biology 2000; 10 (6):399-406 
 329.  Suefuji H, Ogawa H, Yasue H, Sakamoto T, Miyao Y, Kaikita K, Soejima 
H, Misumi K, Miyamoto S, Kataoka K. Increased plasma level of 
 241 
 
soluble E-selectin in acute myocardial infarction. Am.Heart J. 
2000; 140 (2):243-248 
 330.  Sutton-Tyrrell K, Wolfson SK, Jr., Thompson T, Kelsey SF. Measurement 
variability in duplex scan assessment of carotid atherosclerosis. 
Stroke 1992; 23 (2):215-220 
 331.  Suuronen EJ, Wong S, Kapila V, Waghray G, Whitman SC, Mesana TG, 
Ruel M. Generation of CD133+ cells from C. Cardiovasc.Res. 
2006; 70 (1):126-135 
 332.  Svenungsson E, Jensen-Urstad K, Heimburger M, Silveira A, Hamsten 
A, de FU, Witztum JL, Frostegard J. Risk factors for 
cardiovascular disease in systemic lupus erythematosus. 
Circulation 2001; 104 (16):1887-1893 
 333.  Svenungsson E, Jensen-Urstad K, Heimburger M, Silveira A, Hamsten 
A, de FU, Witztum JL, Frostegard J. Risk factors for 
cardiovascular disease in systemic lupus erythematosus. 
Circulation 2001; 104 (16):1887-1893 
 334.  Takahashi T, Kalka C, Masuda H, Chen D, Silver M, Kearney M, Magner 
M, Isner JM, Asahara T. Ischemia- and cytokine-induced 
mobilization of bone marrow-derived endothelial progenitor cells 
for neovascularization. Nat Med 1999; 5 (4):434-438 
 335.  Takubo K, Izumiyama-Shimomura N, Honma N, Sawabe M, Arai T, Kato 
M, Oshimura M, Nakamura K. Telomere lengths are characteristic 
in each human individual. Exp.Gerontol. 2002; 37 (4):523-531 
 336.  Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, 
SCHALLER JG, Talal N, Winchester RJ. The 1982 revised criteria 
for the classification of systemic lupus erythematosus. Arthritis 
Rheum. 1982; 25 (11):1271-1277 
 337.  Tarr T, Gyorfy B, Szekanecz E, Bhattoa HP, Zeher M, Szegedi G, Kiss E. 
Occurrence of malignancies in Hungarian patients with systemic 
lupus erythematosus: results from a single center. Ann.N 
Y.Acad.Sci. 2007; 1108:76-82 
 338.  Taylor PR, Carugati A, Fadok VA, Cook HT, Andrews M, Carroll MC, 
Savill JS, Henson PM, Botto M, Walport MJ. A hierarchical role for 
classical pathway complement proteins in the clearance of 
apoptotic cells in vivo. J Exp.Med 2000; 192 (3):359-366 
 339.  Tepper OM, Galiano RD, Capla JM, Kalka C, Gagne PJ, Jacobowitz GR, 
Levine JP, Gurtner GC. Human endothelial progenitor cells from 
type II diabetics exhibit impaired proliferation, adhesion, and 
incorporation into vascular structures. Circulation 2002; 106 
(22):2781-2786 
 242 
 
 340.  Theodoridou A, Bento L, D'Cruz DP, Khamashta MA, Hughes GR. 
Prevalence and associations of an abnormal ankle-brachial index 
in systemic lupus erythematosus: a pilot study. Ann.Rheum.Dis. 
2003; 62 (12):1199-1203 
 341.  Thompson T, Sutton-Tyrrell K, Wildman RP, Kao A, Fitzgerald SG, 
Shook B, Tracy RP, Kuller LH, Brockwell S, Manzi S. Progression 
of carotid intima-media thickness and plaque in women with 
systemic lupus erythematosus. Arthritis Rheum. 2008; 58 (3):835-
842 
 342.  Toussirot E, Roudier J. Epstein-Barr virus in autoimmune diseases. 
Best.Pract.Res.Clin.Rheumatol. 2008; 22 (5):883-896 
 343.  Tso TK, Huang WN. Elevated soluble intercellular adhesion molecule-1 
levels in patients with systemic lupus erythematosus: relation to 
insulin resistance. Journal of Rheumatology 2007; 34 (4):726-730 
 344.  Tsokos GC, Kammer GM. Molecular aberrations in human systemic 
lupus erythematosus. Mol.Med Today 2000; 6 (11):418-424 
 345.  Uramoto KM, Michet CJ, Jr., Thumboo J, Sunku J, O'Fallon WM, Gabriel 
SE. Trends in the incidence and mortality of systemic lupus 
erythematosus, 1950-1992. Arthritis Rheum. 1999; 42 (1):46-50 
 346.  Urowitz MB, Bookman AA, Koehler BE, Gordon DA, Smythe HA, Ogryzlo 
MA. The bimodal mortality pattern of systemic lupus 
erythematosus. Am.J.Med. 1976; 60 (2):221-225 
 347.  Urowitz MB, Gladman D, Ibanez D, Fortin P, Sanchez-Guerrero J, Bae 
S, Clarke A, Bernatsky S, Gordon C, Hanly J, Wallace D, Isenberg 
D, Ginzler E, Merrill J, Alarcon G, Steinsson K, Petri M, Dooley 
MA, Bruce I, Manzi S, Khamashta M, Ramsey-Goldman R, Zoma 
A, Sturfelt G, Nived O, Maddison P, Font J, van Vollenhoven R, 
Aranow C, Kalunian K, Stoll T, Buyon J. Clinical manifestations 
and coronary artery disease risk factors at diagnosis of systemic 
lupus erythematosus: data from an international inception cohort. 
Lupus 2007; 16 (9):731-735 
 348.  Urowitz MB, Ibanez D, Gladman DD. Atherosclerotic vascular events in a 
single large lupus cohort: prevalence and risk factors. 
J.Rheumatol. 2007; 34 (1):70-75 
 349.  Vaarala O, Alfthan G, Jauhiainen M, Leirisalo-Repo M, Aho K, Palosuo 
T. Crossreaction between antibodies to oxidised low-density 
lipoprotein and to cardiolipin in systemic lupus erythematosus. 
Lancet 1993; 341 (8850):923-925 
 350.  Valdes AM, Andrew T, Gardner JP, Kimura M, Oelsner E, Cherkas LF, 
Aviv A, Spector TD. Obesity, cigarette smoking, and telomere 
length in women. The Lancet 366 (9486):662-664 
 243 
 
 351.  Van Lenten BJ, Hama SY, de Beer FC, Stafforini DM, McIntyre TM, 
Prescott SM, La Du BN, Fogelman AM, Navab M. Anti-
inflammatory HDL becomes pro-inflammatory during the acute 
phase response. Loss of protective effect of HDL against LDL 
oxidation in aortic wall cell cocultures. J.Clin.Invest 1995; 96 
(6):2758-2767 
 352.  Vasa M, Fichtlscherer S, Aicher A, Adler K, Urbich C, Martin H, Zeiher 
AM, Dimmeler S. Number and Migratory Activity of Circulating 
Endothelial Progenitor Cells Inversely Correlate With Risk Factors 
for Coronary Artery Disease. Circ Res 2001; 89 (1):e1-e7 
 353.  Vaziri H, Benchimol S. Reconstitution of telomerase activity in normal 
human cells leads to elongation of telomeres and extended 
replicative life span. Curr.Biol. 1998; 8 (5):279-282 
 354.  Veillard NR, Kwak B, Pelli G, Mulhaupt F, James RW, Proudfoot AE, 
Mach F. Antagonism of RANTES receptors reduces 
atherosclerotic plaque formation in mice. Circ.Res. 2004; 94 
(2):253-261 
 355.  Verma S, Kuliszewski MA, Li SH, Szmitko PE, Zucco L, Wang CH, 
Badiwala MV, Mickle DAG, Weisel RD, Fedak PWM, Stewart DJ, 
Kutryk MJB. C-Reactive Protein Attenuates Endothelial Progenitor 
Cell Survival, Differentiation, and Function: Further Evidence of a 
Mechanistic Link Between C-Reactive Protein and Cardiovascular 
Disease. Circulation 2004; 109 (17):2058-2067 
 356.  Vestweber D, Blanks JE. Mechanisms that regulate the function of the 
selectins and their ligands. Physiol Rev. 1999; 79 (1):181-213 
 357.  Viedt C, Hnsch GM, Brandes RP, K³bler W, Kreuzer Jr. The terminal 
complement complex C5b-9 stimulates interleukin-6 production in 
human smooth-muscle cells through activation of transcription 
factors NF-kB and AP-1. FASEB J. 2000; 00-0468fje 
 358.  Von Feldt JM. Systemic lupus erythematosus. Recognizing its various 
presentations. Postgrad.Med 1995; 97 (4):79, 83, 86 
 359.  Voyta JC, Via DP, Butterfield CE, Zetter BR. Identification and isolation 
of endothelial cells based on their increased uptake of acetylated-
low density lipoprotein. J Cell Biol. 1984; 99 (6):2034-2040 
 360.  Vulliamy T, Marrone A, Szydlo R, Walne A, Mason PJ, Dokal I. Disease 
anticipation is associated with progressive telomere shortening in 
families with dyskeratosis congenita due to mutations in TERC. 
Nat.Genet. 2004; 36 (5):447-449 
 361.  Wais T, Fierz W, Stoll T, Villiger PM. Subclinical disease activity in 
systemic lupus erythematosus: immunoinflammatory markers do 
 244 
 
not normalize in clinical remission. Journal of Rheumatology 2003; 
30 (10):2133-2139 
 362.  Wajed J, Ahmad Y, Durrington PN, Bruce IN. Prevention of 
cardiovascular disease in systemic lupus erythematosus--
proposed guidelines for risk factor management. Rheumatology 
(Oxford) 2004; 43 (1):7-12 
 363.  Wallace DJ. Antimalarials--the 'real' advance in lupus. Lupus 2001; 10 
(6):385-387 
 364.  Walport MJ. Complement. First of two parts. N Engl J Med 2001; 344 
(14):1058-1066 
 365.  Walport MJ. Complement. Second of two parts. N Engl J Med 2001; 344 
(15):1140-1144 
 366.  Walport MJ. Complement and systemic lupus erythematosus. Arthritis 
Res. 2002; 4 Suppl 3:S279-S293 
 367.  Wang X, Zhu J, Chen J, Shang Y. Effects of nicotine on the number and 
activity of circulating endothelial progenitor cells. 
J.Clin.Pharmacol. 2004; 44 (8):881-889 
 368.  Wanner C, Krane V. Lessons learnt from the 4D trial. Nephrol.Ther. 
2006; 2 (1):3-7 
 369.  Ward MM. Premature morbidity from cardiovascular and cerebrovascular 
diseases in women with systemic lupus erythematosus. Arthritis 
Rheum. 1999; 42 (2):338-346 
 370.  Weinrich SL, Pruzan R, Ma L, Ouellette M, Tesmer VM, Holt SE, Bodnar 
AG, Lichtsteiner S, Kim NW, Trager JB, Taylor RD, Carlos R, 
Andrews WH, Wright WE, Shay JW, Harley CB, Morin GB. 
Reconstitution of human telomerase with the template RNA 
component hTR and the catalytic protein subunit hTRT. 
Nat.Genet. 1997; 17 (4):498-502 
 371.  Weng NP, Levine BL, June CH, Hodes RJ. Regulated expression of 
telomerase activity in human T lymphocyte development and 
activation. J Exp.Med. 1996; 183 (6):2471-2479 
 372.  Werner N, Kosiol S, Schiegl T, Ahlers P, Walenta K, Link A, Bohm M, 
Nickenig G. Circulating endothelial progenitor cells and 
cardiovascular outcomes. N.Engl.J.Med. 2005; 353 (10):999-1007 
 373.  Westerweel PE, Luijten RKMA, Hoefer IE, Koomans HA, Derksen 
RHWM, Verhaar MC. Haematopoietic and endothelial progenitor 
cells are deficient in quiescent systemic lupus erythematosus. Ann 
Rheum Dis 2007; 66 (7):865-870 
 245 
 
 374.  Wolak T, Todosoui E, Szendro G, Bolotin A, Jonathan BS, Flusser D, 
Buskila D, Sukenik S, bu-Shakra M. Duplex study of the carotid 
and femoral arteries of patients with systemic lupus 
erythematosus: a controlled study. J Rheumatol. 2004; 31 (5):909-
914 
 375.  Woodfin A, Voisin MB, Nourshargh S. PECAM-1: a multi-functional 
molecule in inflammation and vascular biology. 
Arterioscler.Thromb.Vasc.Biol. 2007; 27 (12):2514-2523 
 376.  Wu CH, Hsieh SC, Li KJ, Lu MC, Yu CL. Premature telomere shortening 
in polymorphonuclear neutrophils from patients with systemic 
lupus erythematosus is related to the lupus disease activity. Lupus 
2007; 16 (4):265-272 
 377.  Wu G, Hu W, Shahsafaei A, Song W, Dobarro M, Sukhova GK, Bronson 
RR, Shi GP, Rother RP, Halperin JA, Qin X. Complement 
regulator CD59 protects against atherosclerosis by restricting the 
formation of complement membrane attack complex. Circ.Res. 
2009; 104 (4):550-558 
 378.  Yang X, Murthy V, Schultz K, Tatro JB, Fitzgerald KA, Beasley D. Toll-
like receptor 3 signaling evokes a proinflammatory and 
proliferative phenotype in human vascular smooth muscle cells. 
Am.J Physiol Heart Circ.Physiol 2006; 291 (5):H2334-H2343 
 379.  Yildirim-Toruner C, Diamond B. Current and novel therapeutics in the 
treatment of systemic lupus erythematosus. J Allergy 
Clin.Immunol 2011; 127 (2):303-312 
 380.  Yildiz M, Yildiz BS, Soy M, Tutkan H. Impairment of arterial distensibility 
in premenopausal women with systemic lupus erythematosus. 
Kardiol.Pol. 2008; 66 (11):1194-1199 
 381.  Yin AH, Miraglia S, Zanjani ED, meida-Porada G, Ogawa M, Leary AG, 
Olweus J, Kearney J, Buck DW. AC133, a novel marker for 
human hematopoietic stem and progenitor cells. Blood 1997; 90 
(12):5002-5012 
 382.  Yudoh K, Matsuno H, Nezuka T, Kimura T. Different mechanisms of 
synovial hyperplasia in rheumatoid arthritis and pigmented 
villonodular synovitis: the role of telomerase activity in synovial 
proliferation. Arthritis Rheum 1999; 42 (4):669-677 
 383.  Yudoh K, Matsuno H, Osada R, Nakazawa F, Katayama R, Kimura T. 
Decreased cellular activity and replicative capacity of osteoblastic 
cells isolated from the periarticular bone of rheumatoid arthritis 
patients compared with osteoarthritis patients. Arthritis Rheum. 
2000; 43 (10):2178-2188 
 246 
 
 384.  Yun S, Leung VW, Botto M, Boyle JJ, Haskard DO. Brief report: 
accelerated atherosclerosis in low-density lipoprotein receptor-
deficient mice lacking the membrane-bound complement regulator 
CD59. Arterioscler.Thromb.Vasc.Biol. 2008; 28 (10):1714-1716 
 385.  Zhang J, Roschke V, Baker KP, Wang Z, Alarcon GS, Fessler BJ, 
Bastian H, Kimberly RP, Zhou T. Cutting edge: a role for B 
lymphocyte stimulator in systemic lupus erythematosus. J 
Immunol 2001; 166 (1):6-10 
 386.  Zhong Z, Shiue L, Kaplan S, de LT. A mammalian factor that binds 
telomeric TTAGGG repeats in vitro. Mol.Cell Biol. 1992; 12 
(11):4834-4843 
 388.  Zureik M, Ducimetiere P, Touboul PJ, Courbon D, Bonithon-Kopp C, Berr 
C, Magne C. Common carotid intima-media thickness predicts 
occurrence of carotid atherosclerotic plaques: longitudinal results 
from the Aging Vascular Study (EVA) study. Arterioscler Thromb 
Vasc Biol 2000; 20 (6):1622-1629 
 
 
